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ABSTRACT OF DISSERTATION

MOLECULAR MECHANISMS BY WHICH C-ABL AND ARG MEDIATE
MELANOMA INVASION AND METASTASIS
Metastasis is one of the main causes of death in cancer patients. Metastatic
melanoma is a death sentence, as chemotherapeutic agents have a 5% success
rate or do not extend survival beyond 10 months. The lack of effective
chemotherapeutic agents for treating metastatic melanoma indicates a dire need
to identify new drug targets and develop new therapies. Our lab has previously
shown that the kinase activity of Abelson family of non-receptor tyrosine kinases
(c-Abl and Arg) is elevated in invasive breast cancer cell lines as compared to
non-invasive cell lines. Previous studies from our lab have shown that Abl
kinases are convergent point of ErbB2 and Src Kinases in melanoma cells and
Abl kinases promote invasion by an undefined mechanism. Although Abl kinases
promote invasion, it is not known whether they are important for metastastic
potential. For the first time, we report that Abl kinases promote melanoma cell
proliferation, survival, matrigel-invasion and single-cell 3D invasion. To
investigate the mechanism by which Abl kinases promote invasion, we found out
that active c-Abl transcriptionally upregulates MMP-1, and using rescue
approaches we show that c-Abl promotes invasion via a STAT3MMP-1
pathway. In contrast, active Arg drives invasion in a STAT3-independent manner,
and upregulates the expression of MMP-3 and MT1-MMP, in addition to MMP-1.
We also found that Abl kinases promote invasion via lysosomal degradation of a
metastasis suppressor, NM23-H1 by activating lysosomal cathepsins B and L,
which directly cleave and degrade NM23-H1. Furthermore, c-Abl and Arg are
activated in primary melanomas and cAbl/Arg activity is inversely correlated with
NM23-H1 expression both in primary melanoma and human melanoma cells. We
also demonstrate, for the first time that active Abl kinases promote metastasis in
vivo, as inhibition of c-Abl/Arg with nilotinib, dramatically inhibits lung
colonization/metastasis in a mouse model using two different melanoma cell
lines. In summary, we identify Abl kinases as critical, novel, drug targets in
metastatic melanoma, and our data indicate that nilotinib may be useful in
preventing metastasis in a select group of patients, harboring active Abl kinases.
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CHAPTER 1: Introduction
1.1

Melanoma

1.1.1 Melanoma incidence and challenges in treatment
More than 1 million cases of skin cancer are diagnosed in the United States of
America. Melanoma a malignant tumor of the melanocytes, the pigment
producing cell in the epidermal layer of the skin, represents less than 10% of all
skin cancer. Melanoma accounts for 75% of all skin cancer related deaths with a
mean survival rate of 6-9 months. The incidence of melanoma has increased to
more than 600% in the last 50 years and is considered to be a significant health
problem in western world countries [1, 2]. Metastatic melanoma is uncurable and
chemotherapeutic drugs have a 5% success rate and do not extend life
expectancy beyond 10 months [1, 3].
Chemotherapy initially was considered an accepted first-line of therapy to
treat melanoma until most of the chemotherapeutic drugs showed poor response
in patients. Various chemotherapies like dacarbazine, temozolomide (oral
analogue of dacarbazine), cisplatin, vinblastine and f1otemustine all showed poor
response rates. Combination chemotherapies such as Dartmouth regimen
(cisplatin/vinblastine/dacarbazine/tamoxifen) have failed to show any better
survival benefit than dacarbazine alone, and many new chemotherapeutic drugs
(temozolomide, carboplatin, vinblastine) failed to elicit any better response [1, 3,
4] Two immunotherapies, high-dose of interleukin-2 and ipilimumab, are currently
recommended for unresectable or metastatic melanoma patients, but these
drugs also have low clinical response rate (10-15%) [1,3]. As an adjuvant therapy
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some patients are treated with interferon-alpha2b [5]. Even though all the above
agents show poor responses, they are still used in the clinic due to the lack of
better agents that can increase the survival rate in melanoma. In the past
decade, there has been a focus on identifying various new targets in metastatic
melanoma. Mutations in BRAF, a serine-threonine kinase in RAS-RAF-MEK-ERK
signaling pathway occur in more than 50% of patients with cutaneous melanoma
[1]. Vemurafenib, selective inhibitor of V600E activating mutation in BRAF,
showed promise in a phase III clinical trial, however, a large number of patients
relapsed in less than one year [1, 6]. Molecular studies led to the identification of
some resistance pathways and thus dampened the initial success seen with
targeting BRAF in melanoma treatment. The pathways that are often mutated in
vemurafenib resistant patient tumors will be discussed later.

1.1.2 Clinical classification and melanoma progression
Melanoma is anatomically classified into the following groups [2]:
1. Superficial spreading melanoma- affects the trunk of men and legs of women.
It is the most common form of cutaneous melanoma, occurring due to sun
exposure and generally evolves from a precursor lesion [2, 7].
2. Nodular melanoma- affects the same sites as superficial spreading but the
frequency of incidence is much lower. Nodular melanomas do not invade the
epidermis in a radial fashion but more vertical growth is observed [2, 7].
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Figure 1.1 Proposed molecular changes in the progression of melanoma.
Aberrant proliferation of normal melanocytes due to UV radiation or genetic
mutations, results in benign nevi. Further mutations lead to the formation of RGP,
where cells invade within the epidermis and epigenetic changes induce
progression to VGP. Many spontaneous mutations and epigenetic modifications
lead to metastatic progression. Figure adapted from Zaidi M R et al; Journal of
Investigative Dermatology (2008) 128, 2381-2391.
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3. Acral lentiginous melanoma- affects non-hair containing palms, soles and
nails.
4. Lentigo maligna melanoma, arising from melanoma in situ, is commonly seen
in the elderly, and is associated with chronic sun exposures but the prevalence is
very low.
5. Noncutaneous melanoma is observed in the ocular and mucosal areas of
patients. Exposure to sun is not a risk factor for non-cutaneous melanoma.
The Clark model (Figure 1.1) describes how melanocytes undergo various
stages of malignant transformation to form a metastatic melanoma. The first
noticeable change is the formation of benign nevus (atypical mole), which have
uncontrolled yet limited growth of the melanocytes [8]. Most nevi remain dormant
for decades; they have to free themselves from growth restraints to become
malignant [8]. Dysplastic nevi having aberrant growth arise within and from the
pre-existing nevus or in a completely new location. During the next step in
progression, Radial Growth Phase (RGP), the cells proliferate in the epidermis
without invading the dermis. RGP melanoma is metastatic incompetent and can
be removed surgically [2, 8]. Some lesions can invade the epidermal layer to
form nodules in the dermis, called as Vertical Growth Phase (RGP). In contrast to
the RGP cells, VGP cells can form colonies in soft agar and can also from tumor
nodules when implanted in nude mice [8]. VGP cells can also invade the local
blood vessels, lymphatics and can also successfully proliferate in the secondary
sites and form metastatic nodules, called as metastatic melanoma [2, 8]. As
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melanoma progresses from RGP to VGP, treatment options and survival rates
decrease [2, 8, 9]. Melanoma staging performed via histo-pathological analysis of
the depth of local invasion, called Breslow index, also serves as a principal
prognostic factor in melanoma progression.
Metastatic spread of cancer cells from the primary tumor is responsible for
cancer patient morbidity and mortality. In cancer metastasis, a small percentage
of cells that are released from the primary tumor ultimately form metastasis in
distant sites. To metastasize to ectopic sites melanoma cell must have the ability
to invade the extracellular matrix (ECM), one of the most important steps in
cancer metastasis. Tumor cells have to breach the ECM in order to metastasize.
As opposed to invasion as a single cell, in the absence of cell-cell junction
melanoma cells invade as a group where cell-cell junctional proteins are retained
[10, 11]. From the primary tumor site the cancer cells also have invade the
collagen layers of the blood vessels, a process called intrasavation and also
invade out from the blood vessels to form metastasis (extravasation) in the
secondary site. In the blood vessels the cells have to survive is the absence of
growth factors, another hallmark of cancer cells. Tumors cells must extravasate
out of the blood stream, form metastasis in a favorable ectopic site. The choice of
the secondary site is in accordance to the “seed soil hypothesis”, which proposes
that the tumor cells colonize in the tissue which releases specific chemokines
favorable for the tumor cells to form a niche. After favorable extravasation, the
cancer cells form micrometastasis and proliferate further to form micrometastasis
[12-14].
5

1.1.3 Environmental and genetic interactions
Sun ray sensitivity and exposure to ultraviolet radiation are risk factors in
melanoma formation. Ultraviolet radiation, known to cause genetic changes in
the skin architecture, elevates the risk of melanoma. Due to exposure of
ultraviolet light, the cutaneous immune response is compromised, which
generates reactive oxygen species that affect melanocytes. As a defensive
mechanism, melanocytes synthesize melanin and transfer it to the keratinocytes,
which absorb and dissipate the ultraviolet energy. Normally, after exposure to
sun light, skin pigmentation increases because of the production of melanin by
alpha melanocyte-stimulating hormone (alpha-MSH). MSH stimulates the
melanocortin receptor1 present on the melanocytes resulting in the production of
excess melanin and thus as a protective mechanism against ultraviolet light, the
skin undergoes tanning. In the light-skinned population there is a germ-line
polymorphism in the MC1R gene that impairs the activity of the receptor [15, 16].
All these factors lead to a genetic predisposition, which promotes the origin of
melanoma.
Previous melanoma or family history of melanoma also are risk factors for
melanoma. BRAF mutation is rare (7%) in all cancers but 50-60% of cutaneous
melanoma patients have a V600E activating mutation patients. In the benign nevi
stage (limited growth stage) BRAF is frequently mutated (80%) (Figure 1.1).
Mutation in the BRAF gene results in the aberrant activation of the mitogen
activated protein kinase (MAPK) pathway [2, 8, 17, 18]. Other genes that are
commonly mutated in melanoma are the metastasis suppressor gene, cyclin6

dependent kinase inhibitor 2A (CDKN2A), activated NRAS mutations and
microphthalima-associated transcription factor (MIFT) amplification/alterations,
predisposing patients to the risk of melanoma. Tumor-suppressor gene,
phosphatase and tensin homologue (PTEN) also is often inactivated in
melanoma leading to phosphatidylinositol-3- kinase (PI3K)/AKT activation [2, 8].
In mucosal melanoma patients, c-Kit is frequently mutated [28]. In zebra-fish
models, mutation of BRAF in combination with inactivation of tumor-suppressor
gene p53 caused melanocytes to become malignant, where as in mouse models
mutant BRAF cooperates with activation to PI3K/Akt and drive melanoma
formation [2, 8, 21]. These sorts of mutations predispose certain populations to
the risk of melanoma. Signaling pathways that are important in melanoma
progression will be discussed in more detail in Chapter 1.1.4.

1.1.4 Growth factor signaling in melanoma progression
Activated growth factor signaling is critical in driving the process of oncogenesis
in melanoma. RAS/RAF/MAPK and RAS/PI3K/AKT, signaling cascades in the
Ras pathway is activated in melanoma. As discussed earlier, V600E BRAF is
the driver mutation in over 50% of melanoma patients, while almost 20-30% of
the melanomas have activating NRAS mutation [2, 8]. The RAS/PI3K/AKT
pathway is regulated by PTEN, a negative regulator of PI3K signaling [2, 8, 21].
Almost 85% of melanoma cell lines have mutations in NRAS, BRAF and loss of
PTEN is also detected in approximately 60% of primary melanoma as compared
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to only 10% of nevi indicating that loss of PTEN can be a driving factor in the
progression of melanoma [19, 20]. Mutant BRAF alone cannot drive the
formation of melanoma in mouse models; loss of PTEN cooperates with mutant
BRAF in melanocytes and drive melanoma formation [21]. The authors also show
that selective inhibition of MEK1/2 by PD325901 and mTorc1 by Rapamycin
respectively, prevented induction of melanoma by mutant BRAF [21], indicating
that there is a cross-talk between signaling pathways that govern
melanomagenesis.
In pursuit of new drugs to treat melanoma patients, research has been
focused on identifying signaling pathways that are activated in melanoma.
Melanoma cells resistant to BRAF inhibitors show upregulated EGFR-Src Family
Kinase (SFK)-STAT3 signaling which promoted invasion, and metastasis in these
resistant cells [22]. Vemurafenib resistant tumors showed increased EGFR and
SFK activity and blocking SFK with dasatinib suppress the growth and
metastasis of vemurafenib-resistant tumors [22]. Some of the resistance
pathways include reactivated ERK signaling which are either Ras/Raf
dependent, activating mutation in MEK, activation of MAPK signaling pathway by
receptor tyrosine kinase and activated Fibroblast growth factor receptor -3
(FGFR-3)/Ras signaling pathway [23]. Identification of new targets and also
combinatorial approaches are now on-going in clinical trials.
Targeting IGF1R in melanoma is also being considered as a therapeutic
option. Insulin-like Growth Factor 1-Receptor (IGF1-R), which activates both the
MAPK and PI3K pathway, is often overexpressed in many tumors including
8

melanoma. Activation of IGF-1R promotes growth of human melanoma cells in
mice [24, 25]. Yeh et al., reported that inhibition of IGF1R signaling inhibits
melanoma cell survival, induces apoptosis in both the wild type and mutant BRAF cells, indicating that mutation of BRAF does not make melanoma cells
resistant to IGF1-R targeting [26]. IGF-R/PI3K activity is upregulated in
melanoma cells which are resistant to selective BRAF inhibitor and relapse
patient samples have increased IGF-1R expression [27 ], indicating that inhibiting
of both these pathways might be of therapeutic benefit.
Unresectable melanoma, known for being resistant to all known
chemotherapies, metastasizes rapidly to ectopic sites. Targeting BRAF was
considered a key discovery in treating melanoma patients but the quick
emergence of BRAF-resistant patient population has dampened the possibility of
treating metastatic melanoma with B-Raf inhibitors alone. There is an urgent
need to identify signaling molecules that are activated in primary melanoma and
cell lines and investigate how these proteins promote melanoma progression.
This study will identify different mechanisms in melanoma progression in order to
identify new drug targets.

9

1.2

Abelson kinases

1.2.1 Abl kinases: Structure and regulation
c-Abl and Arg (Abl-Related-Gene) are the two structurally homologous
protein members of Abelson non-receptor tyrosine kinase family. c-Abl is
essential for development, as c-Abl knockout mice are embryonic lethal [29,30],
but Arg- deficient mice are born normal [31]. c-Abl and Arg double knockout mice
are embryonic lethal and double knock out embryos have defects in neurulation
[31]. The N-termini of c-Abl and Arg are highly homologous and consist of the
kinase domain and Src homology (SH2 &SH3) domains (Figure 1.2). c-Abl and
Arg both have F- and G-actin binding domains which assist in cytoskeletal
reorganization and regulate membrane ruffling and motility [33]. Unlike Arg, c-Abl
has 3 nuclear localization signals and DNA binding domains at the C-terminus
[33, 34]. c-Abl has nuclear export signals, which helps it to shuttle between the
nucleus and cytoplasm [32, 33], and acetylation and binding to 14-3-3 promotes
its cytoplasmic retention. In response to DNA damage, 14-3-3 is phosphorylated
by c-Jun N-terminal kinase (JNK), resulting in dissociation of the c-Abl/14-3-3
complex, and nuclear localization of c-Abl [32, 35].
Nuclear c-Abl promotes DNA damage-induced-apoptosis via a p53mediated pathway [36]. In cancer cells, c-Abl binds and phosphorylates the
oncoprotein, MUC-1. Phosphorylation of MUC1 inhibits the interaction of c-Abl
with 14-3-3 and thus MUC1 permanently sequesters c-Abl in the cytoplasm,
preventing the shuttling of c-Abl to nucleus following DNA damage. Unlike Arg, c-
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Structural Comparison of c-Abl and Arg
Nonreceptor Tyrosine Kinases
Binding sites for:

NLS
b form

c-Abl

DNA

V SH3 SH2

G-actin

F-actin

KINASE
NES

a form

SH3 Domain

Proline
Stretch

Binding Sites

Binding sites for:
b form

Arg

G-actin

V SH3 SH2

KINASE
NES

a form

32%

F-actin

90%

94%

29%

56%

Figure 1.2: Domain structure of Abl Kinases. c-Abl and Arg contain highly
conserved N- termini while the carboxy termini are more divergent. Unlike Arg, cAbl have three nuclear localization signals (NLS), a nuclear export signal and a
DNA-binding domain. c-Abl and Arg both have binding sites for F-actin and Gactin binding domains.

11

Abl is also found in the endoplasmic reticulum (ER) and mitochondria [33]. Ito Y
et al., have demonstrated that during ER stress, ER-localized c-Abl is targeted to
the mitochondria. ER stress induces c-Abl dependent mitochondrial cytochrome
c release and apoptosis [37].
Alternative splicing of the first exon generates Abl1a and 1b, the two
isoforms of c-Abl in mammalian cells [38]. The isoform c-Abl1b is present
ubiquitously in all cell types and carries a myristolate group at its N-terminus.
Although this form is myristoylated, there is no evidence of palmitoylation or
additional polybasic amino acids that can interact with the negatively charged
phospholipids on the cytoplasmic side of plasma membrane. The absence of
such sites confers weak binding of c-Abl1b to the plasma membrane and thus
only a minor fraction of c-Abl 1b is seen in the membrane-proximal site [38]. The
presence of the N-terminal myristoylated cap plays an important role in the
downregulation of the kinase activity of c-Abl. The N-terminal cap binds to the Clobe in the kinase domain of Abl, inducing a bend in the C-lobe, resulting in the
docking of the SH2 domain onto the C-lobe and inducing an auto-inhibitory state
[39]. Activation of c-Abl in the nucleus in response to ionizing radiation and
genotoxic stress, in various cell types leads to apoptosis [30], while activated cAbl in the cytoplasm induces proliferation and survival [33, 40].

1.2.2 Abl kinases: Activation and inhibition
Tyrosine phosphorylation of c-Abl in the kinase domain (Y412) and interlinker
region (Y245) is required for the activation of c-Abl and both these sites are
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phosphorylated by Src [33,40]. In fibroblasts, platelet derived growth factor
(PDGF) activates Abl kinases in a Src-dependent manner, and once activated cAbl induces membrane ruffling [40]. c-Abl is regulated in an autoinhibitory state
by the interaction of its N-terminal cap, SH2 and SH3 domain to the kinase
domain. In hematopoietic cells, the Abl1 gene undergoes chromosomal
translocation [t(9;22)] fusing with the BCR gene to form a mutant fusion protein,
BCR-Abl. Fusion of BCR to c-Abl disrupts the N-terminal auto-inhibition, which
leads to activation and oncogenic signaling[33,41-43]. BCR-Abl promotes the
development of three different types of leukemia: chronic myelogenous leukemia
(CML), acute myelogenous leukemia (AML) and chronic neutrophilic leukemia
(CNL) depending of the break point of BCR. In another translocation event, Abl1
and Abl2 (Arg) forms fusion with the Tel gene (ETS family of transcription factor)
to form Tel-Abl and Tel-Arg, which drive the development of myoproliferative
diseases. A viral, oncogenic form of Abl, v-Abl, is constitutive active and
transforms lymphoid cells [33]. These fusion proteins promote proliferation and
inhibit apoptosis of the leukemic cells. Bcr-Abl also induces membrane ruffling
and invasion of hematopoietic cells and its expression can solely lead to the
development of leukemia in an animal model [33, 44].
Controlling Abl kinase signaling is important for inhibiting its oncogenic
function. PAG/Msp2 and Abl interactor proteins (Abi-1 & 2) are potent Abl
kinases inhibitors [33]. Pag binds to the c-Abl SH3 domain and inhibits the kinase
activity of Abl (45). Abi-1 and Abi-2 activate the inhibitory function of the SH3
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domain, a negative regulatory domain, and activated Abl kinases in-turn induce
the proteosome-mediated degradation of Abi proteins [46, 47].
Imatinib mesylate (Gleevec), an ATP competitor inhibitor, targets the ATP
binding domain in Abl kinases rendering them inactive [48, 49]. Imatinib also
inhibits c-Kit and PDGF receptors [50 ]. Nilotinib, a second generation Abl kinase
inhibitor with the same mechanism of action as imatinib, is more sensitive
towards Abl kinases compared to its other targets (c-kit, PDGFR, DDR and CSF1R) and thus shows greater promise in inducing remission of patients with CML
[51]. Some drugs targeting Src family kinases (SFKs) (SKI-606/bosutinib,
dasatinib) also inhibit Abl kinases [52, 53]. Some CML patients develop
resistance to Abl inhibitors by developing a T315I mutation (gatekeeper), which
renders BCR-Abl resistant to imatinib and nilotinib. Ponatinib, and DCC-2036
inhibit both the wild type and T315I gatekeeper mutation in mouse models and
Phase 2 clinical trial with ponatinib show promising results against imatinibresistant CML [38].
Many proteins are activated by Bcr-Abl and Abl kinases, among which
the Crk family of adapter proteins are the most studied. Phosphorylation of CrkL
is used as a read-out of c-Abl and Arg activities and CrkL binding to Bcr-Abl is
necessary for oncogenic transformation. Another studied Bcr-Abl substrate is the
transcription factor STAT5. Bcr-Abl phosphorylation of STAT5 is independent of
the canonical upstream JAK2 kinase [38].
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1.2.3 Activation of Abl kinases in solid tumors
To investigate the activation status and role of Abelson kinases in solid
tumors, many researchers have examined whether Abl kinases are highly
expressed in solid tumors. c-Abl and Arg expression was significantly increased
in breast, infiltrating lobular and ductal carcinoma, ovarian serous carcinoma,
gastric adenocarcinoma, colon, lung, brain, colon, rectal, ovarian, oral squamous
carcinoma as compared to normal tissue or benign tumors [54]. However these
studies utilized immunohistochemical methods, using c-Abl antibodies, without
the presence of Abl knockout cells as proper control. c-Abl antibodies cross-react
with a lot of other proteins; thus experiments were needed to show antibody
specificity. Also, expression of Abl kinases does not necessarily correlate with
their activation status due to tight regulation of the proteins [54]. Forced high
levels of c-Abl induce its constitutive activation, but such mode of action has not
been demonstrated in solid tumors. Immunohistochemical analyses using c-Abl
and Arg antibodies does not allow for the examination of activation status of Abl
kinases in solid tumors

since specific phospho-Abl antibodies are not

commercially available, as all the phospho- specific c-Abl antibodies cross react
with phospho-EGFR and/or PDGFR [54]. These shortfalls have been overcome
by our laboratory, which suggests that pCrk/CrkL can be used as a read out of
Abl kinase activity as inhibition of Abl kinases with imatinib mesylate in many
breast cancer and melanoma cell lines suppress pCrk/CrkL levels in a dosedependent manner similar to silencing c-Abl and Arg [55].
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Our laboratory was the first to show that Abl kinases are activated in solid
tumors. We showed that Abl kinases are activated in breast cancer cell lines
relative to human mammary epithelial cells by performing in vitro kinase assay,
using GST-Crk as a substrate [55]. Using in vitro kinase assay, other labs have
also shown that Abl kinases are activated in cancer cell lines [56,57]. Using
kinase assays we also showed that activation of c-Abl/Arg did not correlate to the
expression of Abl kinases in breast cancer cells, indicating that expression does
not correlate with activation [55].
Using pharmacological and siRNA approaches our lab has previously
showed that constitutive active IGF-1R, Her-2, EGFR and Src activate Abl
kinases in melanoma and breast cancer cell lines, providing evidence that
mutation or chromosomal translocation is not the mode of activation of Abl in
solid tumors [55]. Human breast cancers have aberrant constitutively active
EFGR family members [54, 55]. Abl kinases are activated by EGFR in breast
cancer cells, the SH-2 domain of c-Abl and Arg bind to EGFR directly and the
binding is EGF inducible [55]. Constitutively active SFKs also induce the
activation of c-Abl in breast cancer cell lines [55]. Inhibition of RTK/SFK did not
completely abolish c-Abl/Arg activities indicating that some other signaling events
are also necessary for c-Abl/Arg activation [55]. Results from our lab also
showed that PDGFR activates Abl kinases in glioblastoma cells and supporting
studies by Furlan et al., demonstrated that Abl kinases are activated downstream
of c-Met in gastric and hepatocarcinoma cells [58].
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1.2.4 Role of Abl kinases in solid tumor development and progression
Results from our laboratory provide evidence that c-Abl/ Arg activities were
highest in triple-negative [Estrogen receptor negative (ER-), Progesterone
receptor negative (PR-) and Her-2 negative] breast cancer cells (BT-549, MDAMB-231 and MDA-MB-468), and Her-2+ breast cancer cell lines as compared to
MCF-7 a non invasive, ER+/PR+/Her-2- cell line [55]. In the breast cancer panel
cell

lines

tested

(MDA-MB-468

and

MDA-MB-231)

Abl

kinases

were

predominantly cytoplasmic [59], which is consistent with them having tumor
promoting functions rather than suppressive functions. Triple-negative breast
cancers are the most aggressive as compared to other breast cancers and
patients harboring these tumors have the worst prognosis [60, 61]. Some triplenegative breast cancer cells, which are highly invasive and metastatic, have
activated c-Abl/Arg. Activation of Abl/Arg promotes matrigel invasion, endothelial
cell proliferation, angiogenesis and invadopodia formation of MDA-MB-231 cells
[62]. Src was shown to activate Arg kinase activity, promote degradation of the
extracellular matrix, and mediate invasion of MDA-MB-231 breast cancer cells
[63]. Abl kinases also mediate anchorage-independent growth and proliferation of
triple-negative, MDA-MB-468, MDA-MB-231 cells and proliferation in BT-549
cells [64]. Abl kinases promote matrix degradation, survival in response to serum
deprivation and motility in triple negative breast cancer cells but no animal
studies have been conducted to determine whether Abl kinases promote breast
cancer metastasis. There also have been no studies directed to determine
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whether Abl kinase activation is associated with grade or stage of breast cancer
progression.
In human non-small lung cancer cells, FUS1, a tumor suppressor, inhibits
c-Abl kinase activity. FUS1 expression is lost in primary lung cancers and the
majority of small cell lung cancer and NSCLC tumor samples have been shown
to have loss of FUS1 expression [57]. However, it is not clear whether Abl
kinases might be activated via this mechanism in other type of cancers. In
prostate cancer cells aberrant activation of Abl kinases by PDGFR induced cells
survival by the inducing expression of the anti-apoptotic protein MCL-1 in a
p68/β-catenin dependent manner [65]. This evidence points towards a role for
Abl kinases in lung and prostate cancer progression.
Although the role of Abl kinases in many solid cancers is established,
there is little information regarding whether Abl kinases are important in
melanoma progression. MDA-MB-435s cells, originally thought to be of breast
cancer origin, were recently identified as melanoma M14 cells [66]. Prior to its
identification as a melanoma cell line, our lab utilized this cell line as a breast
cancel model and showed that Abl kinases are activated downstream of receptor
tyrosine kinases and promote matrigel-invasion and proliferation [55,64]. cAbl/Arg also are activated in metastatic murine melanoma cells (B16F10) relative
to its non-metastatic counterpart (B16F0), and likewise c-Abl/Arg promoted
invasion and matrix degradation [62]. Inhibition of Abl kinases by imatinib
repressed B16F10 tumor growth; and imatinib cooperated with dacarbazine to
restrict B16F10 metastatic progression [67, 68]. Imatinib also inhibited
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proliferation of melanoma cell lines expressing Abl kinases, c-Kit and/or PDGFR,
but the authors did not examine the activities of c-Abl and Arg in these cells [69].
The above studies utilized murine melanoma cells not human melanoma cells
and also none of the above studies other than those performed by our laboratory,
addressed the dependence of these effects on c-Abl/Arg.
Inhibition of SFK by dasatinib, a drug that targets c-Abl and Arg and SFKs,
in

human

melanoma

cells,

decreased

migration,

invasion

and

matrix

metalloproteinase-9 expression; however the authors did not address whether
the effects on invasion and migration were mediated by inhibition of Abl kinases
by dasatinib [70]. Imatinib mesylate showed no effect on tumor growth of
melanoma cells expressing PDGFRα and β injected subcutaneously in nude
mice [71]. These results do not negate the hypothesis that active Abl kinases
may promote melanoma progression and metastasis as none of these studies
probed the activation status of Abl kinases nor did they investigate the effect of
imatinib mesylate or nilotinib on metastasis.
To investigate the effects of Abl kinase inhibitors on metastasis, metastatic
melanoma patients treated with imatinib mesylate for 2 weeks showed decreased
expression of Abl, Arg,c-Kit and PDGFR in their tumor biopsies as compared to
the starting time of enrollment in the study however the authors did not address
the activity status of these molecules [72]. In a human uveal melanoma model,
rabbits were injected with human uveal melanoma cells, treated with imatinib
mesylate, primary tumor cells extracted and re-cultured. Cells from imatinibtreated animals had a lower proliferation rate and were less invasive as
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compared to the controls. The imatinib mesylate-treated cells also had
upregulated expression of SERPINB5, aa tumor suppressor gene, and KISS1, a
metastasis suppressor gene as compared to the vehicle-treated cells. Although a
direct correlation between Abl kinases and the metastasis suppressor gene was
not investigated, it could be a plausible mechanism by which Abl kinases
promote melanoma metastasis [73].
Although our lab previously described that Abl kinases promote melanoma
cell proliferation and invasion, there are no reports that elucidate the mechanism
by which Abl kinases promote melanoma cell invasion. In addition, although Abl
kinases upregulate all the in vitro processes of cancer progression but there are
no studies that test whether Abl kinases promote cancer metastasis. To validate
that Abl kinase inhibitors can be used to treat melanoma patients, the
mechanisms by which Abl kinases promote melanoma progression need to be
identified. The current study will elucidate several mechanisms by which Abl
kinases promote melanoma cell invasion and metastasis.

20

1.3

STAT3

1.3.1 Structure, activation and role in cancer progression
The signal transducers and activators of transcription factor (STAT) family of
transcription factors are composed of seven members STAT1-4, STAT5a, 5b and
STAT6. All the family members have six distinct structural domains, which are
phosphorylated during activation of STATs by growth factor receptor tyrosine
kinases (EGFR), cytokine receptor-associated Janus kinases (JAKs), and Src
kinases. Generally STATs exist as monomers in the cytoplasm and upon
phosphorylation form a STAT: STAT dimer via reciprocal phospho-Tyr (pTyr)SH2 domain interactions. The dimer translocates to the nucleus and acts as a
transcription factor inducing expression of various genes involved in proliferation,
survival, invasion, differentiation, development and inflammation (Figure 1.3)
[74,75].
STAT family member proteins do not all share the same function in the
progression of cancer. STAT1 has been shown to have tumor suppressor
functions [76] and STAT1 deficient mice are susceptible to infection with
microbial pathogens and lack interferon responsiveness [76]. In contrast, one
study showed that STAT1 has tumor promoting functions as silencing STAT1 in
B16F1 cells led to a less aggressive tumor phenotype and decreased lung
colonization of tumors cells [76]. These results indicate that the role of STAT1 in
cancer progression might be tumor cell specific and more studies are needed to
decipher the role of STAT1 in cancer progression. STAT5 another member of
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Figure 1.3 Activated STAT3 signaling promotes cancer metastasis. STAT3
is activated by growth factors, cytokines, Src and Abl kinases by phosphorylation
of a tyrosine residue on STAT3. Phosphorylation of STAT3 results in its
dimerization and translocation to the nucleus and binding to DNA in a sequence
specific manner to upregulate genes involved in proliferation, survival, invasion
and angiogenesis. Figure adapted from Suyun Huang, Clin Cancer Res 2007;
13:1362-1366 [75].
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this family is reported to regulate the transcription of bcl-xl, mcl-1 and cyclin D1 in
similar fashion as STAT3. STAT5 has been reported to promote the progression
of CML, and myoproliferative diseases induced by TEL-JAK2, and BCR-Abl
activates STAT5 [77]. Constitutive STAT5 signaling enhances squamous cell
carcinoma invasion and tumor growth [78], indicating that STAT5 promotes
cancer progression. A seminal study from Bromberg et al., has showed that
constitutively active STAT3 alone can transform immortalized fibroblasts and
induce tumor formation in nude mice, establishing STAT3 as an oncogene [79].
In contrast to other STAT isoforms, loss of STAT3 from mice is embryonic lethal
due to a defect in visceral endoderm function [77, 80].
STAT3 is activated by the cytokine, interleukin-6 and tyrosine kinases, like
BCR-Abl, EGFR, PDGFR, FGFR and Src [77]. Unlike normal cells, many human
cancers have constitutively active STAT3, which promotes invasion and
metastasis of cancer cells [74, 76, 77, 80, 81]. Phosphorylation of tyrosine 705
and serine 727, in response to various cytokines and growth factors activates
STAT3. Constitutive activation of STAT3 is associated with poor prognosis in
many cancers [76, 81]. Activated STAT3 regulates the expression of genes
which mediate proliferation (c-myc, Cyclin D1), inhibit apotosis (Bcl-xL, survivin),
and promote invasion and metastasis (matrix metalloproteinases) [75, 76].
Constitutive activation of STAT3 also promotes Cyclin D1 upregulation in many
forms of cancer [75, 76]
In the majority of human melanoma cells and in primary tumors,
constitutive DNA-binding of STAT3 is reported whereas matched normal skin
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specimens from the same patient lacked this activity indicating the presence of
activated STAT3 in melanoma [82]. Using poorly immunogenic B16 melanoma
tumor cell line, Niu G et al., showed that injection of B16 cells harboring a
dominant negative STAT3 in mice, lead to significant inhibition of tumor growth
followed by tumor cell apoptosis. Dominant negative STAT3 cells are arrested in
the G0-G1 phase of the cell cycle [86]. Inhibition of STAT3 signaling in melanoma
cells also induces the release of TRAIL, a soluble factor which can promote
apoptosis and cell cycle arrest [83]. p53, a commonly studied tumor suppressor,
inhibits cell proliferation and induces apoptosis in cancer cells. p53 is often
mutated in cancer and in large number of cancer cell lines, including melanoma
[85]. Some cancers can progress without p53 mutation and some tumors have
been detected with no p53 mutations but have lower expression of p53. This
phenomenon was explained by the fact that STAT3 directly interacts with the p53
promoter and inhibits the transcriptional activity of p53. Blocking STAT3 activity
in human melanoma cells induced p53-mediated cancer cells apoptosis [84].
These results indicate that activated STAT3 signaling is a negative prognostic
factor in human cutaneous melanoma.
Accumulating evidence demonstrates that STAT3 has role in cancer cell
invasion and metastasis [74, 75, 79, 81]. High STAT3 activation was reported in
human brain melanoma specimens and constitutively activated STAT3 is
required to form brain metastasis because of increased invasive potential of
these cells conferred by STAT3 activation [87]. In melanoma cells, STAT3
promotes invasion by transcriptionally activating Matrix Metalloproteinases -2
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(MMP-2). Blocking STAT3 activity in melanoma cells suppressed MMP-2
expression and downregulated invasion, and inhibited tumor growth and
metastasis in nude mice [88]. STAT3 has also been reported to promote the
expression of MMP-1 and 9 in human cancer cells [89, 90]. In pancreatic cancer,
cells harbouring STAT3 shRNA had reduced tumor growth cell invasiveness,
microvessel density and had reduced expression of collagen degrading enzyme,
MMP-7 [91]. Furthermore, silencing STAT3 activity with a specific Janus Kinase
inhibitor, AG490, repressed invasion and also led to decreased MMP-2
expression [92].
Proliferation and resistance to apoptosis in an intrinsic ability of cancer
cells, and the ability to survive in close proximity of a capillary and to produce
new blood vessels for survival is a must for cancer cells to metastasize. Cancer
cells stimulate the formation of new blood vessels via a process called
angiogenesis. STAT3 has been shown to directly promote transcription of
vascular endothelial growth factor (VEGF), the most potent angiogenesisinducing signal [93, 94]. Forced expression of a constitutively active form of
STAT3 into B16 murine melanoma cells, upregulated the expression of VEGF
and increased tumor vascularization when cell were injected in vivo [93]. STAT3
also is required for VEGF upregulation by Src, Her2/Neu and IL-6 [77, 93, 95]. To
summarize these findings, constitutively active STAT3 promotes cancer cell
survival, proliferation and invasion, which gives mechanistic insight as to how
cancer cells can bypass programmed cell death, and promote invasion and
metastasis.
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Suppressor of cytokine signaling 3 (SOCS-3), a natural inhibitor of STAT3
signaling is negatively correlated with phospho-STAT3 levels in melanoma
patents, also suggesting that deregulated STAT3 may play a significant role in
the development of human cutaneous melanoma [96 ]. SHP-2 and PIAS-3,
function as negative regulators of STAT3 signaling and are expressed at high
levels in normal cells as compared to cancer cells [77, 97]. Curcumin, a proven
anti-cancer agent, has been shown to inhibit STAT3 activity in ovarian cancer
cells by upregulating the expression of PIAS-3 [98], and PIAS inhibits the DNA
binding ability of STAT3. These results indicate that upregulating negative
regulators of STAT3 signaling can be used to as approach to block activated
STAT3 to prevent cancer progression.

1.3.2 Targeting STAT3 in solid tumors
Various approaches have been utilized to inhibit STAT3 signaling in cancer
treatment. Inhibitors of STAT3, which target SH2 domain sequences and prevent
dimerization of STAT3, inhibit malignant cell growth, increase apoptosis and
decrease invasion in a wide variety of cancers such as breast, prostate, lung
cancer and glioblastoma cell lines [74]. In addition, novel platinum inhibitors (IV)
designed to target the DNA-binding domain of STAT3, have been shown to
inhibit STAT3 dependent transcription of Cyclin D and Bcl-Xl and thus inhibit cell
cycle progression and proliferation in breast cancer, prostate cancer and lung
cancer cell lines [76]. A variety of plant polyphenols like resveratrol and circumin
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have shown promise in blocking STAT3 signaling and inhibit cancer progression
[76]. Moreover, FLLL32, a structural analogue of the natural product circumin,
interacts with the SH2 domain of STAT3 and inhibits its phosphorylation and
dimerization, inducing apoptosis and inhibiting VEGF production in human renal
cell carcinoma cells [101]. Some small molecule STAT3 inhibitors (Static, S-3I201) also have shown promise in inducing apoptosis in cancer cells. S-3I-201
inhibits the formation of STAT3:STAT3 complexes and STAT3s DNA binding and
transcriptional activities, and inhibits anchorage independent growth, induces
apoptosis, and xenograft regression of human breast cancer cells containing,
activated STAT3 [102].
All these data establish STAT3 as a potential drug target in cancer
patients. Our lab has shown that Abl kinases activate STAT3 in melanoma cells
independent of Jak [64] however the mechanisms by which Abl kinases mediate
STAT3 activation is unknown. This study will identify the mode of STAT3
activation by Abl kinases and also identify downstream genes affected by Abl
kinase-mediated activation of STAT3 during melanoma invasion and metastasis.
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1.4

Matrix Metalloproteinases

1.4.1 Structure and function
Matrix metalloproteinases (MMPs) aid in the degradation of ECM promote
invasion and metastasis [103-105]. MMPs play a major role in ECM remodeling
in a variety physiological progress including development, rheumatoid arthritis,
pulmonary emphysema, and tumor invasion and metastasis [103-105]. Active
MMPs are secreted from the stromal compartment surrounding the tumor (such
as connective tissue, fibroblasts, endothelial cell, osteoblasts, macrophages and
neutrophils), and cancer cells utilize these stromal-secreted MMPs to invade the
matrix [104, 106]. MMP secretion by the tumor cells also promotes invasion and
metastasis [104].
The MMP family consists of 26 different members which are zincdependent endopeptidases. Most MMPs have four distinct domains, consisting of
the N-terminal pro-domain, catalytic domain, hinge region and the C-terminal
hemopexin-like domain (Figure 1.4). Among the 26 MMPs, 6 are membrane-type
MMP (MT-MMPs) which have additional transmembrane domain which anchors
them to the cell surface [104,107,108]. MMP-7 is the smallest member of the
MMP family, as it lacks a C-terminal domain. The propeptide domain contains a
highly conserved sequence PRCGxPD, and the cysteine in this sequence forms
a covalent bond with a catalytic zinc ion, maintaining the pro-form in a latent form
[112]. A proline rich hinge region links the catalytic domain to the C-terminal
hemopexin domain [104, 107,108] as depicted in Figure 1.4. MMPs are secreted
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Figure1.4: Domain structures of human MMPs (Adapted from Risto Al-aho
and Veli-Matti Kahari, Biochemi 87(3-4) 2005
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in inactive forms and are activated by serine proteases like plasmin as well as by
other MMPs in the extracellular environment [104,110,111]. Under normal
physiological conditions, MMP activity is controlled either by endogenous MMP
inhibitors (TIMPs) or via transcriptional regulation [108,110,112].MMPs have
substrate selectivity for various matrix proteins. Collagenases (MMP-1, -3 and 13) cleave fibrillar collagen of type I, II, III, V and lamin. Stromelysins (MMP-3
and 10) degrade collagen II, III, IV, IX, fibronectin, laminin and elastin and also
activate MMP-1 and 7 [104, 105, 107, 112]. Gelatinases, consisting of MMP-2
and 9 can degrade components of the matrix membrane like gelatin and collagen
IV, and thus, are widely studied for their role in tumor progression. Melanoma
cells injected in mice deficient in gelatinase-A (MMP-2) showed reduced tumor
progression [113].

1.4.2 Role of MMPs in cancer invasion and metastasis
The presence or elevated protein levels and transcript of MMP-1, 2, 3,
7,9,14, in both primary tumors and/or metastasis, positively correlate with tumor
progression and poor disease prognosis in pancreatic, breast, cervical, colorectal
and melanoma [105, 108,100,111,114]. There also is a significant elevation of
MMP levels in metastatic nodules as compared to primary tumors or tumor cells
in cultures [105]. Naglich J et al., reported inhibition of tumor growth in a murine,
B16BL6 model of experimental metastasis by a MMP-1, 2, 7 9 and 14 potent
inhibitor BMS-255291, indicating that MMP activities promote melanoma invasion
and metastasis. Increased expression of MMP-2 and 9 also has been positively
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correlated with increased melanoma invasion and progression, [115] however
MMP-1 has also been identified as one of the most highly upregulated MMPs in a
variety of cancers [105,110]. MMP-1 degrades collagen I, the main component of
ECM and is regarded a prognostic marker for melanoma and breast cancer
[116,117].
Previously, it was widely accepted that MMP-1 was secreted by the
stromal cells surrounding the tumor cells but in the last decade experiments have
shown expression of MMP-1 by the cancer cells themselves as well, indicating a
role for stromal and tumor-secreted MMP-1 in tumor progression [105,118].
Expression of MMP-1 in cancer cells as detected by immunohistochemistical
methods has been associated with a poor prognosis of colorectal carcinoma
patients [119]. Patients with MMP-1 -positive metastases had significantly shorter
disease-free survival than patients with MMP-1 negative metastasis and patients
with MMP-3-positive metastasis also had the same out come as MMP-1 positive
metastasis patients [117]. Furthermore, MMP-1 levels increase during colon
cancer progression and higher levels are associated with shorter disease free
survival [120]. Boire et al., showed that fibroblast-produced MMP-1 activated the
G-protein coupled Protease Activated Receptor (PAR-1) on breast cancer cells to
promote invasion and metastasis [121]. These results indicate that MMP-1 play
an important role in cancer progression. Elevated expression of MMP-1 and
MMP-13 is associated with increased invasion of primary melanomas [122].
shRNA mediated inhibition of MMP-1 reduced metastasis of melanoma cells to
the lungs, but did not affect primary tumor growth. Tumor cells expressing MMP-
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1 shRNA also showed marked reduction in collagenase activity and angiogenesis
[123]. MMP-1 is only expressed in VGP melanoma, its activity promotes
melanoma invasion and metastasis and expression of MMP-1 can convert RGP
melanoma to VGP [123-125]. PAR-1 is expressed in VGP melanoma and MMP-1
activates PAR-1 in an autocrine signaling manner in melanoma cells and
upregulates tumor cell invasion [124]. Summarizing these results, MMP-1 plays
an important role in melanoma, breast and colon cancer progression.
MMP-14, also known as MT1-MMP, another extensively studied MMP, is
over expressed in many tumor types and is a marker for poor patient prognosis
[105, 126,127] MMP-14 degrades interstitial collagens, such as type I, which is
highly resistant to proteolysis due to its complex helical structure [129-131]. Mice
deficient in MMP-14 show severe growth defects like dwarfism, and connective
tissue disease due to the inability to degrade and process intestinal collagen
required in bone and soft tissue formation [132]. A selective MMP-14 peptideinhibitor effectively inhibits migration and invasion of melanoma, or tongue
carcinoma cells and also increases the survival of tumor bearing mice [133].
Along these same lines Devy L et al. showed that DX-2400, a selective antibody
inhibitor to MMP-14, inhibited angiogenesis, slowed breast cancer tumor
progression and metastasis by inhibiting proteolysis and also blocked proMMP-2
processing [134]. MMP-14 cleaves pro-MMP-2 to activate MMP-2 [105,107].
Moreover

Src

kinases

phosphorylate

MMP-14

on

Tyr573,

and

this

phosphorylation event is essential for tumor cell invasion of 3D collagen matrices
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and impaired tyrosine phosphorylation completely inhibits tumor growth in mice
[128]. These results indicate a role for MMP-14 in cancer progression.
In summary, MMPs play an important role in cancer progression, and
specifically in melanoma progression. Prior to our studies no one has linked
activation of Abl kinases to MMP expression. This study will give mechanistic
insights on how Abl kinases promotes melanoma invasion by demonstrating that
they increase MMP expression.

1.4.3 TIMPs
The TIMP family (TIMP-1-4), which initially were thought primarily to be only
endogenous inhibitors of MMPs, bind to MMPs in a 1:1 stiochiometric ratio to
inhibit the matrix degradative function of MMPs [106]. However, in recent years it
has become clear that TIMP-1 has a pro-metastatic function as it is overexpressed in lung, ovarian, breast cancer and this is correlated with decreased
survival and a poor clinical outcome [135]. These findings suggest that TIMP-1
may play a positive role in tumor progression depending on the tumor
environment or the TIMP-1 expression level in the tumor cell. TIMP-1 levels
positively correlate with melanoma cell migration rate [136] and TIMP-1 levels
are higher in unresected stage IV melanoma patients as compared to patients
with resected stage I/II disease [137]. Moreover, TIMP-1 overexpression in
murine melanoma cells decreased tumor latency and increased tumor volume
and metastatic potential [138]. Furthermore, TIMP-1 expression is elevated in
metastatic melanoma as compared to primary melanoma samples, [138]
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indicating that TIMP-1 may exert a metastasis stimulatory function rather than a
metastasis inhibitory function.
The TIMP-1 literature is very contradictory as TIMP-1 has been shown to
induce proliferation in lung and breast carcinoma cells, [135,139] whereas in
MCF-10A, breast epithelial cells, TIMP-1 inhibits cell growth by stabilizing the
cells cycle regulatory protein, p27 [140]. TIMP-1 also has anti-apoptotic effects
independent of its ability to inhibit MMPs [135]. The growth stimulatory function of
TIMP-1 is dependent on TIMP-1- mediated stimulation of the MEK/ERK and p38
kinase pathway [135,141] .TIMP-1 induces the phosphorylation of Akt in breast
carcinoma T47D and MDA-MB-231 cell lines [141,142], indicating that it can
induce activation of the Akt/Bad/Bcl-2 cell-survival pathway and thereby prevent
activation of the caspase cascade. TIMP-1 protects MCF-10A cells from
apoptosis induced by TRAIL, radiation, cell detachment, serum starvation and
chemotherapy treatment by upregulating the FAK/PI3K pathway [143,144].
Not much is known whether or not TIMP-1 has a metastasis-promoting
role in melanoma and the mechanism by which TIMP-1 transcription and
expression is upregulated. This study will shed light on how TIMP-1 expression is
regulated in melanoma cells.
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1.5 NM23
1.5.1 Metastasis suppressor genes
A classical metastasis suppressor gene is one that can suppress the cascade of
metastasis without effecting tumor growth rate. In 1988 seminal experiments by
Steeg et al identified NM23-H1 as a novel metastasis suppressor gene by colony
hybridization studies. They injected seven cell lines derived from a K-1735
murine melanoma cell line in syngenic and nude mice and noticed that all formed
primary tumors but some cell lines had less noticeable metastasis as an end
point. Using differential gene expression studies, they found that NM23 was
highly expressed in the cell lines with lesser metastasis as compared to the ones
which had more metastatic nodules. Re-expression of NM23-H1 suppressed
metastasis without effecting tumor growth in mice [145-149]. Moreover
hepatocarcinoma cells injected in murine homologue of NM23-H1, NM23-M1
knockout mice, did not show any change in primary tumor size but had a
significant increase in metastatic burden [150].
Even though a negative correlation is observed with NM23-H1 expression
and metastatic capacity in melanoma, breast, gastric carcinoma and colon cells
[147-149, 151], there is a positive correlation in testicular, thyroid, prostate and
renal carcinoma, indicating that NM23-H1 might play different roles in different
tissue types [151]. Also, NM23-H1 is dramatically overexpressed in primary
tumors as compared to the late metastatic stages, indicating a dual role of NM23
in cancer progression [151]. More studies are needed to understand this dual
behavior of NM23-H1 in cancer.

35

More recently, studies have focused on identifying other metastasis
suppressors, leading to the isolation of MMK4, KAI1, KISS1, CRSP3 and
VDUP1. Metastasis suppressors affect many aspects of the metastasis cascade
including invasion, cell-cell communication, growth-factor-receptor signaling and
transcription [152]. KAI1, a metastasis suppressor found in prostate and breast
carcinoma attenuates EGF-induced migration [153-155]. MKK4, another example
of metastasis suppressor in prostate and ovarian cancer, suppressed invasion of
ovarian

cancer

cells

by

inactivating

EMT

via

the

downregulation

of

phosphorylated NF-κB, Twist and upregulation of E-cadherin [156].

1.5.2 NM23-H1 inhibits cancer progression
To date, ten different human NM23 members (NM23-H1-10) have been
reported but among them NM23-H1 and H2 are abundantly expressed and
widely studied in terms of their roles in attenuating cancer progression [148],
NM23-H1 and H2 are highly homologus and share 88% amino acid identity, but
have distinct functions . NM23-H1 possesses three enzymatic activities in vitro:
1). Nucleotide diphosphate kinase (NDPK) activity; 2). Histidine protein kinase
activity and 3) 3’-5’ exonuclease activity [157]. In breast carcinoma histidine
kinase activity was shown to be essential for suppressing metastasis and also 3’5’ exonucleases confer proofreading function in DNA replication and repair.
Recently Zhang et al established that disrupting the exonuclease activity of
NM23-H1 inhibits the metastasis suppressor function of NM23-H1 in melanoma
cells [158].
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NM23-H1 silencing disrupted the normal epithelioid clustering of human
liver cancer cells by altering E-Cadherin/ catenin- mediated intracellular adhesion
and inhibition of NM23-H1 promotes migration and invasion in cancer cells [159 ].
NM23-H1 expression is inversely correlated with LPA receptor EDG2 expression,
and overexpression of EDG2 restored motility in NM23-H1-overexpressing breast
cancer cells [160]. Overexpression of NM23-H1 also partially abolished cell
motility of MDA-MB-435 breast cancer cells towards chemoattractants such as
serum, IGF and PDGF and also attenuated anchorage-independent growth [159163. Similar effects of NM23-H1 have been reported in breast cancer, colon and
prostate cancer cells [149,160]. NM23-H1 also plays a significant role in
suppressing in vitro cancer cell invasion through Matrigel components. Silencing
NM23-H1 increased the ability of human liver cancer cells to degrade the type I
collagen matrix and invade through gelatin and matrigel [159,160].
ER-α-positive breast cancer cells express more NM23-H1 as compared to
ER-α-negative cell lines, [164,165] indicating that NM23-H1 could be activated by
Estrogen or its receptor. NM23-H1 interacted directly with ER-α and altered
estrogen-induced gene transcription [164]. NM23-H1 has been reported to
transcriptionally repress PDGF-A promoter activity in lung carcinoma cells [166],
indicating that NM23-H1 can alternatively bind to promoters of oncogenes and
repress their metastatic activity. These results indicate that silencing NM23-H1
promotes invasive capacity of cancer cells by downregulating several metastasisassociated genes.
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Since the discovery of NM23-H1 and its anti-metastatic capacity research
has focused on determining out how this gene could be re-expressed to block the
metastasis cascade. Many compounds like estradiol and idomethacin elevated
NM23-H1 expression in non-metastatic to low metastatic breast cancer cells but
failed

to

increase

NM23-H1

expression

in

metastatic

cells

[165,167].

Medroxyprogesterone acetate (MPA), a glucocorticoid receptor agonist increased
NM23-H1 expression, by elevating the NM23-H1 promoter activity, in
progesterone receptor-negative and glucocorticoid receptor-positive, MDA-MB231 and MDA-MB-435 breast cancer cells [168]. Treatment with MPA
suppressed anchorage independent growth of breast cancer cells and also
reduced the metastatic colonization of breast cancer cells in mice [168,169]. As
an alternate approach, gene therapy was tested to elevate NM23-H1 levels.
Using an adeno-associated virus in an ovarian cancer mouse model, Li et al.,
demonstrated that efficient (95%) delivery of the NM23-H1 gene resulted in the
reduction of the number of animals having detectable lung colonization and a 35
day increase in the median survival time as compared to the control group [170].
Clinical trials based on the hormonal activation of NM23-H1 are also in progress
[171]. In a recent study, Lim et al., demonstrated that the NM23-H1 protein
coupled to a macromolecule transduction domain (MTD), which promotes protein
uptake by cultured cells, inhibits the metastatic phenotype of breast, melanoma
and lung cancer cells lines. Furthermore, systemic delivery of NM23-MTD
inhibited lung metastasis and also eliminated previously established pulmonary
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metastasis in mice [172]. Summarizing these results, NM23-H1 inhibits
metastatic capability of various cancers.

1.5.3 NM23-H1 and endocytosis
In MDCK cells, NM23-H1 plays an important role in endocytosis of
different proteins. NM23-H1 is recruited to the adherens junction by ARF6
GTPase, resulting in endocytosis of E-Cadherin, adherens junction disassembly
and downregulation of Rac-1 GTP activity [173]. Drosophila NM23, abnormal
wing disc (awd) promotes synaptic vesicle internalization by activating dynamin
[174]. In another study Dammai V et al., showed that awd and dynamin are
recruited to the cell membrane, endocytose FGFR, and modulate RTK signaling
to regulate programmed epithelial cell migration in Drosophila trachea [175].
Additionally in Dictyostelium, NM23-H1 reduces both macropinocytosis and
exocytosis, thus increasing the longer residence time of these vesicles and thus
more complete digestion of the nutrients present in the vesicles [176]. These
data demonstrate that NM23-H1 aids endocytosis of various oncoproteins and
thus provide one plausible mechanism for its metastasis suppressor function.
Although, it is well established that NM23-H1 acts a metastasis
suppressor in melanoma and many other cancers, but there is no explanation for
how this protein is lost during in late stages of cancer progression. Mechanistic
studies are needed to demonstrate the mechanism by which this protein is
degraded in highly aggressive and metastatic human cancer cells.
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1.6 Cathepsin Lysosomal Proteases
1.6.1 Activation and processing of cathepsins
The class of cysteine lysosomal proteases is composed of eleven family
members, all of which share a conserved active site formed by cysteine and
histidine residues. These proteases called cathepsins are secreted into the
extracellular milieu by tumor cells and aid in cancer progression [177].

The

majority of cathepsins are ubiquitously expressed in human tissue and play
important roles in protein degradation and turn over [178]. Cathepsins are
synthesized as inactive precursors. The signal peptide is cleaved in the
endoplasmic reticulum, the protein transported to the Golgi, and in the Golgi the
mannose residues are phosphorylated. Cathepsins enter the endocytic pathway
by binding to the mannose-6-phosphate (M6P) receptors on the surface of
endosomes. In endosomes, cathepsins are cleaved into a single chain form and
then further cleaved into an active double chain form in the acidic lysosomes
(Figure 1.5) [178-181]. The lysosomal localization of cathepsins requires it to be
active in a slightly acidic pH. Cathepsins are inactivated at neutral pH, which
protects the neutral pH cytosol from accidental release of cathepsins [182].
Excess cathepsins that do not bind to the M6P receptor are exocytosed outside
the cell.
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Figure 1.5: Cathepsin structure and trafficking. The signal peptide in blue is
cleaved in the endoplasmic reticulum (ER), resulting in protein folding. In the
Golgi, the mannose residues are phosphorylated and form M6P, a rate-limiting
step. By binding to the M6P receptors on the surface of endosomes, cathepsins
enter the endocytic pathway and proteins that are not converted to the M6P form
are exocytosed. These extracellular cathepsins play an important role in invasion
and metastasis during cancer progression. The cathepsins in the endocytic
pathway are cleaved into a single-chain form in the late endosome, and further
cleaved in the acidic lysosomes to form heavy and light chain forms. Figure
adapted from Reisier J et al., J Clin Invest 2010; 3421-3431
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1.6.2 Physiological and cellular function of cathepsins
All cathepsin family members aid in protein degradation in the lysosomes. One
biological/physiological function of cathepsins is to promote apoptosis by
promoting protein degradation [179,180,182, 183]. Cathepsin B has been shown
to induce hepatocyte apoptosis via a caspase-8-dependent process and
cathepsin B knockout mice have reduced hepatocyte apoptosis [184]. In addition,
cathepsin B and L double knockout mice display a significant increase in
apoptotic neuronal cells in the brain [185], indicating that these two proteases
may compensate for each other in vivo. Cathepsin B has been shown to activate
apoptosis in hepatocytes, neuronal cells, and immune cells. During apoptosis
cathepsins are released from the lysosomes into the cytoplasm, where they
activate apoptotic pathways by cleaving the anti-apoptotic proteins Bid and Bcl-2,
thereby increasing the release of cytochrome C and activating caspases-8,
caspases-9 and caspases-3 [183, 186, 187]. Although there is a pleothora of
data, indicating that cathepsins can mediate caspase-dependent apoptosis, other
evidence suggests that cathepsins have anti-apoptotic functions. For example,
forced expression of cathepsin B has shown to protect cells from serum
deprivation-induced apoptotic death [188]. Furthermore, treatment with an
inhibitor of cysteine cathepsins was shown to promote apoptosis in cancer cells
[189]. Thus in some instances (perhaps in normal cells), cathepsin activation
promote apoptosis, while in other instances they prevent apoptosis. This rest of
this chapter will focus on the role of cathepsins during cancer invasion and
metastasis.

42

Increased cathepsin expression correlates with a poor prognosis in breast,
lung, ovarian, melanoma, and many other forms of cancer, and is associated with
a shorter survival in breast, colorectal, and head and neck carcinoma patients
[180,182]. Cathepsin upregulation has documented in many forms of cancer
such as breast, lung, gastrointestinal, colorectal, and melanoma, indicating they
have a role in invasion and metastasis [180,182]. Cathepsin upregulation can be
attributed to various mechanisms such as like gene amplification, presence of
transcript variants due to the presence of alternative promoters, and alternative
splicing. Transcriptional regulation of cathepsins, such as via increased
expression of transcription factors like Ets, Sp1, and Sp3, also promotes
cathepsin overexpression in tumor cells. Post-translation modifications due to
changes in mRNA stability also can increase the half-life of cathepsins, leading to
overexpression [190]. Another potential mode of increased cathepsin expression
in tumors is via downregulation of cystatin and serpins, endogenous inhibitors of
cathepsins [190]. In malignant cells, cathepsin expression can also be
upregulated by preferential overexpression of a splice variant with high efficiency
of translation [190]. Cancer cells upregulate cathepsins via any of these
aforementioned processes, and cathepsin overexpression promotes cancer
progression.
Excess cathepsins, which are secreted by tumor cells, aid in degradation
of extracellular matrix proteins, activate proteases (MMP), and inactivate TIMPs,
thereby promoting angiogenesis, invasion, and metastasis [178, 182, 190].
Extracellular cathepsins also promote invasion by degrading collagen. In the
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extracellular media the process that leads to activation of cathepsins are not well
understood. It is reported that procathepsin L is activated by heparan sulphate,
although activated cathepsins are also secreted by tumor cells [182,190,191].
Like MMPs, cathepsins can also activate each other in the extracellular milieu.
Inactive precursor forms of cathepsins also aid in the invasion of cancer cells
[190]. Expression of cathepsin L is elevated in the sera of metastatic melanoma
patients as compared to normal healthy population [192]. Secreted cathepsin L
promotes invasion, melanoma tumor growth and metastasis in nude mice [193].
Inhibition of cathepsin L reduces migration and invasion of melanoma cells, and
forced expression of cathepsin L in low tumorigenic and non-metastatic
melanoma cells confers metastatic abilities, indicating that cathepsin L activity is
required for melanoma metastasis [194,195]. These studies assume that the
invasion and metastasis-promoting role of cathepsin L is due to its secretion;
however, these studies did not exclude possibility that intracellular cathepsins
also are involved.
Cathepsin B also promotes invasion and metastasis of cancer cells.
Inhibition of cathepsin B delays lung metastasis in a MMTV- PyMT-induced
transgenic mammary carcinoma model reduces collagen I degradation and
inhibits bone metastasis of breast cancer cells [196-198]. Extracellular cathepsin
B also has been shown to increase breast cancer cell invasion by promoting
extracellular matrix degradation [199]. Although, the role of extracellular
cathepsins in promoting cancer cell invasion is widely studied, less is known
regarding how intracellular cathepsins promote invasion
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Lysosomal cysteine cathepsins have been shown to cleave proteins such
as collagen, laminin, a type IV collagen intracellularly, indicating a role for
intracellular cathepsin in cancer cell invasion [200-203, 207].

Invasive Ras

transformed MCF-10A, engulf collagen-IV, in vesicle-like structures and degrade
collagen intracellularly, in a cathepsin-dependent manner, thereby promoting
invasion [202]. Endothelial cells also endocytose and degrade collagen IV
intracelluarly in a cathepsin B-dependent manner, demonstrating its role in
neovascularization process [203]. Intracellular cathepsins also may promote
invasion and metastasis by cleaving the cell adhesion protein E-cadherin and
dynamin, which has a role in endocytosis [179,204]. Like cathepsin B, inhibition
of intracellular cathepsin L has been shown to repress carcinoma cell invasion
and metastasis (Lewis Lung cells). Furthermore, inhibition of intracellular
cathepsin L activation has shown to sequester IGF-1R in a sub-cellular
compartment and reduce its expression at the plasma membrane, resulting in
reduced metastatic propensity of Lewis Lung carcinoma cells, indicating that IGF1R signaling is mediated by the expression of cathepsin L [205, 206].
In Ras-transformed MCF-10A cells, inhibition of intracellular cathepsin B also
was shown to repress matrigel invasion. Inhibition of extracellular cathepsins in
these cells blocked invasion to same levels as blocking intracellular invasion,
indicating that, like extracellular cathepsins, intracellular cathepsins plays an
equally important role in invasion [207].
Several studies have shown that both the intracellular and extracellular
cathepsins promote invasion, indicating that the secretion of active enzyme and
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cathepsin-mediated intracellular degradation pathways are important [182].
However, while the role of extracellular cathepsins in promoting cancer cell
invasion is widely studied, less is known regarding how intracellular cathepsins
promote invasion. This project will determine the mechanism by which Abl
kinases upregulate intracellular cathepsin B and L to promote invasion and
metastasis in melanoma.
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1.7 Project Objectives and Aims
Previous studies from our lab and others have established that Abl kinases
play an important role in breast cancer invasion; however, there are no studies to
determine whether Abl kinases have a role in melanoma progression. Although
Abl kinases are shown to promote melanoma invasion, the mechanism of action
has not been unexplored. This study will identify mechanisms by which Abl
kinases promote melanoma invasion and investigate whether Abl kinases
promote melanoma metastasis. Two aims are intended to determine the role of
Abl kinases in melanoma progression:
1. Specific Aim 1: Determine whether c-Abl and Arg are activated in
melanoma cell lines and in primary melanomas and whether they promote
proliferation and/or survival under nutrient deprivation conditions. We will
ascertain downstream effector proteins, which mediate c-Abl and Arg
effects on melanoma survival, invasion and metastasis (Chapter Two).
2. Specific Aim 2: In parallel with the protein pathways investigated in
Specific Aim 1, we will also evaluate whether c-Abl and Arg mediate
melanoma invasion and metastasis via the downregulation of a metastasis
suppressor protein. We will also investigate the mechanism of c-Abl and
Arg-mediated degradation of the metastasis suppressor (Chapter Three).
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CHAPTER 2: c-Abl and Arg Are Activated In Human Primary Melanomas,
Promote Melanoma Cell Invasion, Single-Cell 3D Invasion, Proliferation,
Survival and Drive Metastatic Progression
2.1 Introduction
Metastatic melanoma is an uncurable disease as known chemotherapeutic
agents have a 5% success rate or do not extend survival beyond 10 months
indicating a dire need for development for new therapies [1-3]. For the
development of new therapies, identification of new targets are necessary. Data
from our lab and others have shown that Abl kinases are activated in breast
cancer cells and also in lung cancer cells [55]. In solid tumors, Abl kinases are
activated by receptor tyrosine kinases like PDGFR and EGFR in contrast to the
chromosomal translocation event found in leukemia, which renders constitutive
activation of Abl kinases; however the role of Abl kinases in melanoma
progression has yet to be identified [55].
MMP’s are known to play an important role in invasion of cancer cells by
degrading the extracellular matrix and several transcription factors have known
MMP promoter binding sites [215-216]. These transcription factors modulate the
function of several MMP’s and in-turn promotes invasion and metastasis of
cancer cells. MMP-1, 3 and 14 activities are elevated in several human tumors
and their expression is negatively correlated with patient survival [103-105, 114].
It is known that MMP-1 expression induces VGP expression in melanoma cells
and acquisition of the VGP phenotype is essential for melanoma metastasis
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[123-125 ].v-Src upregulates MMP-1 transcription in rabbit synovial fibroblasts
[208], and Src is also known to activate Abl kinases [55] indicating that Abl
kinases might also induce the transcription of MMPs.
Recent studies from our lab have shown that Abl kinases promote
invasion and also phosphorylate STAT3 in a Jak-independent manner in
melanoma cells [64]. STAT3 is known to induce VGP to RGP transition in
melanoma cells and STAT3 is constitutively activated in melanoma patients [81,
82, 86]. In colon cancer cells STAT3 activates MMP-1 by binding to the promoter
region of MMP-1 [209]. These results indicate that Abl kinases might promote
invasion in a STAT3-dependent manner. Herein, we will evaluate the molecular
mechanism of Abl kinase mediated invasion and also identify whether activated
Abl kinases promote invasion in melanoma cells.
Cancer cells have the unique ability to survive and proliferate in the
absence of serum [12, 13, 210] and survival in the absence of serum is an
important determinant for cancer cells to grow and proliferate in distant
metastasis sites and form macrometastasis. Excessive proliferation and survival
in the absence of serum are important for neoplastic development. Deregulated
proliferation is required for primary tumor growth and also for growth of
micrometastasis to macrometastasis [12, 13, 210]. When cells undergo apoptosis
molecular changes like cleavage of poly (ADP-ribose) polymerase (PARP) occur.
Prior to PARP cleavage, the cells undergoing stress activate caspases-3, which
mediates the cleavage of PARP into a 89 KDa fragment, resulting in PARP
inactivation and apoptosis [211, 212]. For cancer cells to survive in nutrient
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deprived conditions there has to be self-sufficiency of growth and also an ability
to escape apoptosis. BCR-ABL and v-Abl inhibit apoptosis of leukemic cells, and
Abl kinases promote survival of breast cancer cells in serum-free conditions [33,
64]; however, no one has tested whether Abl kinases-mediate melanoma survival
in serum-free conditions. Based on these evidences, we hypothesize that Abl
kinases promote melanoma cell survival. STAT3 is also known to promote
proliferation and survival in the absence of serum in many cancers and Abl
kinases drive proliferation and survival in absence of serum in breast cancers.
Here, we will test whether active Abl kinases promote proliferation or survival in a
wide range of melanoma cells and we will identify the mechanism of Abl kinasemediated mitogenesis.
Several pieces of evidence point towards a possible role for Abl kinases in
melanoma progression; however, prior to our studies there was no direct
evidence. Using 435s/M14 cells, our lab has shown that Abl kinases promote
proliferation, anchorage-independent growth and invasion of melanoma cells;
however, the mechanism remains to be explored. Along the same lines,
treatment of several melanoma cell lines with imatinib mesylate (STI571,
Gleevec) inhibited proliferation; however, since imatinib also inhibits c-Kit and
PDGFR in addition to Abl kinases, the imatinib target that promotes proliferation
was not determined [69]. Furthermore, imatinib also was shown to inhibit murine
melanoma tumor growth in a model that lacked c-kit and PDGFR [67, 78]. These
data provided the rationale for us to study whether Abl kinases have a role in
human melanoma progression. Here, in this study we demonstrate that Abl
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kinase expression is increased in primary melanoma and in melanoma cell lines
as compared to primary melanocytes. We show that activated Abl kinases
promote melanoma proliferation, invasion, survival and single-cell 3D invasion;
they promote invasion via distinct molecular pathways; and they potently drive
metastatic progression.

2.2 Materials and Methods
Cell Lines:
435S/M14 cells were obtained from University of North Carolina Tissue culture
Facility (Chapel Hill, NC), who purchased them from ATCC. WM239, WM278,
WM164, WM3248, SBCL2 were obtained from the Herlyn Lab (Wistar Institute,
Philadelphia). A375 cells were from Dr Suyan Huang (M.D Anderson Cancer
Centre, Houston, TX. Primary melanocytes were a kind gift of Dr John D’Orazio
(University of Kentucky, Lexington, KY). 435s/M14-GFP-Luciferase cells were
created by Lipofectamine 2000-mediated transfection with pcDNA-EGFP-N1
(Clontech, Mountain view, CA) and selecting with G418 (800µg/ml). Later these
435s-GFP cells were transfected with PGL3-Luciferase and selected with 600
µg/ml of Zeocin. pGL3-Luciferase (Promega, Madison,WI) was cloned into
pcDNA 3.1 Zeo using XbaI and HindIII, by sticky end ligation. Clones that were
Zeocin-resistant were picked and clones that were positive for GFP and
expressing high levels of luciferase activity were pooled to make the cell line.
WM3248-GFP cells were created by transfecting cells with pcDNA-EFGP-N1
followed by 200ug/ml G418 selection. The clones were pooled to make a
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polyclonal population and cells were sorted to make a stable GFP-positive cell
population. 435s/M14-STAT3CA cells were made by transfecting pRc-CMVSTAT3C (Addgene, Cambridge, MA) followed by G418 selection. Clones
expressing similar levels of Flag were pooled to make a stable polyclonal cell
line. Dr Divyamani Srinivasan, a previous graduate student of our lab,
established this cell line. 435s/MMP-1-GFP cells were obtained by stably
transfecting a MMP-1 plasmid (Origene, Rockville, MD), followed by selection
with G418 and sorted to obtain a high GFP positive population.

Reagents:
Antibodies directed against beta-actin, IGF-1R(C-20), Arg (9H5), alpha-tubulin,
PARP and c-Abl (K12; immunoprecpitation) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA); c-Abl (8E9; western blotting), and STAT3 was
procured from BD Biosciences (Chicago, IL). pSTAT3 (pY702), caspase-3 and
pCrkL/CrkL antibodies were purchased from Cell Signaling Technology
(Danvers, MA). MMP-1 and TIMP-1 antibodies were purchased from Millipore
(Billercia, MA).c-Kit antibody and recombinant MMP-1 was purchased from
Upstate Biotechnology (Lake Placid, NY). Antibodies to PDGFR were provided
by Dr Andrius Kazlauskas (Harvard University; Cambridge, MA). The Arg
antibody (16-04) used for immunoprecipitation was prepared by immunizing
rabbits using a sequence in the Arg C-terminus, DKDRPRRVKPK. MMP-3 and
MMP-14 antibodies and recombinant MMP-3 was obtained from Abcam.
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Pharmacological inhibitors to Abl kinases (imatinib a.k.a STI571, Gleevec and
nilotinib) were kind gifts from Novartis Pharmaceuticals, Basel Switzerland.
Imatinib was dissolved in water at a concentration of 10mM and frozen in aliquots
in -800C, while nilotinib was dissolved in DMSO at 10mM and stored in aliquots in
40C. Matrigel invasion assay chambers and collagen I was obtained from BD
Biosciences (Chicago IL) and IGF-1 was purchased from Upstate Biotechnology
(Charlottesville, VA).

Transfection and siRNA:
Cells were transfected with DNA or siRNA using Lipofectamine 2000, according
to the manufacturer’s protocol (Invitrogen, Grand Island, NY). Pre-validated
siRNA against Abl#1 (1336), Abl#2 (s866), Arg#1(1478), Arg #2(s872), MMP-1
(s8848), MMP-3 (s8853), MMP-14 (s8877), STAT3 (s742) and scrambled control
#1 were purchased from Applied Biosystems/ Ambion; Carlsbad, CA. Abl 1336
and Arg 1478 was used at 20nM concentrations and transfected on two
consecutive days to increase silencing efficiency. Abl s866 and Arg s872 and
STAT3 were used at 5nM and transfected only once. MMP-1, 3 and 14 were use
at 10nM and were transfected once.

Cell culture: MDA-MB-435S, originally thought to be of breast cancer origin, is
recently been identified as melanoma M14 [66]. 435s/M14 was grown in DMEM
supplemented with 10%Fetal Bovine Serum (FBS), 1mM Glutamine and 1%
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Insulin (1mg/ml). Melanoma cell lines were cultured in Tu 2% media (80:20
MCDB153:L-15 Media+ 2% FBS+ Insulin 5µg/ml and 1.68mM calcium chloride).
A375 cells were cultured in DMEM supplemented with 10% FBS and 1mM
Glutamine.

Serum starvation: Cells were washed three times in basal media, and
maintained in basal media containing glutamine deprived of insulin and FBS.

Cell lysis and western blotting: Cell lysates were prepared by lysing in RIPA
buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1% triton-X 100, 0.1% SDS, 1%
sodium deoxycholate, 1mM pefabloc,10ug/ml leupeptin, 10ug/ml aprotinin, 1mM
sodium orthovanadate, 25 mM sodium fluoride). Whole cell lysates were taken
and protein concentration was estimated using BCA method (Pierce) and protein
fractions were run on SDS-PAGE gels. Immunoblotting was performed according
to protocols from antibody manufacturers. Bands were quantified using
ImageQuant (GE Healthcare, Piscataway, NJ) on scanned blots.

Kinase assays [55, 64]: Two days after plating, the cells were serum starved
and lysed 20-24 hrs after starvation in a Triton-X-100 based lysis buffer(150mM
Nacl, 50mM Hepes pH7.0, 1% triton-X, 10% Glycerol, 1.5mM Mgcl2 , sodium
deoxycholate, 1mM pefabloc,10ug/ml leupeptin, 10ug/ml aprotinin, 1mM sodium
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orthovanadate, 25 mM sodium fluoride). 30µg of cell lysates were used to
immunoprecipitate c-Abl and Arg using K12 and 16-04 antibodies respectively.
Antibodies bound to protein A-sepharose beads were washed in four different
stringent buffers: two times with RIPA buffer (above) followed by two washes in
buffer#2 (10mM Tris pH7.4, 5mM EDTA, 1% triton-X-100 and 100mM Nacl) with
inhibitors. The complexes were again washed twice in buffer#2 without Nacl
followed by washing twice in kinase assay reaction buffer (20mM Tris pH7.4.
10mM Mgcl2 and 1mM DTT). The immunoprecipitates were incubated with the
Abl kinase substrate GST-Crk 0.5µg, 1 µM cold ATP in kinase assay reaction
buffer having 5µCi 32P-ɣ-ATP for 40 mins at room temperature. At the end of the
reaction equal volume of 2X sample buffer was added, samples were boiled,
loaded onto a 10% SDS PAGE gel and run overnight. The gel was dried and
then exposed to a radiosensitive film and phosphoscreen. The phosphoscreen
was scanned on a Storm phosphoimager (GE Health care) and bands were
quantified before.

Invasion assays [55]: Cells were transfected with siRNAs, and serum-starved
overnight for 16-20hrs. Trypsinized cells were washed with invasion assay media
(basal media containing 1% BSA) thrice and 5X105cells resuspended in invasion
assay medium (serum starvation media) were placed in the top well of matrigel
invasion chambers. The lower chamber contained 10nM of chemoattractant, IGF1, resuspended in invasion assay medium. The cells were allowed to
invade/migrate for 48 hours at 37oC. Cells and matrigel on the upper surface of
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the membrane were removed, and cells on the undersurface were fixed with
methanol for 2 minutes, stained for 2 minutes (1% borax and 1% toluidine blue in
water) and all the cells on the membranes were counted. For some experiments
recombinant MMP-1 or MMP-3 (25ng/ml) were added to the top well of
chambers, along with the cell suspension. Nilotinib was added to the top and
bottom chambers for experiments involving the drug.

MMP expression/activation assays: MMP levels were assessed in serum
starved, similar density subconfluent cells. Cells were serum starved as serum
contains growth factors like EGF, which alters the expression of MMPs [213,
214]. For 8h imatinib treatment, cells were serum-starved overnight prior to
treatment and for 48h treatment, cells were serum-starved and treated
simultaneously. For siRNA experiments, cells were transfected with c-Abl and
Arg siRNA for 2 consecutive days and then replated to obtain equal confluency
and cells were serum starved for 48h. Transcript levels were determined by
semi-quantitative PCR as described below. Activation/ secretion of MMPs was
determined by concentrating the serum-starvation conditioned media using
Ultracel-10K; Millipore; Temecula, CA, USA. As a loading control for activation
experiments media amounts were normalized to β-actin levels from the whole
cell lysates.
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3D Single-cell Invasion assay [217]: Four volumes of Collagen I (Invitrogen,
Grand Island, NY) solution with a final concentration of 1mg/ml was mixed with 1
volume of pre-cooled Basal Media (10x), 2.65 volumes of normal growth growth
media, 5 volumes of HBSS, 1 volume of 0.25M NaHCO3, and 0.3 volumes of 1M
NaOH, to create a pH>9. The collagen gel solution was mixed properly by
pipetting and kept on melting ice. One mililiter of the prepared collagen solution
was placed in 6-well dishes and allowed to harden at 37oC and 10% Co2 for 1h.
Melanoma cells transfected with siRNAs, were trypsinized and plated on the
collagen matrix at 37oC for indicated times, after which time invasive cells (lack
refractile halos and contain invasive extensions) and non-invasive cells were
counted from 20 random fields.

Tritiated Thymidine Assays [64]: Cells were plated in 12-well dishes to obtain
50% confluency one day after plating and treated with imatinib or nilotinib for
24h, or siRNA transfected cells were plated to have equal density a day after
plating. Cells were labeled with 5µCi of tritiated thymidine for two hours, washed
with cold PBS, fixed in 10% tricholoroacetic acid for 40 mins in 40C harvested
with 0.2N NaOH, mixed with 4mls of scintillation fluid, and read on a scintillation
counter.

Semi-Quantitative RT-PCR [55, 64]: RNA was isolated from serum-starved cells
transfected with siRNAs or treated with imatinib using an RNAeasy kit (Qiagen,
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Valencia, CA), and traces of contaminating DNA was removed by DNAase
digestion with DNase I (Applied Biosystems, Carlesbad, CA). c-DNA was
synthesized by incubating five micrograms of DNase-treated RNA with
Superscript Reverse Transcriptase and random primers (Invitrogen, Carlesbad,
CA). Target genes were amplified by PCR using cDNA and specific primers with
internal β-actin control primers, 10x PCR reaction mixture (Invitrogen), MgCl2
(1.5mM), dNTPs, and Taq DNA polymerase (Genscript, Piscataway, NJ). PCR
reactions conditions were optimized for linearity and cycling parameters involved
35 cycles of 95oC-1', 55oC-1', 72oC-1'. The PCR products were run on 2%
agarose gels. Scanned photographs were quantified with ImageQuant (Molecular
Dynamics) and specific bands normalized to β-actin internal control bands as
described in the western blotting section.
c-Abl forward primer, 5'CCTTCATCCCTCTCATATCAACC3',
c-Abl reverse primer, 5'TGGACCACTGCCTGCTGTCGC3'
Arg forward primer, 5'CATCCGTCCATCTGCTCAGAC3'
Arg reverse primer, 5'GGACAGTAGGTCAGCACATTC3'
MMP-1 forward primer, 5'AGCGTGTGACAGTAAGCTAAC3'
MMP-1 reverse primer, 5'TCCTCAGAAAGAGCAGCATCG3'
MMP-3 forward primer, 5'GTTCCGCCTGTCTCAAGATGA3'
MMP-3 reverse primer, 5'ATCCAGCTCGTACCTCATTTCC3'
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MT1-MMP forward primer, 5'GCAGGCCGACATCATGATCTTC3'
MT1-MMP reverse primer, 5'TCCTCTCGTAGGCAGTGTTG3'
TIMP-1 forward primer, 5’TCCTGTTGTTGCTGTGGCTGA3’
TIMP-1 reverse primer, 5’GGACTGGAAGCCCTTTTCAGA3’
β-actin forward primer, 5'CCTTCCTGGGCATGGAGTCCT3',
β-actin reverse primer 5'GGAGCAATGTCTTTGATCTTC3'

Metastasis Assays: 435s/M14-GFP-Luciferase cells were injected (2X106
cells/100ul of Hanks Balanced Salt Solution, (HBSS) into the tail vein of 7-8 week
old SCID Beige mice (Harlan Laboratories, Indianapolis, IN). Following the day of
injection, mice were treated with nilotinib (30mg/kg b.i.d) or vehicle (0.5%
hydroxymethylcelluose/0.05% Tween-80) by oral gavage. On days, 17, 21 and
24 after initial injection of cells, mice were intraperitoneally injected with Luciferin
–D (100/mg/kg) and fluorescence was measured by IVIS Xenogen Spectrum
(Caliper Life Sciences, Hopkinton, MA). The flux values were normalized with
Living Image 3.1 software in order to observe differences between time points
and also for quantification. On Day 24 the mice were euthanatized, lungs were
removed, washed in cold PBS, and fixed in 100% formalin. In the WM3248
metastasis assay, cells (2x106 cells/100ul HBSS) were injected into the tail vein
of 7-8 week-old nude (nu/nu) mice (Harlan Laboratories). Mice were treated with
33mg/kg of nilotinib, same way as described above and on day 34, the mice
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were euthanatized, lungs removed and fixed in 100% formalin. GFP-fluorescent
metastatic nodules were counted and photographs were taken using a 0.63X
objective and 2X-Zoom on an Olympus MVX-10 stereomicroscope with
fluorescence illumination.
Paraffin embedding: Lungs pre-fixed in formalin and stored at 40C were
dehydrated in 70% ethanol, 100% ethanol, 1:1 ethanol/xylene, followed by 100%
xylene. Lungs were placed in melted paraplast X-tra: xylene (1:1) for 1hr at 54oC
with constant shaking followed by overnight room temperature incubation. Warm
paraplast (100%) was then added to the tissue for 1h at 54oC with constant
shaking, incubated at room temperature for 2hr, paraffin was melted, and lungs
were mounted at room temperature. The mounted lungs were stored at room
temperature overnight followed by desiccation for long-term storage. Lungs were
sectioned on a ThermoShandon Finesse microtome.

Statistics: Student t-tests were used for comparisons using a SAS software,
sigma stat or online-website (Vassar website). One-way Anova with Tukey post
hoc tests were performed in experiments, involving multiple groups. p<0.05 was
considered significant (*, 0.01≤p<0.05; **, 0.001≤p<0.01; ***, p<0.001).
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2.3 Results
2.3.1 c-Abl and Arg are activated in invasive melanoma cell lines and in
primary melanomas
Our lab has previously shown that the activities of Abl kinases are dramatically
elevated in highly invasive breast cancer cell lines as compared to non- invasive
breast cancer cell line (MCF-7) [55], and activation of c-Abl and Arg did not
correlate to their expression levels in these cells. To investigate whether Abl
kinases also are activated in invasive melanoma cell lines, serum-starved lysates
of a panel of human melanoma cell lines and primary melanocytes were
immunoblotted for c-Abl and Arg. c-Abl and Arg expression were dramatically
elevated in all the melanoma cell lines as compared to primary melanocytes
(Figure 2.1). Since Abl kinases are tightly regulated by intermolecular interactions
and activation does always correlate with their activity [54], we investigated
whether Abl kinases are activated in these cell lines. Using in vitro kinase assay,
we found that several melanoma cell lines had increased c-Abl and/or Arg kinase
activities as compared to the human primary melanocytes (Figure 2.1).
Immunoblotting for phosphorylation of known Abl kinase targets, Crk and CrkL on
Abl tyrosine phosphorylation sites (Y221/Y207), showed elevated levels in all the
melanoma cell lines as compared to primary human melanocytes, and the level
Crk/CrkL phosphorylation, paralleled c-Abl/ Arg kinases activities with the
exception of WM278. Unlike in breast cancers, we observed that c-Abl/Arg
expression correlated with c-Abl/Arg activities in melanoma cells, in that lines
with higher c-Abl and Arg expression had higher activities. To test whether Abl
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Figure 2.1: c-Abl and Arg highly activated in melanoma cell lines. Melanoma
cells were serum-starved overnight, lysed, c-Abl and Arg were
immunoprecipitated and incubated with GST-Crk in the presence of radioactive
gamma-ATP. Kinase activities were assayed by invitro kinase assay using GSTCrk as a substrate. Lysates were blotted for indicated antibodies (bottom 4
panels). Performed in collaboration with J.W Friend.
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kinases are activated in primary human melanoma samples, we performed
immunohistochemistry on melanoma tissue mircoarrays (TMA). Phospho-specific
antibodies to c-Abl (Y412 and Y245) cross-react with phospho-EGFR and
phospho-PDGF and phospho-specific Arg antibodies are not commercially
available [54]. Therefore we stained the TMAs with an antibody to the Abl
phosphorylation sites in targets, Crk/CrkL, since inhibition of Abl kinase activities
with imatinib or knockdown of c-Abl and Arg expression reduced pCrk/CrkL
levels in a dose response manner [ 55,64], indicating that Crk/CrkL
phosphorylation at Y221/Y207 correlates with c-Abl/Arg activity in cancer cell
lines. In normal skin samples, pCrk/CrkL staining was observed predominantly in
the cytoplasm and nuclei of keratinocytes and the nuclei of lymphocytes (Figure
2.2). Sixty-seven percent of benign nevi demonstrated weak to no nuclear
staining, whereas 33% had moderate-to strong staining (Score >1.4;
Score=Intensity x Proportion of positively stained tumor cells). pCrk/CrkL staining
(red) was nuclear in primary melanomas whereas melanin, which was mainly
cytoplasmic was brown. Cores with strong melanin staining were excluded from
the study owing to difficulty in scoring. Twenty-nine out of forty-eight melanomas
(60%) in contrast to 33% (6/18) of benign nevi had moderate-strong pCrk/CrkL
staining. Chronically and intermittently sun exposed skin samples had more
positive cases of pCrk/CrkL staining in contrast to minimal sun-exposed samples.
These results indicate that c-Abl/Arg is activated in primary melanomas and as
well as in human melanoma cell lines.
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Normal Skin

Benign Nevus

Amelanotic
melanoma

Melanotic
melanoma

Figure 2.2 Abl kinases are activated in primary melanoma. Melanoma
TMAs were incubated with normal rabbit serum (NRS) or pCrk/CrkL
antibody, hemotoxylin-stained and visualized with Dako Red. Cores
having a score > 1.4 was considered moderate-strongly positive
(Score=Intensity x Proportion of positively stained tumor cells). Scores for
each core is indicated in brackets. Photographs were taken under
400Xmagnifications. The staining was performed by Leann Fiore and
scored by Dr. Michael Cibull MD (Director of Surgical Pathology).
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2.3.2 Active Abl kinases promote matrigel-invasion, single-cell 3D invasion,
proliferation and survival of melanoma cells
Our lab has previously shown that c-Abl and Arg promotes invasion in 435s/M14
cells [55].To determine whether Abl kinases promoted invasion in other
melanoma cell lines, we used WM3248 cells, which have highly active c-Abl and
Arg (Figure 2.1). Consistent with our previous findings with 435s/M14 cells,
silencing c-Abl or Arg inhibited matrigel invasion of WM3248 (Figure 2.3A).
These results were confirmed using a second siRNA directed against c-Abl and
Arg (Figure 2.3A). To confirm that active Abl kinases promote invasion in
melanoma cells, we treated WM278, which have low c-Abl and Arg kinase
activities (Figure 2.1) with nilotinib, a second-generation Abl kinase inhibitor and
compared the effects in a variety of melanoma cell lines. Nilotinib did not inhibit
invasion in WM278, which does not contain active Abl kinases (Figure 2.1),
whereas it significantly inhibited invasion in 435s/M14 and WM3248 cells(Figure
2.3B) containing highly active c-Abl and Arg. These results indicate that active
Abl kinases are required to promote invasion in melanoma cells and also
suggests that nilotinib specifically blocks invasion by inhibiting Abl kinases. The
process of invasion involves degradation of the collagen bed in the extracellular
matrix. Collagen I is a prime constituent of the extracellular matrix [104, 105,
217,]. To investigate whether Abl kinases can degrade the collagen bed we
performed a single-cell 3D invasion assay.
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Figure 2.3: Abl kinases promote invasion in melanoma cells. (A) WM3248
cells transfected with two individual siRNA were serum for 16-20 hrs and
incubated in matrigel invasion chambers for 48h with IGF-1 as chemoattractant.
The lower surface of the membranes was stained, and the total number of
invaded cells on the undersurface was scored and compared to Scr control. The
graphs are mean± s.e.m (n=3 independent experiments)*0.01 ≤ p <0.05; **0.001
≤p<0.01. Photographs are in 100x magnification. Knockdown of cells were
analyzed by semi-quantitative RT-PCR using specific c-Abl and Arg primers
(Right). (B). Melanoma cells were serum-starved, treated with 0.5µM nilotinib,
and matrigel invasion assays were performed with nilotinib in bottom and upper
chambers. Invasion assays were performed using 10nM of IGF-1 as a
chemoattractant. Cells were stained and scored as in (A). Graphs were
normalized to vehicle treated controls and plotted as mean±s.e.m (n=3,
normalized to untreated) *0.01 ≤ p <0.05; **0.001 ≤p<0.01.
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In this assay, siRNA-transfected 435s/M14 and WM3248 cells were placed on
collagen I-coated beds and incubated for a period of 5h and 24h, respectively.
Cells that degrade the matrix form extensions and invade the collagen bed,
where as non-invasive cells fail to form extensions [217]. Inhibition of c-Abl or Arg
significantly reduced single-cell 3D invasion in WM3248 cells and 435s/M14
(Figure 2.4), indicating that c-Abl and Arg promote single-cell 3D invasion by
degrading the collagen matrix and thus, likely promote collagenase activity. This
assay also lacks the migratory component that is generally present in Boyden
chamber invasion assays, indicating that Abl kinases promote invasion cannot be
solely explained by an effect on cell motility.
Another key process in cancer metastasis is deregulated proliferation.
Our lab previously showed that Arg but not c-Abl promotes proliferation of
435s/M14 cells. To test whether Abl kinases promote proliferation of other
melanoma cell lines, we examined WM3248 cells. As opposed to 435s/M14, in
WM3248 cells both c-Abl and Arg promoted proliferation/S-phase entry (Figure
2.5 A). To investigate whether active Abl kinases regulate proliferation in other
melanoma cells lines, we treated a panel of lines with nilotinib for 24h (Figure
2.1) and performed tritiated thymidine proliferation assays. Nilotinib inhibits Abl
kinases and other targets such as c-Kit, and PDGFR; thus we examined these
cell lines for the expression of these receptors (Figure 2.6 and Table 2.1).
435s/M14 and WM3248 did not express any of the other nilotinib and imatinib
targets. Adding the targets together gave the total number of targets that nilotinib
can inhibit in these cell lines. Taking the amount of tritiated thymidine
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Abl
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Figure 2.4: Active Abl kinases drive single-cell 3D invasion. Melanoma
cells, transfected with siRNAs, were incubated in a single-cell 3D invasion assay
(deWever et al. 2010) for 20h (A- WM3248) or 5h (B-435s/M14); cells that lose
their refractile appearance, gain invasive potential and form extensions on
collagen bed. The number of invasive cells (containing extensions) and noninvasive cells were counted in 20 random fields obtain an invasion index (cells
with invasive extensions/total cells*100). Representative fields were
photographed. Mean± s.e.m, n=3. *p<0.05, **p<0.01, ***p<0.001. Knockdown of
cells was analyzed by western blotting using specific c-Abl and Arg antibodies
(Right).
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Figure 2.5: Active c-Abl and Arg promote proliferation in melanoma cells.
(A) WM3248 cells, transfected with c-Abl or Arg siRNA were subjected to tritiated
thymidine assays, CPMs were normalized to those obtained in scrambled control
cells. Mean± s.e.m, n=3. *p<0.05. (Performed in collaboration with J.Sims). (B,
Left) Tritiated thymidine incorporation was assessed in melanoma cells treated
with 0.5µM nilotinib or 10µM imatinib for 24h. CPM was normalized to vehicle
treated cells. Mean± s.e.m, n=3. *p<0.05 (B, right) The level of c-Abl and Arg
activation from Figure 1 was added with the number of nilotinib targets from
Figure 2.6 to get a Score. An inverse correlation comparing sensitivity to nilotinib
against the Score was observed (R2=0.45 p=0.011). (B, bottom) Cells treated
with nilotinib under the same conditions as B left bottom, were lysed and blotted
with pCrK/CrkL antibody to demonstrate efficacy of the drugs in inhibiting cAbl/Arg.
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Figure 2.6: c-kit and PDGFR expression in melanoma cells. Melanoma cells
were plated, serum-starved for 24h, lysed, and blotted with indicated antibodies.
WM3211 cells were used as a control for the PDGFR α- blot.
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Table 2.1 Sensitivity of melanoma cells to Abl kinase inhibitor, nilotinib. cAbl and Arg activities from Figure 2.1 were added with other nilotinib targets in
Figure 2.6 and a Score was achieved for each cell line indicating the total
number of nilotinib targets.
Cell line

WM278 WM239

A375

sbcl2

WM3248 435s/M14

Abl activity

-

-

++++

+++

++++

++++

Arg activity

-

++

++

++

++++

++++

c-Kit

-

+

-

-

-

-

PDGFR-α

+

-

-

-

-

-

PDGFR-β

-

-

-

-

-

-

# of nilotinib
targets

1

3

6

5

8

8

3

HThymidine

41±8.4

36±2.07 26±2.4 39.5±1.5

74

12±0.38

32.7±.0.48

incorporation in each cell line versus the total number of targets we found an
inverse correlation, indicating that activation ok known imatinib or nilotinib targets
(including c-Abl and Arg) promotes proliferation of melanoma cells (Figure 2.5B).
However, nilotinib-mediated inhibition of proliferation in WM278 cells is efficient
(Table 2.1), indicating that pCrk/CrkL levels might be more predictive of nilotinib’s
anti-proliferative effects than c-Abl/Arg activities. The anti-proliferative effects of
nilotinib might also be due to the expression of PDGFR-β receptor in WM278
cells. Imatinib, also efficiently inhibited proliferation/S-phase entry of 435s/M14
and WM3248 cells (both harboring highly active c-Abl and Arg activities). Using
imatinib, we also found that the degree of inhibition of proliferation was much
higher in 435s/M14 and WM3248 cells (both harboring highly active c-Abl and
Arg activities) as compared to WM278, which have low Abl kinase activities (Fig
2.1). However, in 435s/M14, WM3248, and WM278 the anti-proliferative effect of
nilotinib is greater than imatinib (Figure 2.1) indicating that nilotinib might be
more effective than imatinib in inhibiting proliferation of melanoma cells.
Cancer cells have the ability to survive in serum-free conditions. This
property helps them survive in nutrient-free conditions, which is essential during
the process of metastasis and resistance to apoptosis also contributes to
chemotherapeutic resistance of cancer cells [12, 13, 210]. Results from our
laboratory have shown that inhibition of Abl kinases promotes apoptosis of breast
cancer cells [64]. Thus we sought to investigate whether Abl kinases promote
survival in melanoma cells in serum-free conditions. As shown in Figure 2.7,
inhibition of Abl kinases in 435s/M14 and WM3248 cells, via imatinib, induced
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apoptosis in serum-starved conditions, as evidenced by PARP cleavage and
caspase-3 activation. Since these cells lines do not express any other known
imatinib targets, these results indicate a role for Abl kinases in melanoma cell
survival.

2.3.3 c-Abl and Arg promote the transcription of matrix metalloproteinases
and induce their activation in melanoma cells
An initial step in cancer invasion involves degradation of the ECM. MMPs aid in
the degradation of ECM, and thus promote invasion and metastasis [103, 104].
Regulation of MMP-1 transcript and activity is important in cancer cell invasion
and metastasis. MMP-1 mRNA and activity is upregulated in breast cancer
tissues as compared to normal breast tissues [218].Transcriptional regulation of
MMP-1 has been shown to be dependent on the MAPK pathway via AP-1 and
Ets family of transcription factors [219, 220]. The MMP-1 promoter has an Ets
binding domain [219, 221]. To evaluate whether MMP’s are essential for invasion
of 435s/M14 cells, we first screened for the presence of MMP expression in
435s/M14 cells. We found that MMP-1, -3 and 14 mRNAs are expressed
whereas MMP-2 was not detected by semi-quantitative reverse transcriptase
PCR (RT-PCR). To investigate whether these detected MMPs are involved in
regulating invasion in 435s/M14 cells, we silenced MMP-1, -3 or 14 and
performed matrigel invasion assays. Inhibition of MMP 1, 3 or 14 independently
decreased invasion of 435s/M14 cells (Figure 2.8), indicating that these MMPs
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Figure 2.7 Active Abl kinases promote survival of melanoma cells in
response to serum deprivation. 435s/M14 cells and WM3248 cells were
treated with vehicle or imatinib and deprived of serum for 96h and 7 h
respectively. Lysates from detached and attached cells were probed with
indicated antibodies. Representative blot shown from one of the three
independent experiments.
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are important in melanoma invasion. Silencing of MMP- 14 had a smaller effect
on invasion as compared to silencing MMP-1 or MMP-3, indicating that MMP-14
probably plays a less significant role in regulating invasion in these cells, perhaps
due the fact that one of its functions is to activate MMP-2 and MMP-2 is not
expressed in these cells.
To determine whether Abl kinases promote MMP transcription, we treated
serum-starved, 435s/M14 cells with imatinib (8h, 48h) and performed semiquantitative RT-PCR on the extracted RNA samples. Imatinib treatment
significantly inhibited MMP-1, MMP-3 and MMP-14 transcription (Figure 2.9).
Silencing c-Abl and Arg also significantly decreased m-RNA levels of MMP-1 in
435s/M14 cells, and silencing Arg significantly decreased the m-RNA levels of
MMP- 3 and 14, respectively (Figure 2.9 A-C,right), whereas silencing c-Abl had
no significant effect on the transcription of MMP-3 and 14. These results indicate
that c-Abl and Arg promote MMP-1 transcription in melanoma cells, whereas Arg
increases MMP-3 and 14 transcription.
Under normal physiological conditions, MMP activity is controlled either by
transcriptional regulation, or by via endogenous MMP inhibitors (TIMPs). Our
previous results (Figure 2.9) indicate that Abl kinases promote MMP
transcription, so we wanted to investigate whether Abl kinases also promote
MMP activation. To investigate whether Abl kinases induce the activation and
secretion of MMPs conditioned media from serum-starved cells expressing c-Abl
or Arg siRNAs were blotted with antibodies that recognize both the inactive and
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Figure 2.8 MMP-1, 3 and 14 promote invasion of 435s/M14 cells. 435s/M14
cells were transfected with siRNAs against MMP-1, 3, 14 or a scrambled control,
and invasion assays were performed. Mean ± s.e.m.for two experiments.
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Figure 2.9 Abl kinases increase MMP-1, 3 and 14 transcription. 435s/M14
cells were plated, serum starved, and treated with the Abl inhibitor imatinib for 4h
(A) or 48h (A-C) or were transfected with c-Abl/Arg siRNAs and serum-starved
(A-C, Right,). Extracted RNA was subjected to semi-quantitative RT-PCR with
MMP and internal control actin primers. Graphs are mean ± s.e.m.for three
experiments. *p<0.05, **p<0.01, ***p<0.001. Knockdown efficiencies were
determined using c-Abl or Arg primers; a representative experiment is shown in
inset. Representative blots are shown.
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active forms of MMP-1, 3 and 14. Silencing c-Abl or Arg decreased the inactive
and active forms MMP-1, consistent with the mRNA results, indicating a role of cAbl and Arg in MMP-1 transcription (Fig 2.10A). Consistent with the mRNA
levels, silencing Arg decreased the inactive and active forms of MMP-3 (Fig
2.10B). Since MMP-14 is trans-membrane MMP and isn’t secreted we blotted the
whole cell lysates with antibodies that recognize both the inactive and active
forms. We found that silencing Arg significantly reduced the inactive and active
forms of MMP-14 (Fig 2.11). The degree of inhibition in active band of MMP-1,
and 3 is much more than the inactive band, indicating that probably Abl kinases
induce activation and secretion of MMPs. Taken these results together we can
conclude that Abl kinases upregulate the transcription, induce activation and
secretion of MMP’s in melanoma cells and thus promote melanoma cell invasion.
MMP transcription is not always a measure of its activation as TIMPs inhibit the
activation of MMPs while several other already active MMPs or several serine
proteases activate MMPs. Inhibiting MMP activation by upregulating endogenous
MMP inhibitors (TIMPs) could decrease the activation of MMPs. Our results
indicate that Abl kinases promote the transcription and activation of MMP but the
mode of activation needs to be determined.
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Figure 2.10 Abl kinases promote activation of MMP-1 and MMP-3. (A-B)
435s/M14 cells, transfected with c-Abl and Arg siRNAs were serum-starved for
48h and attached and detached cells were lysed and blotted for β-Actin. Media
was collected and concentrated as described in Section 2.2, and loaded
according to the β-Actin blot. Recombinant MMP-1 and MMP-3 proteins were
used as positive controls for identifying the location of the inactive and active
bands. Graphs are mean ± s.e.m.for three experiments and representative
experiments are shown. *p<0.05, **p<0.01, ***p<0.001
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2.3.4 Abl kinases induce MMP-1 transcription via activation of STAT3
STAT3 have been shown to induce the expression of MMP-1 in bladder and
colon cancer cells [209, 222], and also is known to promote invasion in many
cancers. Abl kinases activate STAT3 in a JAK-independent manner [64] and
furthermore, the Abl kinase activator, Src phosphorylates STAT3 directly [223,
224]. Here, we set-out to investigate whether Abl kinases induce activation of
STAT3 in 435s/M14 cells and in WM3248 cells under invasion assay conditions
(serum-starved conditions). Inhibition of Abl kinase activity with imatinib inhibited
STAT3 phosphorylation in 435s/M14 cells (Figure 2.12A) and in WM3248 cells
(Figure 2.12B), and silencing c-Abl inhibited phosphorylation of STAT3 in
WM3248 cells (Figure 2.12C). To examine whether Abl kinases induce the direct
activation of STAT3 in the case for Src kinases, we overexpressed Flag-tagged
wild type-STAT3 in a heterologous system, (HEK-293Tcells) and co-transfected
with one of the Abl constructs: wild-type (Abl-WT or Arg-WT), constitutive forms
(Abl-PP or Arg-PP), or kinase-inactive mutants of (Abl-KD and Arg-KD). Massive
overexpression of Abl wild type is known to induce its activation in 293T cells
[225]. Both Abl-PP and Arg-PP induced phosphorylation at STAT3-Y705,
whereas the kinase-dead mutants of both c-Abl and Arg failed to induce
phosphorylation of the Y705 residue of STAT3, indicating that active form of Abl
and Arg induce STAT3 phosphorylation (Figure 2.13A). Abl kinases form a
complex with STAT3 as wild-type and constitutively active forms of c-Abl and Arg
co-immunoprecipitate with STAT3 in 293T cells (Divyamani Srinivasan, data not
shown). To investigate whether c-Abl or Arg directly induced the phosphorylation
of STAT3 we performed an invitro kinase assay. Following c-Abl-PP and Arg-PP
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transfection in 293T cells, c-Abl or Arg was immunoprecipitated and incubated
with GST-STAT3 in the presence of radiolabeled 32P-ATP. Both c-Abl and Arg
were unable to phosphorylate GST-STAT3 in vitro (Figure 2.13B), indicating that
STAT3 is not a direct substrate of Abl kinases. Thus, Abl kinases indirectly
induce the phosphorylation of STAT3 via a yet to be identified tyrosine kinase.
Since Abl kinases promote activation of MMP-1 and STAT3 in melanoma
cells and STAT3 is known to have binding sites in the MMP-1 promoter, we
investigated whether Abl kinases upregulate MMP-1 transcription via a STAT3dependent mechanism. Silencing STAT3 in melanoma cells blocked MMP-1
transcription as assessed by semi-quantitative RT-PCR (Figure 2.14A). Using a
constitutively active form of STAT3 (STAT3CA) overexpressed in 435s/M14 cells,
we were able to rescue the inhibition of MMP-1 transcription observed following
imatinib treatment of vector control cells (Figure 2.14B). These results indicate
that STAT3 lies downstream of Abl kinases in regulating MMP-1 transcription.
Since Abl kinases and STAT3 both promote survival of cancer cells, we
sought to investigate whether Abl kinases induce survival in a STAT3- dependent
manner. Expression of a constitutively active form of STAT3 into 435s/M14 cells
partially (30-40%) rescued STI571-mediated PARP cleavage during nutrient
deprivation (Figure 2.15) These results indicate that c-Abl and Arg prevent
apoptosis in response to serum-deprivation via STAT3-dependent and
independent pathways.
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Figure 2.12: Abl kinases promote STAT3 phosphorylation.(A) 435s/M14
cells (B) WM3248 cells were serum starved, treated with imatinib (10µM) for 48h
and lysates probed with the indicated antibodies. (C) WM3248 cells were
transfected with c-Abl/Arg siRNAs and lystates probed with indicated antibodies.
The graphs are Mean± s.e.m, n=3 *p<0.05, **p<0.01, ***p<0.001. Representative
blots are shown
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Figure 2.13: Abl kinases form a complex with STAT3, and indirectly induce
STAT3 phosphorylation. (A) HEK-293T cells were co-transfected with plasmid
encoding wild type or flag-tagged STAT-3 together with wild-type (WT),
constitutively active (PP) or kinase dead (KD) forms of c-Abl or Arg, lysed and
blotted with the indicated antibodies. (B) c-Abl and Arg were immunoprecipitated
from lysates, and kinase activities were assessed by in vitro kinase assay using
GST-Crk and GST-STAT3 as substrates. KD=Kinase Dead (K290R).
PP=constitutively active Abl/Arg contain a mutation of proline 242 and 249 to
glutamine (P242E/P294E). (A) Performed by Dr Divyamani Srinivasan.
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Figure 2.14: Abl kinases promote MMP-1 transcription via STAT3. (A)
435s/M14 cells transfected with STAT3 siRNA, were serum starved for 48 hr,
and RNA was subjected to semi-quantitative RT-PCR. STAT3 knockdown was
analyzed by western blotting. Mean ± s.e.m, n=3; *p=0.05 (B) 435s/M14 cells
stably transfected with either vector (pcDNA) or a constitutively active form of
STAT3 (STAT3C) were plated, serum starved, treated with imatinib for 48h, and
MMP-1 transcript was analyzed by semi-quantitative RT-PCR. Mean ± s.e.m,
n=3; *p <0.05;
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serum-starved, and treated with imatinib for 60h. Attached and detached cells
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94

2.3.5 Abl Kinases promote TIMP-1 expression via a STAT3-dependent
mechanism
TIMP-1 is an endogenous inhibitor on MMP-1, and has been reported to inhibit
cancer cell invasion. To evaluate whether upregulation of MMP-1 by Abl kinases
is dependent on suppression of the endogenous MMP-1 inhibitor, we wanted to
determine the effect of inhibition of Abl kinases on TIMP-1 mRNA and protein
levels in 435s/M14 cells. Inhibition of Abl kinases with imatinib significantly
reduced TIMP-1 transcript and protein levels (Figure 2.16 A and B), indicating
that Abl kinases promote TIMP-1 expression, contrary to our hypothesis that Abl
kinases downregulated the expression of endogenous MMP inhibitor.In addition
to negatively regulating MMPs, TIMPs also have been shown to have antiapoptotic functions, and high TIMP-1 expression is correlated with decreased
survival and a poor clinical outcome in breast, ovarian, lung and colon cancer
patients [135,139]. Thus, it is possible that TIMP-1 may have anti-apoptotic
functions in melanoma cells, and activated Abl kinases may induce this function
by increasing TIMP-1 expression and secretion.
To investigate the molecular mechanism by which Abl kinases-mediate
upregulation of TIMP-1, we investigated whether STAT3 can upregulate TIMP-1
transcription in 435s/M14 cells. Silencing STAT3 significantly downregulated
TIMP-1 transcript levels (Figure 2.16C). Moreover, expression of a constitutively
activate form of STAT3C rescued the effect of Abl kinases inhibition on TIMP-1
transcription and expression (Figure 2.17A and B), indicating that Abl kinases
promote TIMP-1 expression via a STAT3-dependent pathway.
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Figure 2.17 Abl kinases promote TIMP-1 expression via STAT3-dependent
pathway. (A,B) 435s/M14 cells stably transfected with either vector (pcDNA) or
a constitutively active form of STAT3 (STAT3C) were plated, serum starved,
treated with imatinib for 48h, and TIMP-1 transcript (A) and protein (B) was
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Representative blots shown.
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2.3.6 c-Abl promotes invasion via a STAT3-dependent MMP-1 pathway
whereas Arg increases invasion in a STAT3-independent manner through
MMP-1 and MMP-3
Silencing either c-Abl or Arg significantly inhibited invasion in melanoma cells,
indicating that c-Abl and Arg are required for melanoma cell invasion. Inhibition of
Abl kinases significantly downregulated STAT3 activation in 435s/M14 and
WM324 cells, indicating that Abl kinases activate STAT3 in melanoma cells.
Since silencing STAT3 in 435s/M14 cells also decreased invasion (Figure
2.18A), we investigated whether c-Abl and Arg mediate invasion in a STAT3dependent manner. Matrigel invasion assay were conducted after silencing c-Abl
or Arg in 435s/M14 cells expressing a constitutive expression of the active form
of STAT3 (STAT3CA). Silencing c-Abl or Arg inhibited invasion in vector control
cells (Figure 2.18B) whereas in STAT3CA cells, silencing of c-Abl failed to inhibit
invasion to the basal level (28% inhibition). In contrast silencing Arg reduced
invasion to basal levels as seen in the vector control cells (Fig 2.18B). Thus,
STAT3CA significantly rescued the block in the invasion induced following
silencing c-Abl, indicating that c-Abl drives invasion in a STAT3- dependent
manner and Arg promotes invasion in a STAT3-independent manner. c-Abl and
Arg were efficiently silenced in vector-control and STAT3CA cell lines (Figure
2.18B right) indicating that the results observed were not due to inefficient
inhibition of c-Abl/Arg in 435s/M14-STAT3CA cells.
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Figure 2.18: c-Abl promotes invasion in a STAT3-dependent manner. (A)
435s/M14 cells were transfected with siRNA against STAT3 or a scrambled
control (Scr) and invasion assays were performed. Knockdown efficiency was
determined by taking an aliquot from cells used in the assay and probed for
indicated antibodies (B). Invasion assays were performed on 435s/M14 cells
stably expressing vector or STAT3C, transfected with c-Abl/Arg siRNAs.
Knockdown efficiency was determined by semi-quantitative RT-PCR using cAbl/Arg primer. Mean ± s.e.m, n=3, normalized to scrambled. *0.01 ≤ p <0.05;
**0.001 ≤p<0.01. Pictures were taken in 100x magnification.
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Abl kinases promote the transcription and activation of MMPs, and MMP-1
and 3 drive invasion in 435s/M14 cells (Figure 2.8-2.10). Thus, to evaluate
whether c-Abl and Arg promote invasion in a MMP-1 and MMP-3 dependent
manner, we performed rescue invasion assays. Constitutive expression of MMP1 in 435s/M14 cells significantly rescued the block in invasion following inhibition
of c-Abl or Arg, however the rescue observed was partial (40%). Using a
complementary approach, we also treated the upper well of invasion chambers
with recombinant active MMP-1 in cells silenced with c-Abl or Arg and observed
the same level of rescue as seen with cells over-expressing the MMPs (Figure
2.19B). Since the rescue was partial using recombinant MMP-1, we hypothesized
that MMP-3 might also play a part in Arg-mediated invasion. Using recombinant
MMP-3, we found that inhibition of invasion was partially rescued in Arg silenced,
435s/M14 cells (Figure 2.19C). These results indicated that c-Abl mediates
invasion via a STAT3 and MMP-1-dependent pathway, whereas Arg drives
invasion in a MMP-1 and MMP-3-dependent pathway, which is STAT3independent. These results also show for the first time that that c-Abl and Arg
promote invasion through distinct mechanisms.

2.3.7 Activated Abl kinases promote late stages of melanoma metastasis
Cancer cells invade the extracellular matrix (ECM), intravasate into the blood
vessels, extravasate out of the blood vessels to ectopic sites, seed, and
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Figure 2.19: c-Abl and Arg promote invasion in a MMP-dependent manner.
(A).435s/M14 cells stably expressing GFP or GFP-MMP-1 were transfected with
c-Abl or Arg siRNAs and invasion assays were performed. The efficiency of
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103

proliferate to form tumors in the ectopic sites. This process is termed as
metastasis. In experimental metastasis assay, cells are injected directly in the
blood stream, via a tail vein injection. In this process, the cancer cells bypass the
few initial steps of cancer metastasis cascade, like primary tumor growth,
invasion through the extracellular matrix, and intravasation into the blood stream.
However, the cells still have to extrasavate out of the blood stream and invade
the new organ site to form micrometastasis in the ectopic site, survive in nutrient
free conditions, and proliferate to form macrometastasis. Since c-Abl and Arg
promoted proliferation, invasion and survival in-vitro conditions we assessed
whether active Abl kinases drive late stages of melanoma metastasis by
performing experimental metastasis assays. 435s/M14 cells tagged with GFP
and luciferase was injected into the tail vein of SCID-beige mice. As shown in
Figure 2.20A, in experiments using 435s/M14 cells vehicle-treated mice had
metastatic lung colonization from Day 17 to Day 24, indicating that the cells are
proliferating in the lung microenvironment. Treatment of mice with the c-Abl and
Arg inhibitor, nilotinib, significantly decreased lung metastasis, as measured by
IVIS imaging. Quantifying metastasis-using IVIS imaging at Day 21, we found a
significant decrease in lung metastasis in nilotinib treated mice, as compared to
vehicle treated mice (Figure 2.20A right). Immunohistochemical analysis of
nilotinib responsive mice lungs indicated a decrease in the phospho Crk/CrkL
staining as compared to lungs from vehicle-treated. A mouse that did not
respond to nilotinib (#10) had minimal suppression of c-Abl and Arg activity
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Figure 2.20: Activation of Abl kinases promote melanoma metastasis (A)
435s/M14 cells, labeled with GFP and luciferase (2X106), were injected into the
tail vein of SCID-beige mice. Mice were treated with vehicle or the
pharmacological Abl kinase inhibitor, nilotinib (30mg/kg; b.i.d) by oral gavage,
and imaged with IVIS following luciferin D injection (i.p.). (A; left) IVIS imaging of
representative mice on day 17, 21 and 24 post-injection. (A; right)
Representative mice on day 21 imaged shown with high integration such that
low-level fluorescence could be detected with quantification below. Numbers
refer to mouse numbers shown in (A). **0.001≤p<0.01. (B) WM3248 cells
expressing GFP, were injected intravenously (tail vein) into nude mice, and lungs
were fixed, photographed and metastases quantified on day 34.*p<0.05 using a
student’s t-test.
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(Figure 2.21). Furthermore, inhibition of c-Abl/ Arg activity was inversely
correlated with IVIS fluorescence in all the nilotinib-treated mice, indicating that
the anti-metastatic capacity of nilotinib is linked to inhibition of c-Abl and Arg
kinase activity.
To validate our findings we extended our study to another melanoma cell
line, WM3248. Consistent with our data using 435s/M14 cells, inhibition of Abl
kinase activities with nilotinib for a period of 34 days significantly reduced lung
metastasis of WM3248/GFP cells in a nude mouse model, as assessed by
scoring GFP-fluorescing metastatic nodules under a fluorescent dissecting scope
(Figure 2.20B). Summarizing these results, we can conclude that nilotinib
decreased melanoma metastasis by specifically inhibiting c-Abl and Arg, and for
the first time we report that active Abl kinases promote melanoma metastasis.
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Figure 2.21: Positive correlation between Abl kinase activity and
metastasis burden in nilotinib-treated mice. Lungs from the indicated mice
(graphs is in Figure 2.20 A) were fixed in formalin on day 24, paraffin-embedded,
sectioned, stained with phosphorylated Crk/CrkL (bottom panel), or normal rabbit
serum (top panel). Photographs are 400X magnification. The IVIS fluorescence
values from Figure 2.20 A were plotted against pCrkL/Crk score from the lung
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108

2.4 Discussion
Malignant melanoma accounts for about three fourths of all skin cancer deaths,
and is refractory to all known treatments. Although there is evidence for the
presence of activated Abl kinases in several solid tumors, activation of Abl
kinases in melanoma had, as of yet, remained unexplored. In this study, we
report that c-Abl and Arg kinases activities are elevated in some primary
melanoma tumor samples, as compared to benign nevi, and that many human
metastatic melanoma cell lines have higher c-Abl kinase activity as compared to
non-metastatic cell lines and primary melanocytes. These results suggest that
activation of Abl kinases in melanoma is one of the prerequisite steps in
melanoma metastasis and progression. Activating B-RAF mutations are seen in
80% of benign nevi [226] cases whereas Abl kinases are elevated in only 33% of
cases, indicating that unlike B-RAF, activated Abl kinases probably do not play a
role in the melanoma initiation, but may play a role in later stages, such as
transforming cells from the RGP to VGP stage. Our work also establishes a link
between Abl kinases and metalloproteinases. MMPs are critical in converting
non-invasive RGP to invasive VGP, so c-Abl and Arg are likely to have a role in
this process. This study also reports for the first time that active Abl kinases
promote invasion, proliferation, and survival, and late stages of cancer
metastasis (experimental metastasis) of two human melanoma cell lines. Thus,
Abl kinases may be considered a novel drug-able target in metastatic melanoma
patients harboring high Abl kinases activities.
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c-Abl and Arg kinase activities are highly elevated in aggressive
melanoma cells (WM3248 and 435s/M14), but, in low invasive cells, like WM239,
c- Abl and Arg activities are low. We show that in 435s/M14 and WM3248 cells
harboring high c-Abl and Arg kinase activities, inhibition of Abl kinases by
nilotinib suppressed invasion to comparably, but in WM278 cells, which have
minimal to no Abl kinase activities, there was no inhibition of invasion observed
after nilotinib treatment. These results indicate that active Abl kinases are
necessary to drive the process of invasion in melanoma cells. In order to test
whether activation of Abl kinases is sufficient to drive the process of invasion in
melanoma, future experiments we will need to test whether stable constitutively
activated Abl kinases increases invasion of non/low invasive cells (WM239).
Our results indicate that Abl kinases promote melanoma proliferation in
contrast to their role in other cell types such as fibroblasts. Overexpression of cAbl causes G1 cell cycle arrest in fibroblasts, while we found that activation of Abl
kinases enhances G1/ S phase transition in 435s/M14 cells [55] and inhibition of
Abl kinases resulted in a block in proliferation in breast cancer cells. We found
that in 435s/M14 cells, inhibition of Arg but not c-Abl decreased proliferation [55];
however interestingly, in WM3248 cells both c-Abl and Arg promoted
proliferation. Furthermore, active c-Abl and Arg also increased proliferation in a
panel of melanoma cell lines. It is intriguing that the contribution of c-Abl and Arg
to proliferation differs in 435s/M14 and WM3248 cell lines since both these lines
have the same level of c-Abl and Arg kinase activation and both regulate
invasion in a similar fashion. In addition the finding that active Abl kinases drive
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proliferation in a panel of melanoma cell lines indicates that Abl kinases are
indispensable for driving proliferation in melanoma. Since, proliferative index is
usually considered a standard for identifying patients who have a high risk of
developing metastasis; proteins that can drive proliferation are good markers for
targeted chemotherapy [227, 228]. Cancer cells after they extravasate out of the
blood vessels survive and have to proliferate to form micrometastasis and
proliferate further to form macrometastasis. Hence, Abl kinase inhibitors might be
able to be used to block melanoma progression in a select group of patients
having activated Abl kinases.
Abl kinases promote breast cancer cell survival during nutrient deprivation
[55], and here, for the first time, we report that Abl kinases also promote the
survival of melanoma cells during the stress of nutrient deprivation. Apoptosis is
a major hindrance in tumor growth and metastasis, as tumor cells have to survive
in nutrient free conditions after they extravasate out of the blood vessels. Drugs
that promote apoptosis are attractive agents in the clinic to prevent metastasis
[229,230]. Thus our data indicate that the Abl kinase inhibitor, imatinib, may hold
promise in treating patients with metastatic melanoma.
Recently, Smith-Pearson et al reported that Abl kinases promote
gelatinase activity of MDA-MB-231 breast cancer cells and Src-transformed
NIH3T3 cells. The authors indicated that the mechanism involved Abl-dependent
phosphorylation of MMP-14 and subsequent localization to the plasma
membrane. They also showed that, in 239T cells, overexpression of c-Abl and
Arg induced the phosphorylation of MMP-14 and silencing Arg inhibited the
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localization of MMP-14 in the plasma membrane [62].However, the authors failed
to show endogenous c-Abl/MMP-14 complexes and Abl-dependent tyrosine
phosphorylation of endogenous MMP-14 in human cancer cells. Here, we show
that Abl kinases promote the transcription and activation of MMPs, including
MMP-14. c-Abl induces the transcription and activation of MMP-1 while Arg
induces the transcription and activation of MMP-1, 3 and MMP-14. We also show
that silencing c-Abl and Arg inhibited single-cell 3D single cell invasion, due to
the inability of these cells to degrade the collagen bed. These results indicate
that Abl kinases promote collagenase activity of melanoma cells, an important
prerequisite for promoting invasion. Since collagen I is an important constituent
of blood vessels and extracellular matrix, thus indicates that activation of Abl
kinases is likely to be important for melanoma cells to invade in (intrasavation),
and out of blood vessels (extrasavation).
Our results demonstrate that c-Abl and Arg form a complex with STAT3
and induce its phosphorylation. In our previous studies, we showed that Abl
kinases activate STAT3 in a JAK-independent manner [55]. Here we report that
the phosphorylation is not direct but through a yet to be identified kinase.
Phosphorylation of STAT3 at Y705 residue correlates with the transcriptional
activity of STAT3 [232], and thus, Abl kinases are likely to induce the
transcriptional activation of STAT3. Abl kinase signaling via STAT3 is required for
melanoma cell survival as expression of a constitutively active form of STAT3
partially rescues the block in survival of melanoma cells treated with imatinib.
Since this rescue is partial, it indicates that Abl kinases also promote survival via
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a STAT3-independent mechanism as well. The PI3K/AKT pathway is one of the
major survival pathways studied in melanoma and selective activation of Akt3
has been shown to promote melanoma cell survival [231,233]. These data
indicate that future studies should be directed to investigate this pathway as a
possible additional mechanism by which Abl kinases may promote survival in
response to nutrient deprivation. STAT3 plays a critical role in tumor progression
by controlling important processes such as proliferation, survival, and invasion.
STAT3 has been reported to be involved in tumorigenesis in many types of
cancer, including melanoma, and silencing of STAT3 signaling inhibited
melanoma growth in mice [74, 75, 79, 82, 86, 91]. Thus, it is possible that many
of these effects might be regulated by Abl kinases-dependent STAT3 activation.
Activation of STAT3 and MMPs is critical for transforming non-invasive RGP
melanomas to invasive VGPs. Since Abl kinases modulate the activity of STAT3
and MMPs, they may also play a critical role in RGP to VGP transition.
Arg-dependent proliferation in 435s/M14 cells does not occur via STAT3
signaling (demonstrated by Divyamani Srinivasan), indicating that not all
properties of Abl kinase-mediated oncogenesis occurs via Abl kinase-mediated
activation of STAT3. Abl kinases are known to promote PDGF-mediated cell
cycle progression by activating the Rac/JNK pathway and upregulating c-myc
expression [234] ; thus Arg might promote proliferation via such a pathway, which
is independent of STAT3. Phosphorylation of STAT3 by Abl kinases might also
be important in other biological processes known to be mediated by c-Abl/Arg
and STAT3, such as anchorage independent growth.
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Our findings show that activated Abl kinases upregulate invasion in
melanoma cells (Figure2.3 and [55]). Here, we report for the first time, that c-Abl
and Arg signal through divergent pathways to mediate the same biological
function. c-Abl signals through a STAT3/MMP-1 pathway to promote invasion of
melanoma cells (Figure 2.18 and 2.19), whereas Arg promotes invasion in a
STAT3-independent manner via MMP-1 and MMP-3. We also demonstrate that
c-Abl activates STAT3, which promotes invasion in a MMP-1-dependent manner.
STAT3, activated by EGF stimulation, has been shown to bind to the MMP-1
promoter by interacting with the AP-1 component c-Jun, and promotes bladder
cancer cell invasion and metastasis [222]. Thus, it would be interesting to
investigate whether STAT3 interacts with an AP-1 element to promote MMP-1
transcription in an IGF-1R-dependent manner since 435s/M14 cells express IGF1R receptors, rather than EGFR [55], and IGF-1 activation of STAT3/MMP-1 has
not yet been demonstrated.
Although, we have identified the mechanism by which c-Abl promotes
invasion, it is unclear how Arg promotes MMP expression and invasion. It is
possible that Arg might increase invasion through modulation of Akt-2/Protein
Kinase B, or via the transcription factor NF-κB. Activation of Akt is linked to the
activation of NF-κB in melanoma [235 ]. Overexpression of Akt2, in MDA-MB-435
cells increases invasion through matrigel [236], and thus, it is possible that Arg
may signal through Akt-2 to regulate invasion in melanoma cells. Indeed, we
found that Abl kinases upregulate phospho-pAkt levels and Akt isoforms 1, 2,
and 3 in 435s/M14 cells (S. Ganguly, unpublished data). In addition, our lab
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recently showed that Abl kinases promote transcriptional activation of the p65
subunit of NF-κB [237]. MMP-3 is activated by NF-κB, although there no NF-κB
binding site has been identified in the MMP-3 promoter region [238], indicating
that this interaction is likely to be indirect and mediated by yet another yet to be
identified transcription factor. Thus future experiments will test whether Arg
mediates invasion through a NF-κB and/or PI3K/Akt-dependent pathway.
There is currently controversy in the literature regarding the role of Abl
kinases in solid tumors. Studies from our lab and others have shown that Abl
kinases are activated in some solid tumors, and once activated they promote
invasion, anchorage-independent growth, proliferation, and survival in cancer [54
]. Although there are numerous papers substantiating our finding that Abl kinase
activation promotes solid tumor progression, some data from other laboratories
demonstrate that Abl kinases inhibit invasion and metastasis progression
[239,240,241]. However, these studies did not examine the activation status of
Abl kinases, or have inhibited Abl kinases in cells having low Abl kinase activity.
One study showed that treatment of MDA-MB-435 cells with ephrinB2, transiently
activated EphB4 and c-Abl/Arg, which inhibited proliferation, invasion, MMP
expression and xenograft tumor growth, and these effects were blocked by
inhibition of Abl kinases by imatinib [241]. In this case Abl kinase-mediated
downregulation of invasion could be also explained by the fact that, unlike growth
factors which promote invasion, this stimulus ephrin-B2/EphB4, inhibits invasion.
Moreover, the stimulation with ephrin B2 may not be physiological relevant in this
context as ephrinB2 expression is lost in metastatic cancer cells [241].
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Our studies show that inhibition of Abl kinases, using nilotinib, abrogated
the process of experimental metastasis. However, there are other reports that
have demonstrated some contrasting evidence in Abl kinases-mediated breast
cancer tumor growth, although they did not investigate the effects on
metastasis[239,240] However, their contrasting results can be attributed to the
use of mouse cell rather than human cancer cells and also overexpression of a
mutated, constitutively active form of c-Abl in mouse cancer cell lines. This
constitutive, mutated form of c-Abl is naturally not present in solid tumors. These
authors also showed that low doses of imatinib did not have any effect on tumor
growth in mice. These results may have been obtained due to inadequate
imatinib dosing. The half-life of imatinib mesylate is 4 to 5h, and plasma levels
decrease to less than 1% in 12 h [242] and, the authors only used low doses of
imatinib once daily. It is also possible that imatinib might not inhibit Abl kinases
at the threshold level needed to inhibit metastasis, and a more specific Abl
kinase inhibitor like nilotinib, as used in our study is required to inhibit metastasis
in an animal model. In support of this hypothesis, we found that imatinib mesylate
could not inhibit experimental metastasis of 435s/M14 cells (data not shown).
Since Abl kinases promote experimental metastasis and invasion, we can
hypothesize that Abl kinases will also upregulate spontaneous metastasis, which
involves invasion of cells from the primary tumor, intravasation, and all the other
steps involved in experimental metastasis. Future experiments are aimed at
testing this hypothesis.
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Our study reports for the first time, that Abl kinases are activated in
metastatic melanoma, promote many important steps of cancer progression in
vitro, and promote late stages of metastasis. Thus, our data indicate that
targeting Abl kinases with nilotinib may be effective for treating metastatic
melanoma. Unlike the successful targeting of c-Kit, with imatinib in
gastrointestinal tumors, a number of clinical trials using imatinib have not been
successful [54,243,244]. However, there were many limitations in these clinical
trials. First of all, these trails were conducted on untargeted populations, where
the activation status of Abl kinases in tumors was not evaluated. Secondly,
maximal doses of imatinib were not used to inhibit Abl kinases in these patients,
and thus, it isn’t clear whether the kinases were inhibited. Here, we demonstrate
that nilotinib inhibit metastasis, whereas imatinib failed, which could be due to
increased potency and selectivity of nilotinib towards Abl kinases [46]. Hence,
clinical trials using nilotinib should be conducted on patients whose melanomas
harbor active c-Abl and Arg. In summary, even though there is some conflicting
evidence for the use of imatinib or nilotinib in solid tumors, our work indicates that
in metastatic melanoma patients whose tumors are positive for active Abl
kinases, c-Kit, and/or PDGFR might benefit from nilotinib treatment.
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CHAPTER 3: Abl kinases Promote Invasion Via Cathepsin-Mediated
Lysosomal Degradation of A Metastasis Suppressor, NM23-H1
3.1 Introduction
NM23-H1, the first metastasis suppressor identified, has decreased
expression in metastatic cancer cell lines. Its expression also is inversely
correlated with metastatic progression in a large number of cancers. Although
NM23-H1 is extensively studied in suppressing cancer progression, no
mechanism has been elucidated for its loss of expression metastatic cancers like
melanoma, breast and colon. It also is not known how NM23-H1 is degraded,
and how its re-expression can be induced in metastatic tumors to inhibit cancer
progression [145-150].
Cathepsins, known to promote invasion and metastasis of cancer cells,
can also degrade proteins in acidic lysosomes. In cancer cells, cathepsin
expression is dramatically increased [177,178,190]. In melanoma,
overexpression of cathepsin leads to disease propagation and cathepsin B and L
are critical for melanoma progression. Extracellular cathepsin B and L are
secreted by tumor cells, and as a result promote invasion and metastasis by
degradation of extracellular matrix proteins, activating proteases (MMP) or by
inactivating TIMPs [178,182,190,192,194,195]. Although, the role of intracellular
cathepsins in cancer cell invasion and metastasis is not well studied, few studies
indicate that intracellular cathepsins promote invasion perhaps by degrading
collagen or by degrading proteins involved in invasion/progression such as E-
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cadherin [179,204]. Recently it has been reported that Abl kinases upregulate the
expression of cathepsin B and L in lung cancer cells, resulting in autophagy
[245], indicating that Abl kinases promote cathepsin activation and thus, most
likely also affect the endocytic/lysosomal pathway.
In Chapter 2, we elucidated the mechanism by which c-Abl promotes
invasion by demonstrating that it activates a STAT3-dependent MMP-1 pathway,
whereas Arg promotes invasion in a STAT3-independent, MMP-1 and 3dependent manner. However, the rescue we observed with MMP-1
overexpression or recombinant protein is partial (40%), indicating that there is
likely another parallel pathway that Abl kinases affect to regulate invasion in
melanoma cells.
In a uveal model of melanoma, imatinib treated tumors cells, when
extracted and cultured in vitro, showed an increase in the expression of KISS1, a
metastasis suppressor gene, indicating that inhibition of Abl kinases might
promote the expression of metastasis suppressor genes [73]. Given that Abl
kinases promote melanoma invasion and progression whereas NM23-H1 inhibits
progression, we hypothesize that Abl kinases promote melanoma progression by
downregulating the metastasis suppressor NM23-H1.
This chapter will address if Abl kinases can downregulate the expression
of NM23-H1 in melanoma cells, and will evaluate the mechanism by which Abl
kinase degrades NM23-H1. We will also investigate the biological significance
associated with the Abl kinases -mediated NM23-H1 degradation.
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3.2 Materials and Methods
Cell Lines:
435s/M14 and BT-549 cell lines expressing NM23-H1shRNA were created by
lentiviral-mediated infection of sigma Mission shRNA constructs 182s1c1 or nontarget shRNA (PLKO1). Cells were plated and a day later 8µg of polybrene was
added per milliliter of media prior to infection with 20µl of the virus (MOI 10).8h
after infection, cells were refreshed with fresh media. The cells were selected
with Puromycin, clones were pooled together and stable cell line was made. L.
Fiore established these cell lines.
Other cell lines are as described before in Chapter 2.
Reagents:
The following antibodies were purchased commercially: NM23-H1 (sc-465;
immunofluorescence), LAMP1, NM23-H1 (C-20) was purchased from Santa Cruz
Biotechnology; Santa Cruz, CA; EEA1, Rab7, NM23-H1/H2 (D141), NM23-H1/H2
(D98; immunohistochemistry, western blotting) (Cell Signaling; Danvers, MA),
Cathepsin L was from Sigma (St. Louis MO), Cahepsin B was from Abcam
(Cambridge, MA) and HRP-conjugated secondary antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA), and fluorescently labeled secondary
antibodies (Alexafluor 488 and 555) were from Cell Signaling (Danvers, MA).
pcDNA-c-Abl-PP and pcDNA-Arg-PP constructs were described previously
(Plattner et al 1999). Recombinant NM23-H1 was a kind gift from Drs Rob
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McCorkle and David Kaetzel [Ma et al 2004]. All other antibodies were described
Chapter 2.
siRNA: Pre-validated siRNA against NM23-H1 (s9588; 1nM); cathepsin L1
(s3753; 5nM); cathepsin B (s3740; 5nM), scrambled control #1 (control for nonsilencer select siRNAs), silencer select scrambled #1 (for silencer select siRNAs)
were purchased from Applied Biosystems/ Ambion; Carlsbad, CA. Scrambled
siRNA concentrations were used at concentrations equivalent to the test siRNA.
Other RNAi are described in Chapter 2.

Procedures
Western Blots: Described in Chapter 2.
Soft agar Colony Formation Assay [64 ]: Cells stably expressing PLK01 vector or
NM23-H1 shRNA (4 X103 cells) were plated in 0.3% soft agar on top of 0.6%
agar in 60mm dishes, in the absence or presence of 10µm imatinib. Cells were
fed with media containing 10µm imatinib or vehicle every week once and after 3
weeks of incubation; colonies (≥ 100 microns) were counted. Experiments were
done in triplicates and repeated twice.
Immunohistochemisty: Details are in Chapter 2.
Invasion assay: Details are in Chapter 2.
Single-cell 3D Invasion assay: Details are in Chapter 2.
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In-vitro-Proteolysis Assay [246]: Recombinant NM23-H1 (1ul; 875ng) was
mixed with 3ul Buffer L (25 mM HEPES pH 7.4, 5 mM MgCl2, 1 mM EGTA, 0.5%
Triton X-100, 5 mM DTT), 5ul of recombinant cathepsin B or L, 5ul 3X reaction
buffer (150mM sodium acetate pH 6.0, 12mM EDTA, 24mM DTT) and 1ul water.
Reactions were incubated for the indicated times at 370C, terminated by addition
of SDS-PAGE buffer, ran in 20% SDS-PAGE gel, and blotted for C-termini (C-20;
NM23H-1; Santa Cruz) and N-termini (D-141, NM23-H1; Cell signaling)
recognizing NM23-H1 antibodies.
Mass Spectrometry and Edman Degradation N-terminal sequencing.
Cathepsin B (2.5ug) or L (160ng) were incubated for 30’ with 875ng of NM23-H1
as described above, and reactions terminated by addition of 15% glacial acetic
acid. Due to the presence of glycerol and detergent in the samples, mass
analysis was performed with an AB Sciex (Framingham, MA) 4800 MALDI
TOF/TOF mass spectrometer in linear, mid-mass mode (2-20 kDa) using the
Chait thin layer method [247] by Carol Beach in the University of Kentucky
Proteomics Facility. From the stock reaction mixture a 1:10 dilution of sample
was analyzed which consisted of 10,000 laser shots at a detector voltage of
1.971 kV, and the signal was averaged. Substrate (NM23-H1; 1:10) and
enzymes (cathepsins, 1:10) were also measured using the same criteria.
Cathepsin L spectra could not be visualized due to the low amount of enzyme
utilized. For N-terminal sequencing, proteolysis reactions were run on 20% SDSPAGE gels, transferred to Immobilon PSQ membrane, stained with Coomassie
Blue, and de-stained until bands were visible. C-terminal fragments were
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sequenced by Edman Degradation in the Protein Structure Core Facility at the
University of Nebraska Medical Center (Omaha, Nebraska).
Immunofluoresence and Confocal Microscopy: 435s/M14 cells plated on
glass coverslips in 6 well plates, were allowed to settle overnight, and treated
with imatinib for 4h. Cells were fixed in 4% paraformaldehyde, blocked in 5%
goat serum, incubated with primary antibodies (EEA1-1:100, Rab7-1:25, NM23H1 sc465-1:400, LAMP1-1:10) in PBS/1%BSA/0.3% Triton-X-100, followed by 1h
incubation with fluorescent-conjugated secondary antibodies (Alexafluor 488green or 555-red (1:1000)) (Cell Signaling, Danvers, MA) and mounting in
ProlongGold Antifade solution (Invitrogen, Grand Island, NY). Photographs were
taken on an Olympus FV1000 laser scanning confocal microscope, with 60 X
objectives (oil emersion) with 488nm and 550nm laser lines. Magnified images
are 3X.
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3.3 Results
3.3.1 c-Abl and Arg induce the downregulation of metastasis suppressor,
NM23-H1
Abl kinases mediate melanoma invasion partially through MMP-1 and MMP-3
(Chapter 2), indicating that Abl kinases will also promote invasion via another
mechanism. In the search for some another mechanism, we screened a panel of
melanoma cells for the presence of a metastasis suppressor NM23-H1. As
shown in Figure 3.1A, phosphorylation of Abl kinase substrates, Crk/CrkL, was
inversely correlated with NM23-H1 expression in melanoma cells (Figure 3.1A
right). pCrk/CrkL can be used as a read out of c-Abl and Arg activity as inhibition
of c-Abl and Arg with imatinib mesylate in breast cancer and melanoma cell lines
suppress pCrk/CrkL levels in a dose-dependent manner similar to silencing c-Abl
or Arg [55,64 ]. 435s/M14 and WM3248, which express high levels of
phosphorylated Crk/CrkL ,express low levels of NM23-H1 as compared to the
low invasive cell line, WM239, which has high levels of NM23-H1. To assess
whether Abl kinases mediate downregulation of NM23-H1 in invasive melanoma
cells, both pharmacological and siRNA-mediated inhibition approaches were
used. Silencing of Abl kinases with 2 independent siRNAs targeted against c-Abl
or Arg respectively, stabilized NM23-H1 expression in 435s/M14 cells. Leann
Fiore, a graduate student in our lab, found that inhibition of Abl kinases by the
pharmacological inhibitors, imatinib or nilotinib, also stabilized NM23-H1
expression, in 435s/M14 cells (Figure 3.1B and 3.2, data not shown). To
substantiate that this is not a cell-specific phenomenon, we examined whether
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inhibiting/ silencing Abl kinases induced NM23-H1 upregulation in other cell lines
(WM3248-melanoma, BT-549-breast cancer). Indeed, NM23-H1 upregulation
was observed in both cell lines and tumor types (melanoma, breast) (Figure
3.1C,D and 3.2). To validate our loss of function studies, we also used a gain of
function approach. Constitutive forms of c-Abl and Arg (Abl-PP/Arg-PP) were
transiently expressed in a low invasive cell line expressing low c-Abl and Arg
kinase activities (WM164-melanoma). Mutation of the two-proline residues in the
interlinking region between the SH1 and SH2 domains to glutamate generates
Abl-PP and Arg-PP, resulting in the loss of auto-inhibition, and subsequent
constitutive activation. Overexpression of constitutively active forms of c-Abl and
Arg induced the downregulation of NM23-H1 in WM164 cells (Figure 3.1E and
3.2 C). These results indicate that c-Abl and Arg are necessary and sufficient to
downregulate NM23-H1 in invasive melanoma cells.

3.3.2 NM23-H1 is degraded via the lysosomal, cysteine cathepsins
To assess the mechanism by which Abl kinases degrade NM23-H1 in melanoma
cells, Leann Fiore, first investigated whether the downregulation of NM23-H1 by
Abl kinases is transcriptionally regulated. She found out that siRNA -mediated
knock down of c-Abl or Arg did not have any significant effect on the transcript
levels of NM23-H1 as assessed by semi-quantitative RT-PCR (data not shown).
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Figure 3.1 c-Abl and Arg is necessary and sufficient for NM23-H1 loss in
cancer cells.(A) c-Abl/Arg activities were assessed indirectly via phosphorylation
of Crk/CrkL in melanoma cell lines, lysates were blotted with indicated
antibodies, and log-transformed values for c-Abl/Arg activity plotted against logtransformed NM23-H1 expression values (A right). An inverse correlation was
found between c-Abl/Arg activity and NM23-H1 expression, which was
statistically significant: Pearson's correlation coefficient =-0.85, 95% confidence
interval -0.98 to -0.139, p=0.03. Done in collaboration with W. Friend (B-D)
Cancer cell lines containing highly active c-Abl/Arg were transfected with c-Abl or
Arg siRNAs or treated with vehicle or c-Abl/Arg inhibitor imatinib (10µM) for 8h,
and blotted for indicated antibodies. NM23-H1 expression was quantified and
expressed relative to loading controls and relative to scrambled or vehicle-treated
cells. Knock-down efficiency was determined by blotting with c-Abl and Arg
antibodies. Figure 2B left panel (Set #1 siRNA) was done by Dr R. Plattner.
Figure 3.1B and Figure 3.1 D right panel (imatinib treatments) was performed by
L. Fiore (E) WM164 melanoma cells were transiently transfected with
constitutively active forms of c-Abl and Arg (PP), lysed three days after
transfection, blotted for indicated antibodies and efficiency of overexpresison was
determined by blotting for c-Abl, Arg and pCrk/CrkL.
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WM3248

Figure3.2: Activation of c-Abl and Arg reduces expression of NM23-H1.
Highly invasive cancer cell lines known to express activated c-Abl/Arg, were
treated with imatinib (10µM) for 8h (A), or were transfected with 2 independent
sets of siRNA directed against c-Abl and Arg or scrambled control (B) as
described and shown in Figure 3.1 (C). Low-invasive WM164 cells were
transiently transfected with c-Abl-PP and Arg-PP (constitutively active forms),
and lysates blotted with the indicated antibodies. In all graphs relative NM23-H1
expression was quantified and expressed relative to loading controls and relative
to scrambled or vehicle-treated cells. (Mean± s.e.m for 3-4 independent
experiments). *p<0.05, **p<0.01, ***p<0.001 using single-sample t-tests.
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In addition, treatment with the proteosomal inhibitor, MG132, also did not result in
stabilization of NM23-H1 in 435s/M14 cells, but did stabilize p27, a protein known
to be degraded by the proteosomal pathway. These data indicate that NM23-H1
is not degraded via the proteasome (data not shown). Interestingly, treatment of
435s/M14 cells with the lysosomal protease inhibitors, ammonium chloride and
chloroquine or with a cell permeable cysteine protease inhibitor (E64D), induced
NM23-H1 protein expression (Figure 3.3A). These results indicate that NM23-H1
could be degraded by the lysosomal cysteine proteases E64D is known to inhibit
a wide range of cysteine proteases including cathepsin B and L, which have
known roles in cancer invasion and metastasis. Overexpression of cathepsin B
and L are reported in many carcinomas and is frequently associated with a poor
prognosis. Silencing cathepsin B or L in 435s/M14 cells induced the expression
of NM23-H1 (Figure 3.3B). Taken together these results indicate that NM23-H1 is
degraded via cathepsin B and L. Since degradation of NM23-H1 is dependent on
cathepsin B and L, we investigated whether cathepsin B and L directly
cleave/degrade NM23-H1 in vitro. To test this hypothesis, recombinant, NM23H1 was incubated with recombinant, active forms of cathepsin B or L in acidic
conditions which favor cathepsin activation. Cathepsin L cleaved NM23-H1 as
evidenced by the appearance of a 10kD band detected by blotting with an
antibody, which detects the C-terminus of NM23-H1 (Figure 3.4 A). Using an
antibody that recognizes N-terminus of NM23-H1, we also detected a 6kD band.
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Figure 3.3: NM23-H1 is degraded via the lysosomal cysteine proteases,
cathepsin B and L in 435s/M14 cells. 435s/M14 cells were treated with
lysosome inhibitors (ammonium chloride, 60mM; chloroquine, 100mM, E64Dcysteine protease inhibitor, 20mM) for 8h (A), or transfected with siRNAs against
cathepsin B and L ( B), lysed, and blotted with the indicated antibodies.
Representative experiments are shown and graphed (C) relative to vehicletreated or scrambled control as shown in (A-B). Graphs are Mean±s.e.m for 3
independent experiments; *p<0.05, **p<0.01 using one-sample t-tests. These
experiments were performed by L.Fiore
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Cathepsin L directly cleaved NM23-H1 in a dose- and time-dependent manner
(Figure 3.4A). Similar results were observed with cathepsin B (Figure 3.4B).
These results indicate that cathepsin B and L directly cleave NM23-H1.
To more accurately assess the mass of the cleavage products, the
reactions were analyzed by mass spectrometry (performed by University of
Kentucky Proteomics facility; Carol Beach). An aliquot of the in vitro proteolysis
samples were run in a SDS-PAGE gel and blotted with antibody to the NM23-H1
C-terminus to confirm the efficiency of the reaction (Figure 3.5, 3.6; inset). Mass
Spectrometry analysis of the mock reaction resulted in the visualization of a 17
kD peak, which corresponds to the full length NM23-H1. Incubation of NM23-H1
with the cathepsins led to the appearance of 9.7 kD peak and 6.6 kD peaks, in
addition of some smaller species (Figure 3.5). The C-terminal NM23-H1
fragments were sequenced (Edman Degradation), and their N-termini identified
as “YMHSGP” (Figure3.4C); (University of Nebraska Protein Structure Core
Facility).
We detected 5-6kd, N-terminal NM23-H1 fragments following incubation with
cathepsins as determined by SDS-PAGE analysis. However, the predicted
weight of N-termini fragment should be 7.6 kD if the cathepsins only one time at
the "YMHSGP" cleavage site. Since the predicted mass is more than the actual
mass detected, this indicates that the N-terminal fragment probably was cleaved
more than once resulting in smaller fragments that cannot be detected on a 20%
SDS-PAGE gel. These results indicate that cathepsin B and L directly cleave
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Figure 3.4: Recombinant cathepsin B and L directly cleave NM23-H1.
Recombinant active cathepsin L (A) and B (B) were incubated with NM23-H1
(875ng) at 37oC in acidic conditions as described in Section 3.2, for the indicated
time, run in 20% SDS-PAGE gel, Coomassie-stained or transferred to
nitrocellulose and probed with the indicated antibodies.
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Figure 3.5: Active cathepsin L directly cleaves NM23-H1. Recombinant active
cathepsin L was incubated with recombinant NM23-H1 for 30’ at 37oC as
described in Figure 3.4 the reaction was stopped with 15% glacial acetic acid and
analyzed by MALDI MS using the Chait thin-layer technique. (M+2H)++or
(M+3H)+++ indicates multiple charging due to oxidation. The NM23-H1 protein
was completely cleaved in the reaction (bottom panel). An aliquot of the reaction
was, run on a 20% SDS-PAGE gel, and probed for indicated antibody (as shown
in the bottom panel)
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Figure 3.5: Active cathepsin B directly cleaves NM23-H1. Recombinant active
cathepsin B was incubated with recombinant NM23-H1 for 30’ at 37oC as
described Figure 3.4. The reaction was terminated by the addition of 15% glacial
acetic acid and analyzed by MALDI MS using the Chait thin-layer technique.
(M+2H)++or (M+3H)+++ indicates multiple charging due to oxidation. The NM23-H1
protein was partially cleaved in the reaction (bottom panel). An aliquot of reaction
was taken, run on 20% SDS-PAGE gel, and probed with the indicated antibody
as shown in bottom panel.
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NM23-H1 at the same site, and given the role of cathepsin B and L in degrading
proteins in lysosomes, these results give additional evidence that NM23-H1 may
be degraded in the lysosomes. This hypothesis will be addressed in section 3.3.4

3.3.3 c-Abl and Arg promote cathepsin expression and activation in
melanoma cells
Abl kinases downregulated NM23-H1 in melanoma cells, and degradation of
NM23-H1 is dependent on cathepsin B and L. Thus we tested whether Abl
kinases upregulate the expression and activation of cathepsin B and L. Silencing
c-Abl or Arg in 435s/M14 cells, significantly reduced the expression of the
proform (located in transgolgi and early endosome) of cathepsin B and L,
indicating that c-Abl and Arg promote overall cathepsin expression. Interestingly,
the lysosomal mature double chain active form of cathepsin B and L was
significantly decreased with silencing of c-Abl (Figure 3.7), indicating that c-Abl
activates the cathepsins .To investigate the mechanism by which c-Abl and Arg
increase the procathepsin expression, we assess whether Abl kinases
transcriptionally regulate cathepsin expression. Leann Fiore found out that
silencing of c-Abl or Arg, significantly decreased cathepsin B and L mRNA levels
in 435s/M14 cells, indicating that cathepsin upregulation occur at the mRNA level
(data not shown). These results indicate that although both c-Abl and Arg
upregulate cathepsin expression, activation is promoted only by c-Abl.
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Figure 3.7: c-Abl promotes cathepsin B and L activation. 435s/M14 cells
transfected with scrambled, c-Abl or Arg siRNAs were split 2 days after the first
transfection, and lysed one day later when the cells were of equal confluency.
The lysates were probed for indicated antibodies (A) and graphed (B)
normalizing to loading and scrambled controls. Graph are Mean ±s.e.m *p<0.05,
**p<0.01, ***p<0.001 using one-sample t-tests.
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3.3.4 c-Abl promotes endosome-lysosome trafficking
We found that cathepsin B and L directly cleave NM23-H1, and that cathepsins B
and L are activated by c-Abl. Since cathepsins cleave various proteins in the
lysosome, we tested whether NM23-H1 is degraded in the lysosomes in a c-Abl dependent manner. To confirm that NM23-H1 is localized in the
endosomes/lysosome, and to test whether inhibition of c-Abl and Arg alters the
distribution/localization of NM23-H1 in these vesicles, we performed
immunofluorescence using antibodies that recognize specific surface markers on
vesicles within the pathway as well as NM23-H1 antibody. We found that NM23H1 is located in the cytoplasm in the majority of cells, and silencing of NM23-H1,
abrogated all NM23-H1 (sc 465) staining indicating the specificity of this antibody
for NM23-H1 (Figure 3.8).
To examine whether NM23-H1 is localized within endosomes, we costained cells with antibodies to EEA1 (early endosome marker and effector of
Rab5). In vehicle-treated cells, small NM23-H1 puncta partially colocalized with
EEA1; however inhibition of Abl kinases with imatinib for 4h induced enlarged
EEA1-positive vesicles. Imatinib treatment also increased the clustering of EEA1
positive vesicles in one perinuclear region (Figure 3.9 and 3.10) and increased
the staining intensity. Silencing c-Abl also considerably increased the clustering
of EEA1-positive vesicles in a perinuclear region (Figure 3.9 and 3.10).
Moreover, we observed a greater colocalization between NM23-H1 and EEA1 in
cells in which c-Abl was silenced as compared to scrambled control cells.
Silencing Arg increased the EEA1 perinuclear localization; however, the vesicles
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Figure 3.8: The NM23-H1 antibody specifically stains NM23-H1 in 435s/M14
cells. 435s/M14 cells, transfected with scrambled control or NM23-H1 siRNAs,
were stained with NM23-H1 antibody (sc-465, used for immunofluorescence)
followed by fluorescent-conjugated secondary antibody, and counterstained with
DAPI.
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Figure 3.9 and Figure 3.10: Silencing/inhibiting c-Abl alters the
localization and trafficking of early endosome. 435s/M14 cells were
treated with imatinib for 4h or transfected with siRNAs against c-Abl and
Arg (Set #1). The cells were stained with indicated antibodies, and
counterstained with DAPI. Pictures were taken under confocal microscope
using the brightest EEAI focal plane with a 60X oil-emersion objective. 3X
magnified images from original images are in Figure 3.9. Insets show
enlarged areas from the focal plane shown with an arrow.
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were not confined to one perinuclear region observed following silencing
c-Abl. During endosome maturation early endosomes are acidified and
move along the microtubules to travel to theperinuclear region. The
endosomes become enlarged during the acidification process [248,249].
To test whether c-Abl affects the acidification process, we treated cells
with chloroquine. Chloroquine is lysosomotrophic reagent, which prevents
the acidification of endosomes, and thus prevents the endosomes from
moving to the perinuclear region. Chloroquine treated cells had bigger
early endosomes, but they were not confined to one perinuclear region in
contrast to the effects observed when cells were treated with imatinib or
silenced with c-Abl RNAi (Figure 3.11). Since the effects of
inhibiting/silencing c-Abl were distinct from those obtained with
chloroquine, we hypothesize that c-Abl promotes endosomal maturation
independent of the acidification process.
To analyze whether these large EEA1-positive perinuclear early
vesicles, induced by c-Abl silencing, express late endosome marker
(Rab7), an important step in endosome maturation, we stained cells with
Rab7 (an effector for late endosomes). Rab 5 to Rab 7 conversion is
essential in early-to-late endosome maturation. The transition between
early to late endosome occurs by switching small GTPase Rab5 (early
endosome) to Rab7 GTPase (late endosomes) [248]. Unlike EEA1,
inhibition of Abl kinases or silencing c-Abl or Arg did not change the
localization of Rab7 (Figure 3.12), indicating that the early endosomes
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Figure 3.11: Inhibition of endosome/lysosome acidification by
chloroquine induces larger/clumped non-perinuclear early endosomes.
435s/M14 cells were treated with chloroquine (100mM; 4h), stained with
indicated antibodies and counterstained with DAPI. Pictures were taken under
confocal microscope in the brightest EEAI focal plane using 60X oil emersion
objective. 3X magnified images from 60x magnification pictures are shown here.
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Figure 3.12: Silencing/inhibiting c-Abl has no effect on late endosome
distribution, and NM23-H1 partially colocalizes with late endosomes.
435s/M14 cells were treated with imatinib for 4h or transfected with siRNAs
against c-Abl and Arg (Set #1). The cells were stained with the indicated
antibodies, and counterstained with DAPI. Pictures taken under confocal
microscope in the brightest RAB7 focal plane using 60X oil-emersion objective
and 3X zoom pictures from 60X are shown here.
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detected previously were not hybrid early/late endosomes. Moreover, in vehicletreated or scrambled control cells, unlike EEA1, there was considerable
colocalization of NM23-H1 with Rab7 (Figure 3.12), indicating that, NM23-H1 is
present in Rab7-positive vesicles. Silencing, c-Abl decreased Rab7 staining
intensity. Furthermore, although silencing c-Abl did not change the distribution of
LAMP1 positive vesicles (lysosomes) the intensity of LAMP-1 staining
decreased, similar to Rab7 staining (Figure 3.13). These results indicate that
inhibition of c-Abl likely decreased the total Rab7 (late endosomes) and LAMP1
positive vesicles (lysosomes) present. Thus, c-Abl inhibition results in the
accumulation of early endosomes, and depletion of the late endosomes and
lysosomes, which indicate that c-Abl likely promotes early to late endosome
maturation.

3.3.5 c-Abl and Arg mediate invasion of melanoma cells in a NM23-H1dependent manner
Forced expression of NM23-H1 in invasive cancer cells inhibits invasion,
anchorage-independent growth, and metastasis [145,148.149, 159,160]. Our lab
previously demonstrated that Abl kinases upregulate invasion, anchorageindependent growth [54] and single-cell 3D invasion in melanoma cells
(described in Chapter 2). To investigate whether Abl kinases mediate invasion
via degradation of NM23-H1 in 435s/M14 cells, we stably expressed NM23-H1
shRNA in order to prevent stabilization of NM23-H1 following c-Abl/Arg inhibition.
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In vector-infected 435s/M14 cells, imatinib treatment significantly reduced
matrigel invasion and single-cell 3D invasion; however, these effects were
rescued in cells expressing a NM23-H1 shRNA (Figure 3.14 A and B). Thus the
downregulation of NM23-H1 is required to promote matrigel invasion and singlecell 3D invasion in 435s/M14 cells. However, in BT549 cells the rescue in
invasion using the NM23-H1 shRNA was only partial (Figure 3.15), indicating that
Abl kinases mediate invasion via a NM23-H1-dependent and -independent
pathways. Interestingly, inhibition of NM23-H1 in 435s/M14 cells increased soft
agar growth as compared to the vector control cells, and silencing NM23-H1
partially enhanced anchorage-independent growth in the presence of imatinib
(Figure 3.16), indicating that Abl kinases promoted anchorage- independent
growth in a NM23-H1-dependent and -independent manner.
In Chapter 2 we have described that active Abl kinases promote late
stages of melanoma metastasis (Figure 2.20A), and showed that c-Abl/Arg
kinase activity (assessed by pCrk/CrkL immunohistochemistry (IHC) staining)
correlated with metastatic burden (IVIS luminescence) in lung nodules from
nilotinib-treated mice injected with 435s/M14-GFP/luciferase cells (Figure 2.21).
Mouse that did not respond to nilotinib had large nodules, stained intensely with
pCrk/CrkL antibody as compared to mouse which responded to nilotinib,
indicating that the anti-metastatic capability of nilotinib is linked to inhibition of cAbl/Arg kinase activity. To determine whether anti-metastatic property of nilotinib,
is also associated with upregulation of NM23-H1 in vivo, we stained lungs from
nilotinib-treated mice (Figure 2.21) with NM23-H1 antibody. Significantly, the
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Figure 3.13: Silencing c-Abl decreases the intensity of lysosome staining
(LAMP1). 435s/M14 cells were transfected with siRNAs directed against c-Abl
and Arg (Set#1), stained with LAMP1 antibody, and counterstained with DAPI.
Fields from two independent experiments are shown. Pictures were taken on a
confocal microscope using the brightest LAMP1 focal plane using 60X oilemersion objective and 3X zoom.
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Figure 3.14: Abl kinases promote invasion of melanoma cells by the down
regulation of NM23-H1. (A-B) 435s/M14 cells transected stably with NM23-H1
shRNA or vector control (PLKO1), were treated with imatinib for 20h and serumstarved (A), and used for a matrigel invasion assay for 48h(A; 48h timepoint ) or
single-cell 3D invasion assay (B; 2h timepoint). The graphs are mean± s.e.m
(n=3 independent experiments), normalized to vehicle treated cells. Aliquots of
cells were taken, lysed, and probed for indicated antibodies to assess
knockdown efficiency. Representative blots are shown. One-way ANOVAs
followed by Tukey posthoc tests were used to measure statistical significance.
*p<0.05, **p<0.01
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Figure 3.15: Abl kinases promote breast cancer cell invasion via down
regulation of NM23-H1. BT549 cells, transfected stably with NM23-H1 shRNA
or vector control (PLKO1), were treated with imatinib for 20h, serum-starved and
used in a matrigel invasion assay for 48h. The graphs are mean± s.e.m (n=3
independent experiments), normalized to vehicle-treated cells. Aliquots of cells
were taken, lysed, and probed with the indicated antibodies to determine
knockdown efficiency. Representative blots are shown. One-way ANOVAs
followed by Tukey posthoc tests were used to measure statistical significance.
*p<0.05, **p<0.01
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Figure 3.16: c-Abl/Arg promotes anchorage-independent growth via NM23H1-dependent and- independent pathways. (A,B) Soft agar assays were
conducted with 435s/M14 cells, transected stably with NM23-H1 shRNA or vector
control as described in Chapter 3.2. After 3 weeks of incubation, colonies
(>100mm) were counted and graphed by normalizing to (A) PLKO1(vehicle
alone), vehicle-treated cells or (B) by comparing the effects of imatinib treatment
in both cell lines used. Experiments were performed in triplicate. Graphs are
Mean±s.e.m for two independent experiments.
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mice that responded to nilotinib, having lesser metastatic burden (lesser Flux
number), with small metastatic lesions had more NM23-H1 expression as
compared to the mouse that did not respond to nilotinib. NM23-H1 expression
was inversely correlated with c-Abl/Arg activity and metastatic burden in all
nilotinib-treated mice (Figure 3.17), indicating that c-Abl/Arg inhibition induces
NM23-H1 stabilization, in vivo. Summarizing these findings, we can conclude
that Abl kinases promote matrigel invasion and single-cell 3D invasion assay and
experimental metastasis via the degradation of the metastasis suppressor,
NM23-H1, whereas soft-agar growth is only partially dependent on NM23-H1
degradation.

3.3.6 c-Abl and Arg activity and NM23-H1 expression are inversely
correlated in primary melanomas
As described in Chapter 2, using a commercially available melanoma TMA, we
have shown that c-Abl/Arg is activated in some primary melanomas. In contrast
to B-RAF, which is activated in benign nevi, c-Abl/Arg activity was more highly
elevated in primary melanomas and metastasis as compared to benign nevi. This
is in contrast to NM23-H1 expression, which is induced in primary melanomas,
and suppressed at later stages during progression. To investigate whether
activation of Abl kinases is inversely associated with NM23-H1 expression in
melanoma, Leann Fiore examined c-Abl/Arg activity (assessed via pCrk/CrkL
staining) and NM23-H1 expression in commercially available primary melanoma
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TMAs. As shown in Figure 3.18, cores with high pCrk/CrkL-staining intensity had
very low NM23-H1 staining and vice-versa, indicating that c-Abl/Arg activity is
inversely correlated with NM23-H1 expression in primary melanomas. Thus, the
signaling axis that we have identified in melanoma cell line also exists in the
human disease.
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Figure 3.17: c-Abl/Arg induces NM23-H1 degradation in vivo. Lungs sections
from mice injected with 435s/M14/GFP/luciferase, treated with nilotinib (Chapter
2), were stained with pCrk/CrkL and NM23-H1 antibodies. Representative lungs
section shown from mice which responded to nilotinib treatment (mouse 1) and
mouse which did not respond to the treatment (mouse 2) are shown. IVIS flux
values for all mice are shown (top right). Arrows indicate the mice, lungs shown
in top left. NM23-H1 IHC scores were plotted with IVIS flux values (bottom left) or
pCrk/CrkL values (bottom right). NM23-H1/Flux Pearson's correlation coefficient
= 0.92, 95% confidence interval -0.988 to -0.544, p=0.0033. NM23-H1/pCrk/CrkL
Pearson's correlation coefficient =0.78, 95% confidence interval -0.965 to 0.068, p=0.038. Lungs were stained by L.Fiore
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Figure 3.18: c-Abl/Arg activities and NM23-H1 expression are inversely
correlated in primary melanomas. An NCI Progression TMA containing nevi
(n=81), primary melanomas (n=60), and lymph node/organ metastases (lymph,
n=37; organ, n=67) were stained with pCrk/CrkL antibody as described in
Chapter 2.2. The cores were blindly scored by pathologists as described earlier
in Figure 2.2. Representative regions of the slides shown with screen shots
obtained with Aperio software (left); Mean pCrk/CrkL scores (Mean±SEM, right).
Bracket indicates p-value for one-way ANOVA, **p<0.01. This experiment was
performed by L. Fiore and scored by Dr. Michael Cibull MD.
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3.4 Discussion
Although there is extensive literature describing the metastasis suppressor
function of NM23-H1, there is little evidence of how it is degraded in invasive
cancer cells. Here, we report for the first time that Abl kinases downregulate
NM23-H1 in a cathepsin-dependent manner. We also identify that cathepsin B
and L directly cleave NM23-H1at the same site, which results in protein
degradation. To date, no studies report the mechanism by which NM23–H1 is
degraded in invasive cancer cells. Our work provides the first evidence that
NM23-H1 is degraded in the acidic lysosomes, in a cathepsin B and L-dependent
manner, and we also provide the first evidence demonstrating that a protooncogene degrades a metastasis suppressor to promote invasion (Figure 3.19).
We also show that the pathway we identified has clinical relevance as c-Abl/Arg
activation is inversely correlated with NM23-H1 expression in primary
melanomas.
In the previous chapter, we have shown that Abl kinases activity is highly
upregulated in melanoma cells, and once activated, Abl kinases promote
invasion, survival, proliferation and metastasis of melanoma cells. Here, we show
that c-Abl/Arg activity is inversely correlated with NM23-H1 expression in
melanoma cells. Very low invasive WM239 and Sbcl2 cells have very high levels
of NM23-H1 expression as compared to the invasive WM3248 and 435s/M14
cells, indicating that low Abl kinase activity and high NM23-H1 expression render
a cell with low invasive capacity, in contrast to 435s/M14 and WM3248 cells,
which are highly invasive and have low NM23-H1 expression and high c-Abl/Arg
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activity. Silencing c-Abl and Arg induces stabilization of NM23-H1 in 435s/M14
and WM3248 cells as well as in BT549 breast cancer cells. Inhibition of Abl
kinases by imatinib also stabilizes NM23-H1 to a similar extent as silencing of cAbl/Arg, indicating that the effects that we observe are dependent on the kinase
activities of c-Abl/Arg. Moreover, transient transfection of constitutive active Abl
and Arg-PP into low invasive WM164 melanoma cells induces downregulation of
NM23-H1 in low invasive melanoma cells. Thus we have used gain-of-function
and loss-of- function approaches to show that c-Abl/Arg are required and
sufficient for NM23-H1 downregulation in cancer cells.
Extracellular cathepsins play a pivotal role in the invasion of cancer cells;
however, not much is known regarding how intracellular cathepsins promote
invasion. Intracellular cathepsins may promote invasion by cleaving proteins
such as laminin, type IV collagen, the cell adhesion protein, E-cadherin, as well
as dynamin, which functions during endocytosis of cells [179, 200-204, 207]. We
demonstrate a previously unrecognized role for intracellular cathepsins:
degradation of the metastasis suppressor, NM23-H1 via cathepsins B and L.
Using an in vitro cleavage assay, we also show that cathepsin B and L cleave
NM23-H1 directly in the same site in a low acidic environment, indicating that
both these cathepsins might have redundant functions in regulating NM23-H1
activity. Silencing c-Abl suppresses the activation of cathepsin B and L while
silencing Arg had no effect on cathepsin double chain processing. However, Arg
promotes the expression of cathepsin B and L and also induces NM23-H1
degradation, indicating that Arg probably affects some other cathepsins important
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in NM23-H1 degradation. Non-metastatic melanoma cells can be transformed to
metastatic cells by overexpressing cathepsin L [195] indicating that Abl/Arg-PP
overexpression in non-metastatic melanoma cells can make them metastatic via
the upregulation of cathepsins L and subsequent downregulation of NM23-H1.
Abnormal vesicular trafficking plays a crucial role in cancer progression.
Endocytosis permits the internalization of signaling receptors, and targets them
to be destroyed in the acidic lysosomes [250]. For example, EGFR and TGFβ-R
are endocytosed resulting in recycling back to the plasma membrane or
degradation [251]. In the case of a metastasis suppressor, endocytosis might be
considered an attenuator of signaling as degradation of the metastasis
suppressor can lead to cancer progression. In a recent study, it was
demonstrated that, in human astrocytoma cells, ARF6 recruits NM23-H1 and
regulates clathrin- and dynamin- dependent P2Y1 and P2Y12 internalization. P2Y1
and P2Y12 are purinoreceptors whose activation by ADP is required for normal
platelet aggregation, and thus, facilitating thrombus stability [252]. Hus T et al
showed that von Hippel-Lindau tumor suppressor protein requires the activity of
NM23-H1 to endocytose FGFR1, and thus, prevents abnormal activation of
FGFR1 [253]. In Dictyostelium, NM23-H1 reduces both macropinocytosis and
exocytosis, thus, increasing the time for complete digestion of the nutrients
present in the vesicles [254]. Since c-Abl and Arg activation induces NM23-H1
degradation, there is a possibility that this will result in decreased receptor
endocytosis, resulting in sustained signaling and efficient metastatic progression.
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In this chapter, we demonstrate that Abl kinases play an important role in
the endocytotic pathway. Abl kinases affect endosome maturation as early
endosomes increase in size following inhibition of Abl kinases. Acidification is an
essential step for the perinuclear localization of endosomes, as demonstrated by
treatment of 435s/M14 cells with chloroquine (Figure 3.11). This is in contrast to
the effects observed following inhibition of Abl kinases, indicating that Abl
kinases do not effect endosome maturation at the acidification step. Inhibition of
Abl kinases might affect endosome maturation by promoting the movement of the
early endosomes along microtubules. Alternatively, inhibition of Abl kinases and
silencing c-Abl shows similar effects as overexpressing Rab5 or expressing a
GTPase -eficient Rab7, which results in the presence of giant enlarged
endosomes [255]. Thus, Abl kinases might prevent the switch between Rab5 and
Rab7. Inhibition of this switch does not allow early endosomes to fuse with late
endosomes, and thus, the endocytic cargo fail to traffic to the acidic lysosomes
for degradation. Silencing c-Abl also decreases LAMP staining intensity,
indicating that fewer lysosomes are present. In the absence of Rab7, the
endocytic cargo is entrapped in the late endosomes /multivesicular bodies, and
lysosomal activity is decreased, as indicated by the presence of fewer lysosomes
[Vanlandingham et al]. Inhibition of Abl kinases and silencing c-Abl exerts similar
effects on lysosomes, indicating that Rab5 activity is overexpressed, or there is a
decrease in Rab7 expression following inhibition of Abl kinases. Inhibition of Abl
kinases may thus prevent the switch between Rab5 and Rab7, leading to an
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accumulation of NM23-H1 in early endosomes and preventing its degradation in
lysosomes. Future experiments are ongoing to test this hypothesis.
Abl kinases also have been shown to have a role in endocytosis. c-Abl
has been shown to inhibit EGFR internalization, which results in sustained EGFR
signaling and cellular transformation [256]. Likewise, here we show that Abl
kinases promote invasion/metastasis by inducing endocytosis of NM23-H1, a
metastasis suppressor protein (Figure 3.19). In another report, RIN1 activation by
c-Abl was shown to prevent endocytosis, and promote cell surface expression of
EGFR following EGF stimulation of Hela cells [257], indicating that Abl kinases
promote oncogenesis by preventing the endocytosis of EGFR. In nontransformed cells, endogenous c-Abl induces the endocytosis of B-cell receptor
(BCR) by cytoskeletal remodeling, and regulates the extent and time of BCR
activation, which is essential for the antigen presenting function of BCR [258].
Furthermore, in a mouse model of cutaneous leishmaniasis, inhibition of Abl
kinase decreases lesion development and parasite burden by phagocytosis of
Leishmania [259]. In summary, all these results indicate that Abl kinases prevent
endocytosis of proteins critical for cancer or disease progression and here, for
the first time, we report that Abl kinases promote endocytosis of NM23-H1, and
alter its stability in invasive cancer cells, thus promoting cancer progression.
In this chapter, we demonstrate that Abl kinases mediate invasion via the
downregulation of NM23-H1, as silencing NM23-H1 rescued imatinib effects
(almost 80%), indicating that most of invasive properties of c-Abl/Arg are
mediated through the downregulation of NM23-H1 in 435s/M14 cells. In Chapter
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2, we demonstrated that Abl kinases mediate invasion by upregulating MMP-1
and -3, but the rescue of silencing c-Abl or Arg effects by MMP-1 overexpression
was only 40%. It is possible that these two mechanisms are parallel pathways, or
alternatively, there might be crosstalk between these two pathways. Rescue
invasion assay needs to be conducted to test whether Abl kinases promote
MMP-1 and MMP-3–dependent invasion via the downregulation of NM23-H1.
Here we show that silencing NM23-H1 with shRNA increases single-cell
3D invasion through collagen I, which support the results by Bossian et al, who
reported that NM23-H1 loss increased both gelatin degradation and invasion of
native type I collagen and that NM23-H1 silencing promotes MMP-14 activity. We
showed that Arg kinase promotes MMP-14 expression/activity, and is possible
that the pathway by which Arg-mediates MMP-14 activity might be dependent on
NM23-H1 degradation. NM23-H1 depletion is casually involved in increasing the
expression of MMP-1 and- 3 [159] and silencing NM23-H1 promotes collagen I
degradation. Taken these results and our findings, we can hypothesize that Arg
promotes MMP-14 activation and collagen degradation via the downregulation of
NM23-H1. Future experiments will examine if Arg/NM23-H1/ and MMP-14 lie in
the same pathway.
This work shows for the first time that Abl kinases and NM23-H1 are
inversely correlated in melanoma cell lines and primary melanomas. Moreover,
we show that activated Abl kinases-mediate the degradation of NM23-H1 in a
cathepsin B and L-dependent manner. Research since the discovery of NM23H1 has demonstrated the degradation of this metastasis suppressor in many
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cancers, including melanoma and agents that can induce its re-expression are
being pursued in the clinic [171]. In this chapter, we show that Abl kinases
inhibitors promote the upregulation of NM23-H1 in invasive cancer and targeting
Abl kinases in metastatic melanoma can be of therapeutic benefit.
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Figure 3.19. Model for the mechanism by which c-Abl/Arg promote
vesicular trafficking and NM23-H1 degradation. c-Abl induces cathepsin
activation by promoting endosome to lysosomal trafficking. Endosomal NM23H1 is transported to lysosomes and degraded by lysosomal protease cathepsin B
and L. Inhibition or silencing c-Abl/Arg prevents cathepsin expression and
activation, which leads to stabilization of NM23-H1. MT=microtubules,
MVB=multi-vesicular body. Model provided by Dr R. Plattner
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Chapter 4: Conclusions and Future Directions
4.1 Conclusions
Melanoma, the most lethal form of skin cancer, represents only 4% of the
total number of skin cancer diagnoses, but accounts for approximately 80% of
skin cancer-related deaths [1-3], with a 5-year survival rate of under 5%. This
survival rate has not improved in the past decade. Recent advances in the
development of new drugs for treating melanoma have raised enthusiasm for the
identification of new therapeutic targets. However, the paucity of understanding
of the mechanisms that lead to melanoma progression has unfortunately led to
the failure of many of these drugs. These clinical failures underscore the need for
identification and characterization of the molecular mechanism(s) that drive
melanoma progression, thus leading to identification of new targets for its
treatment.
While c-Abl and Arg are known to play an important role in breast, lung,
prostate and liver cancer progression, little is known about their role in
melanoma. Our study demonstrates a previously unrecognized role for c-Abl and
Arg in melanoma progression and shows that c-Abl and Arg are activated in
primary melanomas (60%), benign nevi (33%) and in some human melanoma
cells lines in comparison to primary melanocytes. Our data also indicate that
active c-Abl and Arg drive invasion, proliferation, and metastasis as well as
survival following nutrient deprivation. Furthermore, we demonstrate that c-Abl
upregulates melanoma invasion through a STAT3/MMP-1-dependent pathway,
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whereas Arg promotes invasion through STAT3- independent MMP-1 and MMP3 pathways. To our knowledge we are the first to report that c-Abl and Arg
promote the same biological process via distinct mechanisms.
As a likely parallel pathway in melanoma progression, we show that Abl
kinase activities are inversely correlated with expression of the metastasis
suppressor, NM23-H1, in human melanoma cells. We further show that c-Abl and
Arg are required for NM23-H1 degradation. NM23-H1 is degraded in a lysosomal
cysteine cathepsin-dependent manner and that cathepsins B and L directly
cleave NM23-H1. Moreover, we show that c-Abl promote the activation of
cathepsins B and L. Our data indicate that c-Abl promotes the degradation of
NM23-H1 by altering the endocytic pathway and that c-Abl likely promotes early
to late endosomal maturation. The effects we observe have biological
consequences as c-Abl/Arg promote melanoma cell invasion and metastasis by
inducing NM23-H1 degradation, and promote anchorage-independent growth
partially via NM23-H1 loss. The Abl/NM23-H1 pathway is clinically relevant as
there is an inverse correlation between c-Abl/Arg activity and NM23-H1
expression in primary melanomas. Thus, this study identifies for the first time that
a proto-oncogene has the ability to promote invasion and metastasis via
degradation of a metastasis suppressor.
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4.2 Future Directions
Our lab has previously shown that Abl kinases are activated by growth
factor receptors and SFKs. Here we demonstrate that activated c-Abl and Arg
promote melanoma proliferation, survival, invasion and late stages of metastasis.
Our study in Chapter 2 shows that MMPs play an important role in c-Abl and Argmediated invasion of melanoma cells, indicating that targeted therapy directed
against c-Abl and Arg may also inhibit MMPs. Inhibition of MMP-1 in cancer cells
has been shown to inhibit collagen degradation and decrease tumor size in mice
[123]. Conversely, over-expression of MMP-1 in the skin of transgenic mice
increased their susceptibility to skin carcinogenesis [260,261]. Thus, future
directions could include testing whether c-Abl and Arg promote melanoma
metastasis in an MMP-dependent manner. To test this, we would need to
perform immunohistochemisty on lung samples from nilotinib-treated mice to
determine whether expression of MMPs is decreased as compared to vehicletreated animals. We could also perform rescue experiments by injecting
435s/M14 cells overexpressing MMPs into mice to investigate whether c-Abl and
Arg promote melanoma metastasis in a MMP-dependent manner.
In the past decade, multiple MMP inhibitors such as the peptide MMP
inhibitors, Batimastat and Marimastat, have been used in the clinical setting
[262,263]. However, none showed promising results in extending patient survival,
indicating that MMPs may not be good targets for inhibiting cancer progression.
Careful appraisal of these failures will help to identify the cause(s) of the
problems encountered with the use of these drugs in these clinical trials.
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Batimastat had poor solubility and could not be administered orally and hence
was replaced by Marimastat. Marimastat is a broad-range MMP inhibitor, similar
to Batimastat and thus, it also lacked specificity. Other non-peptidic MMP
inhibitors, BAY-12-9566 and AG3340, were also used in clinical trials but showed
poor clinical efficacy [262-265]. In addition, all these MMP inhibitors showed
significant side effects such as musculoskeletal syndrome, which manifests as
pain and immobility in the shoulder joints and contractures in the hands. These
side effects were specifically seen when MMP-1 was targeted, which led to the
development of MMP inhibitors that do not target MMP-1. In this study we show
that MMP-1 is critically important in promoting invasion of melanoma cells. Thus,
drugs targeting upstream regulators of MMP-1, such as STAT3 or c-Abl and Arg,
might be better alternatives than MMP inhibitors and may have fewer sideeffects.
Due to intolerable side effects associated with MMP inhibitors, such as
musculoskeletal pain and tendinitis, many patients withdrew from the clinical
study, thus, decreasing the group size in the treatment arm, rendering evaluation
of the drug efficacy difficult. Thus, in follow-up trials, either MMP-specific small
molecules or antibody-based inhibitors should be used. In mouse models, MMP
inhibition has been effective in preventing cancer progression perhaps because
they were used at an early stage of disease, prior to the presence of overt
metastases. However, in human clinical trials, these inhibitors were used in
patients who were in advanced stages of diseases, after metastatic progression,
and were not utilized in combination with other chemotherapeutics [262-265].
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These drawbacks may explain the poor performance of these drugs in the clinic.
Our studies indicate that MMPs are important targets in melanoma metastasis
and that they can be targeted using Abl kinase inhibitors, which do not exhibit
any of the side-effects associated with MMP-1 inhibitors.
Recent data indicate that c-Abl and Arg promote gelatinase activity of
breast cancer cells [62]. Our data suggest that c-Abl and Arg also promote
collagen I degradation (single-cell 3D invasion assay). c-Abl/Arg promote the
activation of MMP-1, -3 and -14, and all of these are known to degrade collagen
I. Future experiments designed to demonstrate that c-Abl and Arg induce
degradation of fluorescently-labeled collagen I could answer the question
whether c-Abl and Arg promote collagenase activity in melanoma cells via the
upregulation of MMPs. siRNA-mediated inhibition of MMP-1, -3 and -14 will
identify which of the MMPs play a major role in collagen degradation in 435s/M14
cells. The collagenase activity could also be quantified using another type of
assay, an in vitro collagen degradation assay. In this assay, 435s/M14 cells
transfected with c Abl or Arg siRNAs would be incubated with collagen I, the
collagen/gel solution allowed to gel followed by the addition of basal media on
top of the gel and incubation at 370C [123]. The weight of the media at the start
of the assay, subtracted from the total media weight at the end of the assay,
would allow one to quantify the extent to which Abl kinase inhibition prevents
collagen degradation. Future experiments will also be designed to investigate
whether c-Abl and Arg-mediated collagen degradation is MMP-dependent by
performing rescue experiments using MMP overexpression cells transfected with
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c-Abl or Arg siRINA. These experiments will establish the role of c-Abl and Argmediated MMP upregulation in collagen degradation, a prime constituent in ECM
and will also identify if c-Abl/Arg promote melanoma metastasis in a MMPdependent pathway.
Our studies indicate that c-Abl promotes melanoma invasion in a STAT3dependnet manner (Chapter 2) and activated c-Abl and Arg promote STAT3
phosphorylation, in a JAK-independent manner [64]. Phosphorylation of STAT3
at Y705 induces its transcriptional activity [232], but we have not yet
demonstrated that c-Abl and Arg promote STAT3 transcriptional activity. Thus,
future experiments will involve the use of luciferase reporter assays to confirm
that c-Abl and Arg promote STAT3 transcriptional activity. Likewise, one could
also test whether inhibition of c-Abl and Arg decrease the nuclear pool of
phospho-STAT3 in melanoma cells. It also would be interesting to examine the
STAT3 activation status in WM164 cells, which have low invasive potential and
concomitantly have low c-Abl and Arg kinase activities as compared to the more
highly invasive WM3248 and 435s/M14 cells. If transfection of constitutivelyactive c-Abl and Arg -(PP) into WM164 cells increases invasion by activating
STAT3, we could conclude that activation of STAT3 is essential for c-Ablmediated invasion as we showed in invasive 435s/M14 cells.
Our results indicate that c-Abl and Arg form a complex with STAT3 and
induce its phosphorylation and activation. We also report that the
phosphorylation of STAT3 is indirect and probably mediated by another tyrosine
kinases. Src kinases can phosphorylate STAT3 directly [223, 224].Our lab has
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previously shown that PDGFR-β phosphorylates c-Abl in vitro, and
overexpression of constitutively active c-Abl induces the phosphorylation of
kinase-dead PDGFR, indicating a bi-directional signaling pathway [266]. c-Abl
can also phosphorylate EGFR and prolong EGFR signaling in the membrane
[256]. Based on these data it would be interesting to investigate if c-Abl can
phosphorylate Src kinase in a bi-directional manner and therefore activate
STAT3 in a Src kinase-dependent manner and thus promote invasion. To test
this hypothesis we would perform co-immunoprecipitation experiments to
investigate if the c-Abl/STAT3 complex is disrupted following silencing of Src,
and additionally, we could test whether expression of constitutively active c-Abl
can induce the phosphorylation of a kinase-dead mutant of Src kinase.
In colorectal cancer, the transcription factor, STAT3, is known to bind to
the promoter region of MMP-1, but the adjacent AP-1 binding site also has been
shown to be essential for STAT3-mediated transcription of MMP-1 [209].
Moreover, in Chapter 2 we report that c-Abl promotes MMP-1 transcription via a
STAT3-dependent mechanism. Thus, future experiments will be designed to test
whether c-Abl promotes the direct binding of STAT3 to the MMP-1 promoter
region. A reporter gene construct, including a promoter sequence from the
human MMP-1 gene driving luciferase expression, will be transfected into
435s/M14 cells to test whether inhibition of c-Abl/Arg can repress MMP-1
promoter-driven luciferase activity. Rescue experiments utilizing this reporter
construct transfected into 435s/M14-STAT3CA (cells expressing constitutively
active STAT3) would be expected to result in rescue of the inhibitory effects of
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imatinib. Furthermore, experiments involving mutation of the STAT3 binding sites
in the MMP-1 promoter region could also address the question whether this
binding occurs directly through STAT3. To investigate the necessity of the AP-1
element in this c-Abl/STAT3/MMP-1 interaction, AP-1 binding sites will be
mutated in the presence of intact STAT3 binding sites. If the interaction is
dependent on AP-1, the luciferase activity will be inhibited in the absence of the
AP-1 promoter element.
The hepatocyte growth factor (HGF) has been shown to signal through cMet to promote melanoma progression. In human squamous cell carcinomas, the
HGF/c-Met/STAT3 signaling pathway promotes cancer cell invasion [267].
Blocking constitutive activation of STAT3 disrupts this pathway, reduces c-Met
activity, and inhibits invasion of human squamous cell-carcinoma cells [267]. cMet signaling through c-Abl/Arg in gastric carcinoma cells also promotes
anchorage-independent growth, survival and metastasis. All of this experimental
evidence in gastric cancer cells suggests that this c-Met/c-Abl/STAT3 axis might
also regulate melanoma invasion, survival and metastasis. Furthermore, in
pancreatic cancer cells, c-Met regulates IGF-1R-mediated invasion, indicating
the presence of a considerable amount of crosstalk between these two receptors
[268]. Moreover, our lab has previously shown that IGF-1R activates c-Abl and
Arg [54]. For these reasons, it would be interesting to examine whether HGF
stimulation, which activates c-Met, promotes invasion and survival in a c-Abl- and
STAT3-dependent manner. c-Met also has been shown to activate Src kinases
[269] and Src kinases directly phosphorylate and activate c-Abl and Arg in a
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manner independent of IGF-1R. Thus, it was would be interesting to test if c-Met
activates c-Abl and Arg in a Src-dependent or independent manner. To test this
hypothesis, first we will silence c-Met and investigate the activation status of cAbl/Arg by in vitro kinase assay following HGF stimulation. IGF-1R and Src also
activate c-Abl and Arg, so we will also silence IGF-1R and Src to rule out that
activation of c-Abl and Arg occurs via IGF-1R or Src, respectively. To investigate
the dependence on Src during c-Met-induced c-Abl and Arg activation, we will
examine if constitutive activation of Src can rescue the block in c-Abl and Arg
activation following c-Met inhibition.
If silencing c-Met in 435s/M14 cells inhibits invasion, and constitutive
expression of c-Abl-PP rescues the block in invasion induced by c-Met inhibition,
this would suggest that c-Met and c-Abl lie in the same pathway to promote
invasion of melanoma cells. Further experimentation using STAT3 siRNAs or
constitutively active forms of STAT3 will identify whether c-Met/c-Abl/STAT3 lie in
the same pathway. Interestingly, HGF binding to c-Met also activates MMPs and
uPA. Hence, it would also be interesting to test whether c-Met activates MMPs in
an Abl kinase/STAT3-dependent manner. These studies involving STAT3 will
identify how c-Abl activates STAT3 in melanoma cells. The studies designed will
identify other regulators that can activate c-Abl to promote the transcriptional
activity of STAT3. These studies are of prime significance as it will establish cAbl/STAT3 as an essential pathway in melanoma progression.
In Chapter 2, we demonstrated that c-Abl promotes transcription and
activation of MMP-1, whereas Arg promotes the transcription and activation of
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MMP-1, -3 and -14. The level of promotion of MMP-14 transcription and
activation by Arg is very dramatic (almost 90%). In Chapter 3, we reported that
Arg promotes the degradation of NM23-H1; however, this pathway seems not to
be dependent on cathepsins B or L, as Arg does not promote the processing of
the cathepsin to its double-chain form. Therefore, future experiments will involve
investigating whether Arg, NM23-H1, and MMP-14 lie in the same pathway.
Bossian et al, reported that NM23-H1 loss increased both cellular degradation of
gelatin as well as cell invasion on native type I collagen. They also reported that
NM23-H1 silencing promoted MMP-14 expression. Therefore, we will silence
NM23-H1, in 435s/M14 cells, in order to assess whether NM23-H1 loss can
rescue the block in MMP-14 induced by silencing Arg. Silencing of NM23-H1
induces β-catenin-TCF/Lef-1 transactivation and MMP-14 is a direct target of βcatenin/TCF signaling [159]. Moreover our lab had shown that Arg promotes the
nuclear localization and expression of β-catenin in 435s/M14 cells [ W. Friend,
unpublished data]. These data led us to hypothesize that Arg may promote MMP14 expression via a NM23-H1/β-catenin dependent pathway. Future experiments
will be designed to evaluate whether Arg can induce the transcriptional activation
of β-catenin using the TOP/FOP flash reporter assay and also by determining
whether inhibition of nuclear translocation of β-catenin inhibits MMP-14
expression. To test whether Arg mediates MMP-14 transcription in a β-catenindependent manner, we will investigate if transcriptionally active form of β-catenin
(S374A) rescues the effects of silencing Arg on MMP-14 transcription. We will
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also investigate if silencing of NM23-H1 can rescue the inhibitory effects of
silencing Arg on MMP-14 transcription.
Another potential pathway by which Arg may promote MMP-14-mediated
invasion is the PI3K-Akt pathway. c-Abl and Arg activate the Akt pathway during
nutrient deprivation (S Ganguly, unpublished observation) and Arg promotes
invasion via MMP-3 and MMP-1 in a STAT3-independent manner. Akt is
constitutively activated in melanoma and promotes RGP to VGP conversion
[270,271]. Moreover Akt also stimulates the transactivation potential of the p65
subunit of NF-κB [272]. Furthermore, our laboratory showed that c-Abl/Arg
induces nuclear translocation of p65 [237]. A consensus binding site for p65 has
been detected in the MMP-14 gene, and NF-κB has been shown to promote
MMP-14 expression in murine melanoma cells [273-275]. This evidence
suggests that Arg also could promote the activation of MMP-14 via a Akt/ NF-κBmediated pathway. We will test this hypothesis by investigating if constitutive
activation of NF-κB in 435s/M14 cells (transfecting a constitutive active form of
IκB kinase, IKK-2 S177E/S181E) rescues the inhibition of MMP-14 transcription
following silencing of Arg. We will also investigate whether constitutive activation
of NF-κB rescues the inhibition of invasion induced by silencing Arg. If inhibition
of MMP-14 following constitutive activation of NF-κB inhibits invasion in
435s/M14 cells and overexpression of MMP-14 rescues the block in invasion
after Arg silencing, this would indicate that Arg/ NF-κB/ MMP-14 lie in the same
pathway to promote invasion of melanoma cells. These studies proposed are of
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prime significance as it will discover new targets in Arg-mediated melanoma
invasion and metastasis.
Survival in the absence of nutrients is an important determinant for cancer
cells to grow and proliferate in distant metastasis sites and form
macrometastasis. Excessive proliferation and survival in the absence of nutrients
are important for neoplastic development. We show that c-Abl and Arg promote
survival in response to nutrient deprivation via STAT3-dependent and independent pathways. Even though c-Abl and Arg do not promote AKT
activation under serum conditions in 435s/M14 cells [55], they activate AKT
under serum-free conditions (S. Ganguly, unpublished data) and BCR-ABL is
known to induce the activation of the PI3K-AKT pathway to promote leukemic cell
survival [276]. Furthermore, c-Abl and Arg promote the expression of AKT
isoforms in serum-starved conditions (S. Ganguly, unpublished data), and AKT
isoforms play a major role in the survival of cancer cells. Inhibition of c-Abl/Arg in
435s/M14 cells induces the downregulation of AKT3 and silencing AKT3 in
435s/M14 cells sensitizes the cells to cell to death following nutrient deprivation
(S. Ganguly, unpublished data). These data indicate that c-Abl and Arg might
promote survival via an AKT3-dependent pathway. Constitutive expression of a
myristoylated form of AKT3 into 435s/M14 cells could be used to test whether
activation of Akt3 rescues the apoptotic effects caused by inhibition of c-Abl and
Arg. We also could investigate the mechanism by which c-Abl and Arg activate
Akt. Recently our lab has shown that c-Abl/Arg activate Akt in response to
doxorubicin-induced stress via a p38/HSP27-mediated pathway in melanoma
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cells [237]. Alternatively, c-Abl and Arg also could activate Akt via the
downregulation of PTEN, since PTEN mediates the dephosphorylation of
phosphatidylinositol (3,4,5)-triphosphate back to phosphatidylinositol (4,5)biphosphate and thus Akt activation is compromised. Future experiments will test
this hypothesis by examining whether c-Abl and Arg can phosphorylate PTEN
and keep it in an inactive closed conformation. We will establish a
phosphorylation-resistant PTEN (substituting the serine and theonine residues in
COOH-terminal domain to alanine) to investigate this can inhibit activation of Akt
in the presence of constitutively active c-Abl/Arg-PP.
NM23-H1 is reported to have no effect on the proliferation of cancer cells
either in vivo or in vitro [159], whereas silencing of NM23-H1 has been shown to
increase anchorage-independent growth of human hepatocarcinoma cells [159].
Here, we report that silencing NM23-H1 promotes anchorage-independent
growth of 435s/M14 cells and that c-Abl and Arg mediate anchorage-independent
growth partially via NM23-H1 loss. Anchorage-independent growth is the ability
of cancer cells to proliferate and survive in an anchorage-independent state.
Since inhibition of NM23-H1 does not promote proliferation, silencing NM23-H1
might promote survival during anchorage –independent conditions. NM23-H1
silencing has been shown to induce resistance to apoptosis in hepatocarcinoma
cells treated with chemotherapeutic reagents; however the mechanism was not
investigated. NM23-H1 also has been shown to induce apoptosis in Burkitt’s
lymphoma cells via a p53-dependent pathway and upregulation of caspases 3, 9
and Bcl-xL [277]. In human ovarian cancer cells and in ovarian clear cell
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adenocarcinomas, low levels of NM23-H1 expression were correlated with
activation of Akt, indicating that loss of NM23-H1 may confer resistance to
apoptosis via a Akt-dependent pathway [278], although no direct evidence for
this mechanism was demonstrated. Taken together, all these results indicate that
expression of NM23-H1 could reverse resistance to apoptosis and render cancer
cells sensitive to chemotherapy-induced apoptosis or apoptosis induced by
serum deprivation. Chemotherapy-resistance is associated with a poor prognosis
in many types of cancer, and is a common problem encountered in the clinic. Our
laboratory has shown that imatinib reverses resistance to chemotherapy via a
STAT3-dependent Akt pathway in breast cancer and melanoma cells [237]. Here,
we report that c-Abl and Arg promote melanoma cell survival and activate Akt in
nutrient-deprived conditions. Taken together, all these results indicate that
activated c-Abl and Arg may mediate resistance to apoptosis in serum-deprived
conditions via down-regulation of NM23-H1. To test this hypothesis, we will
investigate whether silencing NM23-H1 can rescue the apoptotic effects of
imatinib following serum-starvation. To investigate the dependence of Akt in this
pathway, we will test if constitutively activated, myristoylated Akt can rescue the
apoptotic effects mediated by NM23-H1 overexpression in 435s/M14 cells.
Reversal of chemotherapy resistance by imatinib could also be attributed to
inhibition of Akt mediated by stabilization of NM23-H1-dependent. To test
hypothesis, first, we will investigate if silencing NM23-H1 rescues the synergistic
apoptotic effects observed following treating cells with imatinib and other
chemotherapies [237]. We will also investigate if inhibition of Akt can prevent the
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rescue induced by silencing NM23-H1. Proteins that promote survival of cancer
cells in nutrient deprived conditions and in response to chemotherapy play a
critical role in cancer progression. This study will identify proteins that promote
survival in c-Abl and Arg-dependent manner and will shed light on how c-Abl/Arg
promotes melanoma progression.
In Chapter Two, we demonstrated that c-Abl and Arg promote the
expression of TIMP-1. It is important to further investigate the role that c-Abl and
Arg play in mediating TIMP-1 activation during the survival of melanoma cells.
Our results suggest that TIMP-1 exerts effects contrary to its antimetalloproteinase activity (Figure 2.16). Various prior studies suggest that TIMP1 enhances tumor growth and metastasis [135,136]. Our study largely supports
the hypothesis that TIMP-1 promotes oncogenesis rather than having tumorsuppressive effects. Elevated expression of MMP-1 and MMP-13 along with
TIMP-1 and -3 is associated with increased invasion of primary melanomas
[122]. The Oncomine cancer microarray database suggests that TIMP-1 is
augmented in cutaneous melanoma patients as compared to normal skin or
benign nevi [279,280], indicating that TIMP-1 expression may be necessary for
melanoma progression. Since the transcription and activation of TIMP-1 by cAbl/Arg is dependent on STAT3 activation (Figure 2.17), it is likely that TIMP-1
overexpression would result in the same partial rescue of imatinib-induced
apoptosis as observed with STAT3CA expression. However, this hypothesis
needs to be tested by investigating whether overexpressing TIMP-1 in 435s/M14
cells rescues the block in apoptosis induced by imatinib. Furthermore, if silencing
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TIMP-1 blocks the partial rescue in survival observed with 435s/M14-STAT3CA
cells following expression of STATCA cells treated with imatinib, then we can
conclude that c-Abl/Arg, STAT3, and TIMP-1 all lie in the same pathway and that
together they promote survival of melanoma cells in response to serumdeprivation conditions.
Our laboratory showed that c-Abl and Arg promote survival in response to
nutrient deprivation in both breast cancer [54] and melanoma cells (Figure 2.7). A
closely related survival phenomenon is anoikis resistance, which refers to the
ability of cells to resist death in suspension as a result of loss of physical contact
with extracellular matrix. Activation of Src kinases promote survival, invasion,
resistance to anoikis, and metastasis in breast cancer and lung adenocarnima
cells [281,282]. TIMP-1 overexpression also has been shown to promote anoikis
resistance in murine melanocyte lineage melan-a cells [279]. Our laboratory
showed that Src kinases activate c-Abl/Arg in 435s/M14 cells [54], and here we
show c-Abl and Arg promote TIMP-1 expression in a STAT3-dependent manner.
Hence, it is possible that activated c-Abl and Arg induces resistance to anoikis in
melanoma cells. To test this hypothesis, we could examine whether silencing or
inhibiting c-Abl/Arg promote cell death in the absence of matrix attachment. To
investigate whether the pathway is dependent on STAT3, we will assess whether
expression of constitutively active STAT3 (STAT3CA) can rescue imatinibmediated cell death in the absence of matrix attachment. To test if c-Abl and Arg
mediate anoikis resistance via a TIMP-1-dependnet pathway, we will investigate
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if overexpression of TIMP-1 can rescue imatinib-mediated apoptosis in the
absence of matrix attachment.
Most of the survival and cell growth effects of TIMP-1 on cancer cells may
be attributed to the direct binding of TIMP-1 to a cell surface receptor [284,285].
Binding of TIMP-1 to CD63 activates integrin β1 in human breast cancer
epithelial cells [284]. This complex can interact with PI3K to activate the AKT
pathway, thus, preventing the activation of the caspase cascade in breast
carcinoma cells [285]. Thus, future experiments will investigate whether inhibition
of c-Abl and Arg can inhibit activation of this pathway. TIMP-1 interacts with the
CD63/integrin β1 complex [284,285], so we will investigate if inhibition of c-Abl
and Arg disrupts TIMP-1 binding within this complex using confocal microscopy
and co-immunoprecipitation methods. Future experiments also will be designed
to test if overexpression of CD63 can rescue the effects of imatinib on caspase-3
activity and apoptosis following nutrient deprivation. These results will also
provide evidence that c-Abl and Arg can modulate an outside to inside cell
signaling cascade via TIMP-1. Future experiments also will be designed to test
whether c-Abl and Arg prevent caspase activation (Figure 2.7) in a TIMP-1dependnet manner. It has been reported that Arg modulates integrin β1signaling
and regulates epithelial cell polarity [286]. There also is contrasting evidence
regarding the role of integrin β1 signaling in cancer progression as there is
evidence to support both a pro-neoplastic function as well as a function in
suppressing cancer progression. Given, the role of c-Abl and Arg on TIMP-1
expression and its potential role in modulating integrin β1 signaling, we
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hypothesize that c-Abl and Arg regulate integrin β1signaling through TIMP-1, and
thus promote survival and metastatic progression. Experiments proposed in this
section will give additional evidence in the role of c-Abl and Arg to promote
melanoma metastasis in a TIMP-1-dependent manner. Experiments designed in
this section will also identify how c-Abl and Arg activate cell surface proteins in
an outside to inside cell signaling cascade via TIMP-1.
Invasion of cancer cells through the ECM, intravasation, extravasation,
survival in nutrient free conditions in the ectopic site and proliferation of cancer
cells from micrometastasis to macrometastasis are important steps in cancer
metastasis. Previous studies in this section were aimed to determine the
mechanism that c-Abl and Arg may upregulate to promote various in vitro steps
in cancer metastasis. Here in this section we will discuss how various in vivo
steps in melanoma metastasis can be promoted by activated c-Abl and Arg. We
have shown that activated c-Abl and Arg promote melanoma metastasis using
two different cell lines and two different mouse models. It would be interesting to
test whether inhibition of c-Abl/Arg enhances overall survival of nilotinib-treated
animals in comparison to vehicle only-treated mice. In order to test this, we need
to repeat the experimental in vivo metastasis assay without euthanizing mice on
a specific day but rather extend the study until all of the vehicle- treated mice
expire due to disease progression. These data would then be used to generate a
Kaplan-Meier survival chart, which would be important in determining whether
nilotinib might be useful in the clinic in enhancing survival of melanoma patients.
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We have shown that nilotinib, which inhibits both c-Abl and Arg, inhibits
late stages of melanoma metastasis. To specifically identify whether c-Abl and/or
Arg drive the process of melanoma metastasis, we will use Tetracycline-inducible
(Tet-on) systems. Commercially available shRNA against c-Abl and Arg, cloned
in a Tet-on-inducible vector, will be stably transfected in 435s/M14/GFP cells,
and the resulting cells injected into mice for both spontaneous and experimental
metastasis assays. One group of animals will be given water supplemented with
doxycycline, in order to induce the activation the c-Abl and/or Arg shRNAs, and
extent of metastasis will be compared with mice that do not receive doxycycline.
These experiments will identify whether activated c-Abl and/or Arg can drive
melanoma metastasis.
We also found that inhibition of c-Abl/Arg does not affect primary tumor
growth of two melanoma cell lines (435s/M14 and WM3248)(S Ganguly,
unpublished observation). However, another study demonstrates that inhibition of
Abl kinases reduces primary tumor growth of gastric hepatocellular carcinoma
cells [58], indicating that the effect of c-Abl/Arg inhibitors in reduction of tumor
size might be cancer type-specific. Our data suggest that reduction in the size of
primary tumors does not predict the efficacy of a c-Abl/Arg inhibitor in melanoma
settings, since we found that a c-Abl/Arg inhibitor prevented metastatic
colonization using experimental metastasis assays. Unfortunately, due to
technical difficulties, we were unable to evaluate the metastatic endpoint using
spontaneous metastasis assays (metastasis form a primary tumor). Thus, more
studies need to be performed in the future. However, we did show that c-Abl and
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Arg promote experimental metastasis (late stages of metastasis). In this process,
the cancer cells bypass the few initial steps of cancer metastasis cascade, such
as primary tumor growth, invasion through the extracellular matrix, and
intravasation into the blood stream. However, in an experimental metastasis
assay, the cells still have to extrasavate out of the blood stream and invade the
new organ site to form micrometastasis in the ectopic site, survive in nutrient free
conditions, and proliferate to form macrometastasis. Our studies have identified
that Abl kinases promote cancer cell invasion in a MMP-1 and MMP-3 dependent
manner and invasion is a very important process of cancer metastasis. Cancer
cells have to degrade the ECM around the primary tumor, invade though the
ECM and further invade into the blood vessels (intravasation). Although c-Abl
and Arg do not promote tumor growth of melanoma cells, they may affect the
process of invasion of tumor cells from the primary tumor or intravasation. Tumor
invasion is associated with a characteristic distorted edge of the primary tumor,
where tumor cells actively invade the ECM surrounding the primary tumor.
Tissue samples of primary tumors from cancer patients and animals have shown
elevated expression of MMPs [105]. Thus, future experiments will involve
performing immunohistochemisty to determine whether there is a decrease in
MMP-1 expression at the invasive front of the tumors extracted from mice treated
with nilotinib. Expression of MMPs is generally observed in higher levels around
the invasive front of the tumor [287]. To investigate whether c-Abl and Arg
promote the process of dissemination of tumor cells in a MMP-1 dependent
process, 435s/M1/GFP cells will be injected in the flank region by subcutaneous
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injection and the mice treated with vehicle or nilotinib. We will investigate if
inhibition of c-Abl/Arg can inhibit the tumor cell interaction with adjacent ECM,
and we will analyze local invasion the cells by analyzing with intravital
multiphoton microscopy or Spinning (Nipkow) disk confocal microscopy [105,
288-290]. To track the tumor cells for several imaging sessions (several days),
435s/M14 cells can be photomarked with photoconvertable flurophores like
Kaede and Dendra2 to mark regions of interest in a tumor for over several days
and intravital microscopy along with ‘mammary imaging window’ can be
performed [283]. Mammary imaging window allows to visualize the metastatic
process for several days [283].To investigate if c-Abl and Arg promote cancer cell
invasion around the primary tumor in a MMP-dependent manner, cells
overexpressing MMPs and GFP will be utilized to test if MMP overexpression –
GFP labeled cells rescues the block in local tumor invasion following c-Abl and
Arg inhibition and aid in increased tumor cell dissemination.
Escape of cells from the primary tumor involves invasion and polarization
of tumors cells towards the blood vessels. Tumors cells invade through the
collagen layers of the blood vessels (intravasation) and remain in the circulation
until they extravasate into a favorable ectopic site. Since c-Abl and Arg promote
invasion in vitro, it is possible they may affect the intravasation process.
Quantification of intravasation can be performed by periodic examination of blood
samples from vehicle and nilotinib-treated mice from spontaneous metastasis
assays, and analyzing the blood for specific tumor-cell markers by RNA-targeted
PCR methods [105]. Cytokeratin-20, a carcinoembryonic antigen has been used
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to identify colorectal circulating cells to quantify intravasation [105]. Blood
samples from vehicle and nilotinib- treated mice from spontaneous metastasis
assays can also be analyzed by radioactive or fluorescence-based PCR
techniques to detect human-specific DNA sequences. This analysis also will give
a quantitative estimation of how many human-derived tumor cells are present in
the bloodstream and thus, will give an estimation of the differences in
intravasation efficiency between vehicle- and nilotinib-treated mice. Intravasation
can also be measured using by intravital multiphoton microscopy on live animals
[105,288]. 435s/M14-GFP cells will be injected to form primary tumor, and mice
treated with vehicle or nilotinib. The blood vessels will be labeled by injecting
Texas red-Dextran in the carotid artery [291]. The presence of GFP- positive
cells in the red fluorescent blood vessels will be monitored by intravital
multiphoton microscopy in order to detect differences in intravasation following
inhibition of c-Abl/Arg. Since blood vessels have collagen layers and MMP-1 and
MMP-3 can efficiently degrade collagen, we hypothesize that c-Abl and Arg may
mediate the process of intravasation via MMP-1 and -3-dependent pathways. We
predict that overexpression of these MMPs will rescue the block in intravasation
induced by nilotinib treatment.
Since we have demonstrated that c-Abl/Arg promote late stages of cancer
metastasis and there is an increase in the metastatic burden in the lungs of
vehicle-treated mice and significant decrease following nilotinib treatment, we
can hypothesize that nilotinib may inhibit proliferation and survival of these
cancer cells after they seed in the ectopic site. We can test this hypothesis by
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staining the lung metastases with antibody to a proliferation index marker (Ki67),
and use TUNEL stain to identify apoptotic lesions. Since c-Abl and Arg promote
both proliferation and survival of melanoma cells, in vitro, nilotinib might exert its
anti-metastatic effects by inhibiting both of these processes.
Metastasis is the main cause of death in cancer patients. Some patients who
receive adjuvant therapy initially respond to the drugs, but come back later to the
clinic with metastases. Most of the tumor cells that disseminate from the primary
tumor and intravasate into the blood vessels do not progress to form clinically
overt metastases [292, 293]. This process is called as metastatic insufficiency.
Only a small fraction (2%) can grow to form micrometastasis and even a smaller
fraction (0.02%) can survive to form macrometastasis, making this last step of
conversion from micro metastasis to macro metastasis an important part step in
inhibiting tumor dormancy [293]. Tumor dormancy can persist for months or even
for years. These dormant cells stay quiescent in solitary state without
proliferating and survive in nutrient deprived conditions. The property to survive
in nutrient-free conditions helps them to maintain dormancy, and later, they revert
back to a proliferative state and form metastases. Although relatively little is
known regarding tumor dormancy several key pathways have been identified,
including p21,p27,p38, uPAR, and cells that express very low levels of
angiogenic markers or high levels of angiogenic inhibitors also can attain tumor
dormancy [ 294,295 ].
In chapter 2, we showed that activated c-Abl and Arg promote survival of
melanoma cells in nutrient deprived conditions and promote late stages of
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metastasis, indicating that c-Abl and Arg can promote the survival of a small
fraction of solitary cells after extravasation and lead to dormancy. Using in vivo
video microscopy techniques, we could determine if activated Abl kinase promote
dormancy of melanoma cells by examining whether some 435s/M14 cells
injected intravenously attain tumor dormancy after successful extravasation from
the blood vessels and if nilotinib is effective in eradicating these dormant cells.
Using in vivo video microscopy at periodic intervals starting from 30 minutes after
intravenous injections of 435s/M14-GFP cells to days after injection, we could
ascertain the percentage of fluorescent-labeled 43s/M14 cells that successfully
reach the lung and survive to form micrometastasis, and form macrometastasis,
or remain solitary as dormant cells. This experimental procedure also will allow
us to assess the percentage of cells that remain dormant following treatment with
nilotinib. The inability to extravasate has been considered a rate-limiting step in
cancer metastasis. We could also assess whether inhibition of activated cAbl/Arg by nilotinib, can decrease the percentage of cells that can successfully
extravasate as compared to vehicle-treated mice. The cells that attain tumor
dormancy will be analyzed for Ki67, TUNEL via immunohistochemical methods,
to assess their proliferative index and apoptotic nature. We can also stain these
cells to detect the activation status of c-Abl and Arg and determine whether these
dormant cells have activated c-Abl and Arg. The tumors that leave dormancy and
form macrometastasis will be assessed for level of c-Abl/Arg activation, using
immunohistochemistry, to investigate if increased c-Abl/Arg activation is
associated with loss of dormancy. Future experiments will also identify if nilotinib
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can exert its anti-metastatic capacity by promoting apoptosis of these dormant
cells. We could also extract a subset of these dormant cells and grow them in
culture to assess if these dormant tumor cells have upregulated the p38 pathway,
which makes them growth arrested and dormant, or whether the Erk pathway is
downregulated, so that the cells do not proliferate and remain dormant [294,295].
Alternatively we can stain the lung sections using specific antibodies against p38
or Erk. Dormant cells lack angiogenic signals and stay quiescent and survive in
nutrient free conditions. p38 leads to downregulation of VEGF and upregualtion
of anti-angiogenic factor like TSP [296,301 ], and c-Abl and Arg promote the
activation of p38, so activated c-Abl/Arg may promote tumor dormancy via this
pathway. To test this hypothesis we can perform immunohistochemistry on the
lung sections of nilotinib and vehicle-treated mice to investigate if nilotinib can
effectively inhibit p38. Inhibition of p38 by nilotinib will free the cells from
dormancy and also make them sensitive to the anti-metastatic capacity of
nilotinib. Ki67 and TUNEL staining will also be performed to investigate if nilotinib
can promote apoptosis of these quiescent (Ki67-negative) dormant cells.
We also could study dormancy by labeling 435s/M14 cells expressing
GFP cells (435s/M14-GFP) with fluorescent nanospheres, which will identify cells
that have not divided [297]. As cells divide, nanospheres will be diluted to
undetected levels in rapidly proliferating cells. 435s/M14-GFP cells with
nanospheres will be injected intravenously and periodically imaged and later
dormancy will be defined by detection of fluorescence nanosphere in vivo against
a background of growing metastases. We will also investigate if nilotinib can
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promote apoptosis of these dormant cells in the lungs. Lower levels to no
detection of these nanospheres in the lungs after nilotinib treatment will indicate
that nilotinib can effectively prevent cancer dormancy. As an alternate approach,
these solitary cells in the lungs, can be stained for Ki67, negative Ki67 staining
will define non-proliferating, quiescent cells.
The spontaneous and experimental mouse models describe above utilizes
the use of injecting human tumor cells into immunocompromised mice. To
recapitulate the clinical settings, genetically engineered mouse models (GEMMs)
will be utilized to evaluate the dependence of c-Abl and Arg in melanoma
metastasis. These GEMMs also are immune component, and the tumors that
develop in the mice reflect the human counterpart, having stroma and
vasculature of the same species [298]. Currently mouse models of melanoma are
available, where oncogenes are ectopically expressed. Our lab has shown that
c-Abl/Arg are highly activated in melanoma arising from chronic-sun-exposure,
indicating that UV-induced model of mouse melanoma like MT::HGF could be
utilized. c-Abl/Arg PP oncogene will be cloned under the control of
metallothionein-1(MT promoter) in the melanocytes, generating a MT::Abl mouse
model in C57BL6 background. These neonatal mice will be UV-radiated, the
incidence and latency of metastasis will be compared against control mice having
β-galactosidase gene in place of c-Abl/Arg PP. To investigate if nilotinib is
effective in treating metastasis arising from activated c-Abl/Arg-PP in the GEMM
model, mice harboring the c-Abl/Arg-PP transgene will be treated with nilotinib
and metastatic endpoint will be compared with vehicle-treated mice. Similarly the
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tyrosinase distal regulatory element (DRE) or constructs in which SV40 large T
antigen is under the control of the mouse tyrosinase promoter could be utilized to
enhance transgenic expression of c-Abl/Arg-PP oncogene in melanocytes of
C57BL6 background [299]. The different animal experiments proposed in this
section will identify in vivo processes that activated c-Abl/Arg upregulate to
promote melanoma metastasis. These proposed experiments will also identify
whether activated c-Abl/Arg can promote tumor dormancy and whether nilotinib
can induce apoptosis of these dormant cells. These experiments are of prime
significance as it will identify if c-Abl/Arg inhibitors can be used to treat patients
with metastatic melanoma.
Abnormal vesicular trafficking plays a crucial role in cancer progression,
as endocytosis permits the internalization of signaling receptors, and targets
them to be destroyed in the acidic lysosomes [250]. In Chapter 3 we showed
that c-Abl likely effects endosome maturation, which is independent of the
acidification step. Endosomes are motile, and they move from the cytoplasm to
the perinuclear region along the mircotubules, which is an important step in
endosomal maturation, independent of endosomal acidification [248,249]. During
endosome maturation, early endosomes migrate towards the nucleus along
microtubules. Early endosomes which are Rab5-positive, are replaced with larger
perinuclear-located endosomes (late endosomes), which express Rab7. This
process is called Rab5/Rab7 switching, and it can be blocked by expression of a
constitutively active from of Rab 5(Q79L) [248]. Our results indicate that silencing
of c-Abl block endosome maturation, independent of acidification (chapter 3).
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Although silencing c-Abl alters the distribution of early endosomes, it does not
change the localization or induce perinuclear clumping of Rab7-positive late
endosomes or LAMP1-positive lysosomes, indicating that c-Abl impairs the
Rab5/Rab7 switching during endosome maturation. We will test this hypothesis
by investigating if constitutive active Rab7 can rescue the block in endosome
maturation observed after silencing c-Abl. Another possibility in the delay of
endosome maturation might be due the presence of Rab5 on endosomes
together with Rab7 (hybrid endosomes) [300]. Double staining of Rab5 or EEA 1
and Rab7 following silencing of c-Abl will answer the question whether some
amount of EEA 1 positive vesicles are also positive for Rab7. We will also
investigate whether silencing c-Abl delays the loss of Rab5 from early
endosomes and thus, prevents endosomal maturation and cargo movement.
Thus, inhibition of c-Abl may delay the removal of Rab5 from endosomes by
keeping it in an active GTP bound state. To test this hypothesis, we will express
a dominant-negative form of Rab5 (Rab5S34N) and test whether it can rescue
the inhibitory effects of silencing c-Abl on endosome maturation. Using videoenhanced fluorescence microscopy in live cells transfected with c-Abl siRNA we
can track if Rab5 persistently stays on Rab5/Rab7 hybrid vesicles and thus,
delays endosome maturation.
Another possible mechanism in that may explain the defect in endosome
maturation following inhibition/silencing of c-Abl is disruption of the endosomal
sorting complex required for transport (ESCRT-0, -I, II, -III), which is present on
the cytosolic surface of early endosomes [248]. The ESCRT complex drives the
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process of sorting ubiquitinated-tagged cargo in the early endosomes and
processes it to the intralumenal vesicles (ILVs) present in the late endosomes.
Disruption of the ESCRT machinery leads to the accumulation of cargo in the
early endosomes and subsequent decreased number of multivesicular bodies
[245,302]. Thus, we will investigate whether inhibition of c-Abl deplete any of the
ESCRT complexes by western blotting techniques. Immunoflouresence assays
will be used to identify the depletion of the ESCRT components following
silencing of c-Abl. These experiments proposed will specifically identify how
inhibition/silencing of c-Abl blocks endosome maturation and thus prevents
degradation of NM23-H1. In the case of a metastasis suppressor, endocytosis is
considered an attenuator of signaling as degradation of the metastasis
suppressor can lead to cancer progression
Metastatic melanoma is a death sentence as all known chemotherapeutic
drugs have less than a 5% success rate and do not extend life expectancy
beyond 10 months [1,3]. The emergence of vemurafenib, a selective inhibitor of
the V600E activating mutation in BRAF, showed promise; however, the success
has been dampened due to relapse, which is observed in a large number of
patients within one year [6]. These data indicate a dire need to find new
treatment options to increase survival rates and reduce relapse/recurrence. Our
studies indicate that c-Abl and Arg are activated in primary melanomas and
melanoma cells, and c-Abl promote invasion in a STAT3 and MMP-1 dependent
manner, survival, proliferation and metastasis (Chapter2). We also demonstrate
that c-Abl and Arg promote invasion and metastasis via downregulation of NM23196

H1 (Chapter 3). Melanoma cells resistant to BRAF inhibitors have upregulated
EGFR-SFK-STAT3 signaling which promotes invasion and metastasis in these
resistant cells [22]. Previous studies from our lab demonstrate that Src and
EGFR activate c-Abl and Arg in cancer cells, indicating that nilotinib might be
able to be used in a group of patients who do not respond to vemurafenib. Our
studies indicate that nilotinib could be used to treat patients with metastatic
melanoma; however, patients should be selected properly in order to increase
the likelihood of a favorable response. Patients whose tumors have activated cAbl and Arg should be pre-screened and preferentially selected for treatment
over other patients.
All of the studies proposed here will strengthen the hypothesis that c-Abl
and Arg are required for melanoma progression, will identify various effector
targets of c-Abl and Arg-mediated melanoma progression, and will establish
tumor expression signatures (STAT3, Akt, NF-κB, MMP and TIMP) that can be
used to identify patients with metastatic melanoma who are likely to respond to cAbl and Arg inhibition.
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